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Abstract 
The development of type 2 diabetes (T2D) and obesity is a complex interaction of 
genetics and environmental factors. By identification of susceptible genes, prevention 
can be approved and personalised treatment might be possible. The aim of this study 
was to contribute to the identification of genetic variants involved in the development 
of T2D and obesity.   
In this present study three candidate genes, abelson helper integration site 1 (AHI1), 
uncoupling protein 2 (UCP2), and lamin gene (LMNA) have been investigated for its 
influence on the development of T2D and obesity. AHI1 encodes the protein jouberin 
and its function is not clarified. Two variants, rs1535435 and rs9494266, have 
previously been associated with T2D. In this study their potential associations with 
T2D have been investigated in 17,521 individuals. UCP2 encodes UCP2 located in the 
inner mitochondrial membrane and forms a pore through the membrane. This pore is 
an alternative route for the protons to flux through the membrane and thereby 
uncouple oxidative phosphorylation instead of synthesizing ATP. The promoter variant 
rs659366 has previously been studied according to obesity and T2D; however, the 
results have been inconsistent. In this thesis it was investigated if the rs659366 was 
associated with obesity in two case-control studies of 3,153 non-obese and 1,550 
obese individuals and in 1,567 non-obese and 2,455 obese individuals. Furthermore, it 
was investigated if rs659366 was associated with T2D in a case-control study of 4,904 
T2D cases and 3,214 glucose tolerant controls. 
LMNA encodes lamin A and C, they form a polymer that is a part of the nuclear 
lamina. The LMNA variant rs4641 has shown an association with pre-diabetic traits 
and a nominal association with T2D. It was investigated in twins if rs4641 was 
associated with T2D or any T2D-related traits. The rs4641 is located in a splice site in 
exon 10 and alternative splicing of exon 10 produces two isoforms, lamin A and lamin 
C. By functional studies it was further investigated if rs4641 influenced the splicing of 
LMNA by measuring the mRNA expression of lamin A and lamin C and by exon 
trapping. 
The rs1535435 and rs9494266 of AHI1 were not associated with T2D in 17,521 
individuals or in a meta-analysis. The UCP2 rs659366 was no associated with T2D or 
with obesity; however, we found a nominal association with obesity in the ADDITION 
study. In a meta-analysis we did not find any association with obesity or with T2D. 
Nevertheless, we found a nominal association with improved insulin sensitivity. We 
found no association of the LMNA rs4641 with any pre-diabetic traits. Most of the gene 
expression measurements of lamin A and C did not pass our quality check. Thus it was 
not possible to draw any conclusion of this study. Unfortunately, it was not possible to 
fulfill the exon trapping experiment investigating the rs4641 influence on alternative 
splicing why there are no results from this study.  
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In conclusion, the rs1535435 and rs9494266 in AHI1 were not associated with T2D or 
any pre-diabetic traits in our populations. The promoter variant in UCP2 was not 
associated with obesity or T2D in our populations. The LMNA rs4641 was not 
associated with any pre-diabetic traits in twins and the gene expression ended up with 
too few individuals to draw any conclusions as well as the exon trapping was not 
possible to complete why further studies are needed to clarify the effect of rs4641 on 
alternative splicing of LMNA. 
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Resume (Dansk) 
Udviklingen af type 2 diabetes (T2D) og fedme er et kompleks samspil mellem genetik 
og miljøfaktorer. Ved at klarlægge den genetiske baggrund kan forebyggelse forbedres 
og individualiseret behandling kan blive mulig. Formålet med dette speciale var at 
medvirke til at identificere genetiske varianter involveret i udviklingen af T2D og 
fedme. AHI1 koder for proteinet, jouberin, hvis funktion ikke er klarlagt. To varianter, 
rs1535435 og rs9494266, er for nylig blevet associateret med T2D. I dette speciale er 
deres potentielle association blevet undersøgt i 17.521 danske individer. UCP2 koder 
for UCP2, som er placeret i den indre mitokondrielle membran, hvor den danner en 
pore gennem membranen. Dette er en alternativ rute for protonerne, hvorved oxidativ 
fosforylering afkobles i stedet for, at der syntetiseres ATP, når de passerer igennem 
membranen. Varianten, rs650366, i UCP2s promoteren er for nylig blevet undersøgt i 
forhold til fedme og T2D, men resultaterne har ikke været entydige. I dette studie 
blev det undersøgt, om rs659366 var associeret med fedme i to case-control-studier 
bestående af 3.153 kontroller og 1.550 fede individer og i 1.567 kontroller og 2.455 
fede. Endvidere blev det undersøgt, om rs659366 var associeret med T2D i et case-
control-studie bestående af 4.904 T2D-patienter og 3.214 glukosetolerante individer. 
LMNA koder for lamin A and C, som sammen danner en polymer, der er en del af 
nuclear lamina. LMNA-varianten, rs4641, er associeret med pre-diabetiske træk og en 
nominel association med T2D. I dette studie blev det undersøgt i tvillinger om rs4641 
var associeret med T2D eller andre T2D-relaterede træk. Varianten findes i et splice 
site i exon 10 og alternativ splicing af exon 10 producerer to isoformer, lamin A og 
lamin C. Ved funktionelle studier blev det undersøgt, om rs4641 påvirkede splicingen 
af LMNA ved at måle mRNA ekspressionen af lamin A og lamin C samt ved exon 
trapping.  
De to varianter, rs1535435 og rs9494266, i AHI1 var ikke associeret med T2D eller 
prædiabetiske træk i 17,521 individer eller i en meta-analyse. UCP2 rs659366 var ikke 
associeret med T2D eller med fedme, men vi fandt en nominel association for G-allelet 
med fedme i ADDITION. I en meta-analyse fandt vi heller ingen association med præ-
diabetiske træk. Derimod fandt vi en nominel association med forbedret 
insulinfølsomhed. Vi fandt ingen association med LMNA rs4641 med præ-diabetiske 
træk. De fleste af målingerne for genekspressionsforsøgene af lamin A og C passerede 
ikke vores kvalitetscheck. Derfor var det ikke muligt at drage nogen konklusioner for 
dette studie. Desværre var det heller ikke muligt at gennemføre exon trapping-
eksperimenterne, hvorfor der ikke er nogen resultater for dette studie. 
Det kan konkluderes, at rs1535435 og rs9494266 i AHI1 ikke var associeret med T2D 
eller med nogen præ-diabetiske træk i vores populationer. Promotervarianten i UCP2 
var ikke associeret med fedme eller T2D i vores populationer. LMNA rs4641 var ikke 
associeret med nogen præ-diabetiske træk i tvillinger og studiet af geneekspression 
endte op med at have for få individer til at drage nogle konklusioner på det. Ligeledes 
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blev der ikke opnået nogle resultater for exon trapping-experimenterne, hvorfor flere 
studier behøves for at klargøre effekten af rs4641 på alternative splicing.  
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1 Introduction 
The incidence of type 2 diabetes (T2D) and obesity has reached epidemic proportions 
due to a marked increase in energy-dense food and a sedentary lifestyle that are 
some of the main risk factors for T2D and obesity. Because of the increasing incidence 
of T2D and obesity it is essential to perform basic and clinical research to improve the 
quality of treatment strategies and prevention. In 2002, an estimated 6.3 % of the 
U.S. population had diabetes, corresponding to approximately 18.2 million people 
[reviwed in Engelgau et al., 2004]. Approximately 100.000 to 150.000 in Denmark 
have diagnosed T2D and it is estimated that about the same number have 
undiagnosed T2D and furthermore, about 10.000 to 20.000 Danish people develop 
T2D every year [web].  
Lately, the prevalence and incidence of T2D have also been increasing explosively in 
developing countries such as India and China, partly due to an increase in obesity. The 
lifestyle contributes enormously to the increasing incidence of obesity. Changes in 
work patterns from heavy labour to sedentary lifestyle with increasing computerisation 
and mechanisation and improved transportation are just a few of the changes that 
have had an impact on human health. A busy life often gives rise to an increased 
intake of more unhealthy, pre-cooked and energy-dense food. Moreover, computer-
use and television watching increases the sedentary lifestyle and are often combined 
with the intake of energy-dense snacks.  
The term diabetes mellitus, which in the rest of this report will be referred to as 
diabetes, covers a group of diseases that  have very diverse causes, but are all 
characterised by chronic hyperglycaemia with disturbances in the metabolism of 
carbohydrates, fat, and proteins due to defective insulin secretion, insulin action or 
both. Diabetes was first described in ancient times with the symptoms polyuria, 
polydipsia, and polyphagia [reviewed in Engelgau et al., 2004]. These symptoms are 
still valid with polyuria due to high blood glucose levels, polydipsia attempting to 
compensate for the increased urination and polyphagia because of cell starving to the 
reason that there is a decreased uptake of glucose and decreased glycogen synthesis.  
1.1 Overall aim  
The overall aim of this thesis is to contribute to the knowledge of how genetics 
influence the development of T2D and obesity. By epidemiological and genetic studies 
variants in the genes AHI1, UCP2, and LMNA are investigated to clarify if these 
variants are associated with T2D and obesity. Furthermore, it is investigated if the 
LMNA rs4641 influences the alternative splicing of LMNA by functional studies. 
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1.2 Gluocose homeostasis 
Insulin plays an essential regulatory role in glucose homeostasis by keeping glucose 
concentrations within narrow limits. Glucose is an important energy source needed to 
maintain proper function of the body. While low blood glucose concentrations might 
lead to cellular death, prolonged elevated blood glucose concentrations may result in 
organ damage. Thus tight regulation of the glucose homeostasis is essential for 
survival. Two hormones work in opposite direction in the body to regulate blood 
glucose; insulin and glucagon. In diabetes glucose homeostasis is not proper regulated 
and the disease is biologically defined as a state where carbohydrate and lipid 
metabolism are improperly regulated by insulin. This results in elevated fasting and 
serum glucose concentration that often leads to acute or chronic complications. 
Knowledge of glucose homeostasis and the action of insulin is essential to understand 
the pathogenesis of T2D, which this thesis deals with. 
1.2.1 Function of insulin 
Insulin stimulates the skeletal muscle, fat, and liver cells to take up glucose and store 
it as glycogen and fat whereas glucagon stimulates the muscle and liver to release 
glycogen as glucose to the blood. By this regulation of insulin and glucagon fasting 
plasma glucose concentration remains relatively constant in healthy people at around 
5 mmol l-1. Insulin and glucagon are synthesised in the pancreatic islets of langerhans; 
insulin is synthesised in the β-cells and glucagon is synthesised in the α-cells. Insulin 
also activates glycolysis and fatty acid synthesis.  
Insulin regulates the plasma glucose concentrations by binding to its receptor, a 
receptor tyrosine kinase receptor, expressed in almost every tissue, although skeletal 
muscle, liver and white adipose tissue are regarded as the major organs involved in 
regulation of glucose homeostasis. The binding activates the intrinsic tyrosine kinase 
in the cytoplasmic domains resulting in autophosphorylation and phosphorylation of 
insulin receptor substrates (IRSs) on multiple tyrosine residues. Activation of their 
molecules triggers the recruitment of multiple downstream signalling proteins, which 
mediates the unique insulin response depending on the cells or tissues involved 
[reviewed in Rhodes & White, 2002]. IRS proteins are linked to two main signalling 
pathways: the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway, 
which is responsible for the most of the metabolic actions of insulin, and the mitogen-
activated protein kinase (MAPK) pathway, which regulates expression of genes 
involved in cell cycle and cooperates with phosphatidylinositol-3-kinase (PI3K) 
pathway to control cell growth and differentiation [Avruch, 1998].   
The catalytic subunit of PI3K is activated when it associates with IRS bound to the 
insulin receptor. Active PI3K phosphorylates the membrane phospholipid 
phosphatidylinositol biphosphate 2 (PIP2) to phosphatidylinositol triphosphate (PIP3). 
Further activation of downstream effecter molecules promotes the intracellular 
translocation of GLUT-4 to the plasma membrane [Wilcox, 2005]. GLUT-4 is the main 
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insulin-responsive glucose transporter in skeletal muscle and adipose tissue, and is 
therefore crucial for glucose uptake. In the absence of insulin GLUT4 is stored in 
vesicles inside a lipid bilayer in muscle and fat cells, but when the insulin receptor is 
activated GLUT4 is translocated to the cell membrane. Insulin increases the rate of 
GLUT4 vesicle exocytose and slightly decrease the rate of internalisation, thereby 
enhancing glucose uptake, and storage of glucose as glycogen or fat [reviewed in 
Rhodes & White, 2002] (Figure 1.1). 
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Figure 1.1.Insulin signaling through its receptor, mediated by insulin receptor substrate (IRS) 
leading to conversion of phosphorylated phosphatidylinositol PI (3,4) biphosphate (PIP2) to 
PIP3, which acts as a co-factor to stimulate pyruvate dehydrogenase kinase and activation of 
the protein kinase B (PKB). This leads to an activation of transcription in nucleus. The activity of 
PI3K is opposed by conversion of PIP3 back to PIP2. PIP3 activates protein kinase C (PKC) and 
by a yet unknown pathway the GLUT-4 is translocated to the cell membrane and transports 
glucose through the cell membrane. IRS also activates the map kinase kinase (MEK) -mitogen 
activated kinase (MAPK) pathway also leading to an activation of transcription.  
1.2.2 Glycogen synthesis  
When plasma insulin increases, glycogen synthesis becomes predominant; however, a 
defect in glucose storage is a characteristic finding in all insulin resistant states, 
including obesity, IGT and in patients with overt diabetes. The synthesis of glycogen in 
liver and skeletal muscle is a second mechanism of importance in insulin regulated 
glucose homeostasis. Glycogen synthase kinase-3 is phosphorylated by protein kinase 
B (PKB) and is thereby inactivated. The glycogen synthase is active in its 
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dephosphorylated form and is thus indirectly inactivated by PKB. A third event in the 
regulation of glucose homeostasis is the insulin mediated decrease of hepatic 
gluconeogenesis. PKB inhibits the expression of gluconeogenetic enzymes by 
regulating the activity of a class of transcription factors [reviewed in Taniguchi et al., 
2006] 
1.2.3 Synthesis of insulin 
The insulin is produced as pre-proinsulin. It consists of a signal sequence and three 
different parts A, B, and C. The signal sequence is cleaved off and proinsulin makes a 
specific folding, which is stabilised between the A- and B-chains. The C-chain is 
cleaved off by a peptidase (figure 1.2). Both the native insulin and the C-peptide are 
stored in storage granules and they are therefore secreted in equimolar amounts to 
the blood stream. Because of the equimolar secretion into the blood and because the 
C-peptide is not removed by the liver, C-peptide can be used to estimate the capacity 
of the insulin secretion and thereby in diagnosing T2D and insulin resistance 
[DeFronzo, 1997]. 
 
1.2.4 Secretion of insulin 
Insulin is secreted in discrete pulses into the portal vein in a biphasic pattern and the 
level of insulin is highly responsive to the prevailing glucose value [Meier et al., 2005]. 
Insulin release has an early burst within the first 10 minutes followed by a gradually 
increasing phase of insulin secretion that persist as long as the hyperglycaemic 
stimulus is present. The first phase insulin response is release of insulin from the 
granules. The second phase insulin secretion is a prolonged release of newly 
synthesised insulin [reviewed in Wilcox, 2005]. 
Figure 1.2 Synthesis of insulin. In the top preproinsulin, in the middle preinsulin and in the 
bottom insulin [Beta cell Biology Consortium]. 
Introduction 
 
  Page 5 
1.2.5 Action of insulin 
Glucose is transported into β-cells by the glucose transport protein, GLUT-2, which is 
primarily expressed in β-cells. In the cytoplasm glucose is converted by glucokinase to 
glucose-6-phosphate and the ATP/ADP-ratio increases which in turn stimulates the 
secretion of insulin. This conversion is the first and rate-limiting step in the glycolytic 
pathway. GLUT-2 expression is tightly regulated in β-cells and markedly decreased in 
the diabetic state when glucose-stimulated insulin secretion is impaired; however, at 
some level other glucose transporters, GLUT-1 and GLUT-2, compensate for the 
absence of GLUT-2 [Thorens, 2006]. The ATP which further is synthesised through 
oxidative phosphorylation triggers the closure of ATP-sensitive K+-channels in the 
membrane. Furthermore, this leads to depolarisation of the cell membrane with 
subsequent opening of voltage-dependent Ca2+-channels and influx of Ca2+. The rise in 
intracellular Ca2+ stimulates the release of insulin from granules in the cells [Rhodes & 
White, 2006] (Figure 1.3).  
 
 
1.3 Diabetes 
Type 2 diabetes (T2D) is the most prevalent form of diabetes; however, a number of 
other diabetes forms exist. The four main groups of diabetes are T2D, T1D, 
gestational diabetes and other specific forms of diabetes.  
Type 1 diabetes (T1D), also called insulin-dependent diabetes, is due to an 
autoimmune-mediated destruction of the pancreatic β-cells and the disease has a high 
heritability. Certain genetic loci are believed to be involved in the pathogenesis; most 
important is the human leukocyte antigen (HLA) locus, which is a post of the major 
Figure 1.3. Insulin secretion caused by glucose stimulation in β-cells [Thorens, 2006]. 
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histocompability complex, important for immune mediated recognition [reviewed in 
Florez, 2003]. The disease is chronic and progressive and leads to metabolic 
abnormalities. T1D is one of the most prevalent diseases in childhood and account for 
about 5-10 % of all cases of diabetes in the U.S [American Diabetes Association, 
2004]. Insulin as therapy for T1D was initiated in 1922 and has prevented the 
majority of deaths due to insulin deficiency abnormalities [reviewed in Castano & 
Eisenbarth, 1990].  
Gestational diabetes (GDM) is a condition in which women without previously 
diagnosed diabetes have increased blood glucose levels during pregnancy [reviewed in 
Engelgau et al., 2004], probably due to an impairment of insulin sensitivity, which is 
believed to be affected by hormones produced during pregnancy. The condition is 
reversible and it affects approximately 14 % of pregnancies in the U.S [Kim et al., 
2002]. No specific causes of GDM have been identified and the disease normally has 
only a few symptoms. It is most commonly diagnosed by screening during pregnancy 
by measuring blood glucose levels [reviewed in Engelgau et al., 2004]. Women with 
GDM have a higher future risk of T2D and children of GDM women have increased risk 
of complications such as growth abnormalities and low blood glucose levels following 
delivery. They are also prone to develop obesity with risk of T2D later in life [reviewed 
in Jovanovic, 2005]. 
The last group of diabetes includes other specific forms of diabetes such as MODY, 
diabetes cause by genetic defects in β-cell function and insulin action, and diabetes 
due to drug-induced diabetes. An example of a monogenic subtype in the group of 
other specific forms of diabetes is maturity-onset of the young (MODY) with age of 
onset usually before 25 years. MODY is the most common form in this group and it is 
an autosomal dominantly inherited disease and is characterised by mild to moderate 
fasting hyperglycaemia and impaired insulin secretion in response to glucose and 
other stimuli. Contrary to T2D patients the MODY patients normally do not suffer from 
insulin resistance [Xu et al., 2005]. A number of mutations in six different genes 
expressed in β-cells are known to participate in the development of MODY [reviewed 
in Hansen et al., 2002].  
1.3.1 Type 2 diabetes  
T2D is the most common form of diabetes, accounting for 90 % of all diabetes cases. 
It is a chronic multi factorial disease and is a rapidly growing health problem causing 
increased morbidity and premature mortality. In 2003 it was estimated that 5.1 % of 
the world’s population suffer form diabetes and that this will increase to 6.3 % in 2025 
[Diabetes atlas, second edition, 2003]. 
T2D is characterised by endocrine dysfunction with abnormalities in insulin action and 
insulin secretion. T2D is not only a disease among the elderly, overweight individuals 
but is also seen in younger individuals. This is in part due to the lifestyle in including 
high intake of energy-dense food and physical inactivity. People that are genetically 
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predisposed to T2D and who are overweight or obese and/or inactive are at high risk 
of developing the disease. This T2D arises as a result of complex combinations of 
many factors such as genetic, environmental factors and physiological dysfunction 
[reviewed in Kahn et al., 2006]. 
Insulin resistance is the first detectable sign of T2D characterised by impairment in 
sensitivity to insulin in the skeletal muscle and/or liver tissue [Zimmet et al., 2001]. 
To compensate for the insulin resistance the β-cells secrete more insulin, thus 
maintaining normal or near-normal glucose levels. The insulin secretion will rise but at 
a certain stage no longer fulfil the requirements, which will lead to hyperglycaemia 
[reviewed in Kahn et al., 2006; reviewed in Kasuga et al., 2006].  
The definition of T2D and the pre-diabetic conditions is based on plasma glucose 
concentrations after an overnight fast and two hours after 75g oral glucose load, 
known as an oral glucose tolerance test (OGTT). A fasting venous plasma glucose 
concentration of less than 6.1 mmol/L and a 2-hour plasma glucose < 7.8 mmol/L is 
considered as normoglycaemia [WHO, 1999]. Pre-diabetes is divided into two 
subtypes: Impaired glucose tolerance (IGT) (fasting plasma glucose < 7.0 and 2-
hours plasma glucose concentration post glucose load during an OGTT ≥ 7.8 mmol/L) 
is a condition where the oral glucose load is not well tolerated and causes the plasma 
glucose to raise more than in normal glucose tolerant individuals but below the 
diabetic threshold. In impaired fasting glycaemia (IFG) (fasting plasma glucose ≥ 6.1 
and 2-hours plasma glucose post glucose load during an OGTT < 7.8 mmol/L), it does 
not reach the diabetic threshold. Individuals with pre-diabetes are at high risk of 
progressing to T2D [Knowler, 2002]. T2D is defined as fasting plasma glucose ≥ 7.0 or 
2 hours plasma glucose post glucose load during an OGTT ≥ 11.1. 
 
 
 
         Glucose concentrations are in mmol/l in venous plasma. 
The risk of T2D increases with age and about 60 - 90 % of T2D cases are related to 
obesity. Approximately 20 % of T2D cases are lean and they have a more impaired β-
cell function than obese diabetic patients [reviewed in Anderson et al., 2003]. In 
general, there is 40 - 60 % reduction in the β-cell mass in T2D patients and it is 
possible to detect the reduction in β-cell function already in the IGT stage [reviewed in 
Kasuga, 2006].     
Insulin sensitivity and β-cell function are proportionally related and their product is 
referred to as the disposition index, defined as the product of insulin sensitivity and 
insulin secretion. If the β-cells are able to compensate for increasing insulin resistance 
Table 1.1. Diagnostic criteria of diabetes and other categories of hyperglycaemia 
 Fasting 2-hours post glucose load 
Diabetes mellitus ≥ 7.0 or ≥ 11.1 
Impaired glucose tolerance < 7.0 and ≥ 7.8 
Impaired fasting glucose ≥ 6.1 and < 7.8 
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the disposition index will be constant, why people who are insulin-resistant do not 
necessarily develop T2D. Both impaired β-cell function and insulin resistance are 
events that lead to the development of T2D; however, only a minority of T2D patients 
are diabetic solely due to impaired insulin secretion (Figure 1.3). Likewise, no well-
documented cases exist for which impaired insulin secretion is absent and insulin 
resistance is the immediate cause of T2D [reviewed in Stumvoll et al., 2005]. 
Environmental causes of insulin resistance are a high-fat diet, decreased physical 
fitness, increase in visceral fat, smoking, pregnancy, and certain medications. 
 
The reduced insulin secretion in T2D can be caused by two different mechanisms; 
insulin deficiency and disturbed secretion combined with impaired glucose stimulus-
secretion coupling. Reduction in insulin secretion can be due to decreased β-cell mass, 
e.g., caused by hyperglycaemia. Chronic blood glucose concentrations of 5.6 mmol/l 
or above induce β-cell apoptosis. Normally, β–cells will respond to small elevations in 
glucose concentrations by secreting more insulin while a higher elevation during a 
prolonged time-span might lead to proapoptotic signals via the β-cell glucose-sensing 
pathways. Persistently elevated free fatty acids in individuals predisposed to T2D may 
contribute to β-cell lipotoxcity progressing to β-cell failure and free fatty acids will 
inhibit glucose-induced insulin secretion and insulin gene expression. Free fatty acids 
are fatty acids that are not bound or attached to other molecules, such as triglycerides 
or phospholipids. In addition, the chronic increase in inflammatory mediators observed 
in T2D might not only affect insulin-sensitive tissues and blood vessel walls but could 
also affect pancreatic β-cells [reviewed in Wajchenberg, 2007].  
Figure 1.4. Relationship between β-cell function and insulin sensitivity. In normal glucose 
tolerant individuals a hyperbolic relation exists between cell function and insulin sensitivity. 
When insulin sensitivity decreases, β-cell function will increase. The same relationship exists for 
impaired glucose tolerant individuals and T2D. NGT-individuals who are at a risk for becoming 
impaired glucose tolerant represent the upper curve [Stumvoll et al, 2005]. 
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Long-term hyperglycaemia induces the generation of reactive oxygen species (ROS) 
as the electron transport chain is overloaded resulting in chronic oxidative stress. 
Especially, the β-cells are exposed to damage of ROS as the level of antioxidant 
enzymes in the β-cells I slow. ROS can also be generated through other pathways 
such as the polyol pathway and hexosamine pathway both suggested to upregulate 
protein kinase C (PKC). Through the pathway of activation of PKC, ROS is also 
produced [reviewed in Rolo & Palmeira, 2006]. 
Prevention of T2D can be accomplished by physical activity and wholesome nutrition 
but requires a public health approach with major changes in society [Zimmet et al., 
2001]. Physical activity is a very important approach in prevention as it increases the 
amount of the glucose transporter, GLUT-4 which transports glucose across the 
membrane and decreases blood glucose levels and adipokines.  
T2D is often associated with chronic complications such as microvascular neuropathy, 
nephropathy and retinopathy and macrovascular accelerated atherosclerosis resulting 
in myocardial infarction and stroke. Furthermore, diabetic patients have poor wound 
healing, particularly of the feet, which can lead to gangrene and may require 
amputation [reviewed in Zgonis et al., 2008]. 
1.4 Obesity 
There is a strong link between T2D and obesity as the release of pathogenic adipocyt 
factors such as free fatty acids and adipokines including pro-inflammatory cytokines is 
increased in obeosity which decreases the insulin sensitivity of other metabolic tissue 
[reviewed in Bays et al., 2008; reviewed in DeFronzo, 2004] 
The prevalence of obesity in developed as well as developing countries has increased 
enormously during the last two decades and is now considered one of the most serious 
health issues [Warren et al., 2004]. This is due to more plentiful and energy-dense 
food and physical inactivity. Obesity is caused by a positive energy balance due to 
excessive energy intake compared with energy expenditure.  
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1.4.1 Definition and measurement of obesity 
Body mass index (BMI) is most often used to measure the degree of obesity. This 
surrogate gives a prediction of the degree of obesity as it has a good correlation with 
obesity. BMI is defined as weight (kg)/ height (m)2. WHO has classified weight into 
five categories as shown in Table 1; however, BMI does not account for the body 
composition or the fat distribution, which means that a body builder rich in muscle 
mass, which has a higher density, has a high BMI and would be classified as 
overweight or even obese according to WHO definitions. 
Figure 1.5. Components of the energy homeostasis. Positives energy balance arises when 
energy intake exceeds energy expenditure; food intake is metabolised and stored as fat if 
energy intake exceeds total energy expenditure consisting of adaptive thermogenesis, 
obligatory energy expenditure required for performance of cellular and organ function, and 
physical activity. 
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Obesity with visceral fat accumulation associates closely with diabetes, 
hyperlipideamia, hypertension, and atherosclerosis [reviewed in Okamoto et al., 
2006]. Thus, knowledge of the fat distribution accumulation is important for 
optimisation of BMI measurements, therefore it is advantageous to use BMI in 
conjunction with waist circumference or the ratio of waist-to-hip as these 
anthropometric measures correlate well with intra-abdominal fat mass [Deurenberg & 
Yap, 1999]. A more precise method for measurements of body composition is bio-
impedance, which measures the impedance or opposition to the flow of an electrical 
current through the body. Impedance is low in lean tissue, where intracellular fluid 
and electrolytes are primarily contained, but high in adipose tissue. Thus, impedance 
is proportional to body water volume. Lean body mass is estimated using an assumed 
hydration fraction for lean tissue. Fat mass is calculated as the difference between 
body weight and lean body mass [reviewed in Mattsson & Thomas, 2006]. 
Dual-energy X-ray absorptiometry (DEXA) is an enhanced form of X-ray technology 
and it is more accurate in estimating fat mass than bio-impedance. DEXA meassures 
the whole body composition by sending a thin beam of low-dose X-rays with two 
distinct energy peaks through the body of the person being examined. One peak is 
absorbed mainly by soft tissue and the other by bone. The soft tissue amount can be 
subtracted from the total and what remains is a patient’s bone mineral density. 
[reviewed in Mattsson and Thomas, 2006].  
Classification BMI (kg/m2) 
Under-weight <18.5 
Normal-weight 18.5-24.99 
Over-weight ≥ 25 
Obese ≥ 30 
Morbidly obese ≥ 40 
Table 1.2. Classification of weight categories according to BMI 
Introduction 
Page 12 
1.4.2 Prevalence of obesity 
Almost one in three adults in the United States are currently defined as clinically obese 
with a BMI above or equal to 30 kg/m2. The prevalence in other developed countries is 
approaching the same level. Furthermore, the developing countries are adopting the 
lifestyle of the developed countries and thus have a very high increase in the incidence 
of obesity. This world-wide expansion in obesity may be considered to be a pandemic 
[reviewed in Bell et al., 2005]. The WHO estimated that in 2005 around 1.6 billion 
adults (age 15 years or above) were overweight, at least 400 million adults were 
obese, and at least 20 million children under the age of 5 years were overweight. If 
this projection continues: 2.3 billion adults will be overweight and at least 700 million 
adults will be obese in 2015. Already more people are currently overweight than 
underweight [WHO, 1999]. The economic burden of obesity is enormous and in 
combination with its human costs it is one of the most urgent issues in medicine today 
[Bell et al., 2005]. In Denmark are 33 % of the people overweight whereas 11 % are 
obese [Ekholm et al., 2005].  
1.4.3 Adipose tissue as an endocrine organ 
The adipose volume in the body is determined by the balance between lipogenesis and 
lipolysis. Lipolysis is the breakdown of fat stored in fat cells and free fatty acids are 
released into the blood stream. The central engine of differentiation of adipose tissues 
is the peroxisome-proliferator-activated-receptor-γ (PPAR-γ). When it is activated by 
an agonist ligand in fibroblastic cells it activates a full program of differentiation 
including morphological changes, lipid accumulation and the expression of almost all 
genes that are characteristic of fat cells [Rosen & Spiegelman, 2006]. 
A gain in adipose tissue can result from hypertrophy, hyperplasia or a combination. 
The number of adipocytes reflects the ability to recruit adipocyte precursors to mature 
into adipocytes [Drolet et al., 2008]. 
Two types of adipose tissues exist, brown adipose tissue and white adipose tissue. 
Excess energy is mainly stored as triglycerides in white adipose tissue and it consists 
of single lipid droplets. Brown adipose tissue only exists in mammals and is the main 
fat storage in rodents. Its main function is to generate heat why it is present in 
newborn humans. The generation of heat without concomitant ATP is made by 
uncoupling proteins (UCPs), mainly UCP-1, which uncouples the proton gradient and 
leaks protons through the inner mitochondrial membrane -an alternative route than 
the ATP synthase [reviewed in Rosen & Spiegelman, 2006]. Brown adipose tissue 
contains numerous lipid droplets and is rich in mitochondria and it contains more 
capillaries than white adipose tissues because it has a greater need for oxygen and a 
high number of mitochondria [reviewed in Duncan et al., 2007]. 
Adipose tissue functions as an endocrine organ and is required for normal insulin 
sensitivity and glucose homeostasis. It is important that the size of the adipose tissue 
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does not enlarge too much as it then secretes execs amounts of secretory proteins 
and thereby disturbs the homeostasis of glucose and energy balance. Approximately 
20-30 %, of the genes expressed in subcutaneous and visceral adipose tissue, are 
bioactive secretory proteins i.e. adipocytokines, such as tumor necrosis factor α (TNF-
α), interleukin 6 (IL-6), and the hormones leptin, resistin, and the most abundant one, 
adiponectin (Figure 1.5). Adipocytes metabolize only four to five percent of circulating 
glucose; however the adipokines, including pro-inflammatory cytokines, decrease 
insulin sensitivity in other metabolic tissues. Expansion of adipose tissue and 
especially hypertrophy of adipocytes leads to an increase release of pathogenic 
adipocyte factors including free fatty acids [Rosen & Spiegelman, 2006].  
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1.4.4 Lipid metabolism  
Lipogenesis encompasses the processes of fatty acid synthesis and subsequently 
triglyceride synthesis from glucose. Triglycerides and cholesterol are transported in 
lipoproteins, there are four different types of lipoproteins: Chylomicrons, very low 
density proteins (VLDL), low density protein (LDL), and high density proteins. 
Chylomicrons, VLDL, and LDL transport cholesterol from the liver to the bloodstream 
whereas (HDL) transport cholesterol and triglyceride to the liver from the 
bloodstream. LDL is referred to as the bad cholesterol as it is strongly associated with 
atheromatous disease and HDL is referred to as the good cholesterol as it transports 
cholesterol to the liver for excretion away from the blood. Triglycerides can be stored 
in the liver and adipose tissue and when energy is needed glycagon signals the 
breakdown of triglycerides to free fatty acids. The brain can not use free fatty acids as 
an energy source; therefore, the fatty acids are converted to glucose by the 
Figure 1.5. Selected substances released from the human adipocyte. 
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glyconeogenesis. Except from the brain, cells can take up the free fatty acids by a 
fatty acid transporter and utilize the energy. 
1.4.5 Inflammatory states of obesity 
Adiponectin, leptin, and resistin regulate a number of metabolic processes including 
glucose regulation and fatty acid catabolism. There is overwhelming evidence that 
obesity and type 2 diabetes are inflammatory states. The production of TNF-α, IL-6, 
and resistin are contributing to the inflammation [reviewed in Rosen & Spiegelman, 
2006 and in Okamoto et al., 2006] and bone marrow derived macrophages are 
recruited to the fat pad which also indicates an inflammatory state [reviewed in 
Okamoto et al., 2006]. There are conflicting results of the inflammation in obese 
people suggesting that TNF-α and IL-6 are contributing to insulin resistance but also 
that they are contributing to insulin sensitization [Carey et al., 2006; Rotter et al., 
2003]. The cytokines can promote the insulin resistance through several mechanisms, 
among those, serine phosphorylartion of insulin substrate, inhibitor кB kinase 
activation, and production of ROS [Reviewed in Rosen & Spiegelman, 2006]. 
1.4.6 Obesity and insulin resistance 
Liver insulin resistance leads to increased gluconeogenesis and thus increased glucose 
output because gluconeogenesis fails to be inhibited by insulin. Insulin resistance in 
skeletal muscles results in decreased uptake of glucose as the muscles do not respond 
to the insulin stimulation. Because the insulin does not exert its antilipoplytic effect 
the insulin resistance leads to increased release of fatty acids from the adipose tissues 
[Rosen & Spiegelman, 2006], which are taken up by other metabolic tissues such as 
liver and skeletal muscle. It is suggested that mitochondrial-derived by-products of 
lipid oxidation may have a key role in the development of insulin resistance in skeletal 
muscles. Chronic exposure to elevated lipids in skeletal muscle induces an increase in 
the expression of genes in fatty acid oxidation; however, it is not coordinated with 
upregulation of tricarboxylic acids and the electron transport chain, which lead to 
incomplete metabolism of fatty acids in the β-oxidation pathway and accumulation of 
lipid-derived metabolites in the mitochondria. In liver the elevated exposure to free 
fatty acids and the impairment of free fatty acids oxidation lead to hepatic steatosis 
which further leads to glucose intolerance [reviewed in Muoio & Newgard et al., 2008].   
1.4.7 Regulation of energy intake 
Leptin is indicated to be a sensor for fat mass and acts in a negative feedback loop 
which regulates the amount of fat in relation to a sudden amount of fat storage via the 
central nervous system. In the model an increase in energy intake will induce a 
release of leptin which again will inhibit food intake. The model is well established in 
rodents, but in human there are still obscure parts to understand the precise 
mechanisms [Oswal & Yeo, 2007]. 
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Leptin acts through different pathways. Leptin regulates appetite via its main pathway, 
the melanocortin pathway, shown in figure 6. This pathway includes the direct action 
of leptin on two descent classes of neurones; one class co-expresses the anorexigenic 
peptides pro-opiomelanocortin and cocaine and amphetamine-regulated transcript 
(CART) which reduces food intake while the other classes of neurones co-expresses 
the orexigenic peptides neuropeptide Y (NPY) and agouti-related protein (AgRP) which 
reduce satiety and increase food intake [Oswal & Yeo, 2007]. By acting through the 
central neural pathway combined with direct activation of AMP-activation of AMP-
activated protein kinase, leptin improves insulin sensitivity in muscles and it also 
reduces intra-myocellular lipid levels [reviewed in Rosen & Spiegelman, 2006]. Leptin 
given to obese people as a drug is not inducing weight loss indicating that obese 
people are resistant to leptin [reviewed in Oswal and Yeo, 2007]. Leptin activates the 
PI3K pathway which also plays an important role in regulating energy homeostasis. 
The activated leptin receptor stimulates the tyrosine phosphorylation of IRS proteins 
by. Afterwards IRS recruits, phosphorylates, and activates phosphoinositide (PI) 3 
kinases, leading to downstream signalling [Oswal & Yeo, 2007].  
In opposite to leptin ghrelin stimulates appetite by stimulating the NPY/AGRP neuron 
and inhibit the POMC/CART neurons. Ghrelin is down regulated in obese people, which 
is probably a consequence of elevated insulin or leptin, because fasting plasma ghrelin 
levels are negatively correlated with fasting plasma levels of insulin and leptin. It is 
suggested that the decrease in plasma Ghrelin concentrations observed in obesity 
represents a physiological adaptation to the positive energy balance with obesity 
(Figure 1.6) [Tschop et al., 2001].  
Insulin circulates at levels proportional to body fat mass and controls meal size via 
inhibition of POMC/CART neurons [Schwartz et al., 2000]. The hepatic glucose 
production in the fasting states is promoted by the counter regulatory hormones 
glucagon, adrenalin, and corticosteroids. The brain coordinates many of these effects 
through direct and indirect intake, glucose sensing, and neural outputs to peripheral 
organs [Reviwed in Rosen & Spiegelman, 2006]. 
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1.5 The metabolic syndrome 
The metabolic syndrome is a cluster of cardiovascular risk factors including visceral 
obesity, dyslipidaemia, hyperglycaemia, and hypertension. Obesity and particularly 
visceral obesity is commonly associated with the development of the metabolic 
syndrome, which is considered to be one of the major public health inconveniences. 
Many behavioural factors are involved including a lifestyle of inactivity and food 
abundance. It is difficult to determine the primary contributor to the metabolic 
syndrome as all the risk components are closely interrelated. The importance of the 
metabolic syndrome is that it helps to identify individuals at high risk of cardiovascular 
diseases [Alberti et al., 2005]. There have been many suggestions to the diagnostic 
criteria since the metabolic syndrome was defined; however, there have been general 
consensus regarding the core components of the syndrome which features obesity, 
especially visceral obesity, insulin resistance, dyslipideamia, and hypertension. In 
many of the metabolic cases medical treatment is needed; however, no specific treat-
Figure 1.6. Regulation of energy balance in the hypothalamus. Peripheral signals from leptin, 
insulin, and grhelin affect neuro peptide Y (NPY) / agouti-related peptide (AGRP) and pro-
opiomelanocortin (POMC) / cocaine- and amphetamine-regulated transcript (CART) neurons. 
These signals in the neurons and interaction with other neurons change food intake and energy 
expenditure. 
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ment exists hence individual medicine directed against the specific abnormalities is 
used.  
1.6 Genetics  
Knowledge of the human genetics underlying metabolic diseases is very important for 
the understanding of biological pathway as a diagnostic approach may also be helpful 
when optimising the treatment of patients. Much work is put into identifying new 
genetic variants involved in the development of common diseases such as T2D. Even 
though genetics play an important role in the development of T2D, it is a set of 
complex interactions between genetic and environmental factors that determine 
whether the phenotype of the disease is expressed.  
Two human genomes of approximately 3 billion nucleotides are roughly 99.9 % 
identical leaving only about 0.1 % of the nucleotides attributable to genomic 
differences among individuals [Kruglyak & Nickerson, 2001]. The most abundant 
source of known genetic variation in the genome is single-nucleotide polymorphisms 
(SNPs) defined as one-base variation in the DNA sequence with an allele frequency of 
> 1% in a given population. Approximately 10 million SNPs exist in the human 
population, which is about one site per 300 bases [Kruglyak & Nickerson, 2001]. 
Sequencing of the human genome provided the location of 2.1 million SNPs with less 
than 1 % of them resulting in variations in proteins [Venter et al., 2001]; 
nevertheless, it is estimated that 10-11 million SNPs exist with a minor allele 
frequency of at least 1 % [The International HapMap Consortium, 2007]. 
Other forms of genetic variation are large-scale and small-scale insertions and 
deletions, inversions, mini-and micro satellites and copy number variants [Feuk et al., 
2006]. SNPs are distributed throughout the whole human genome; however, many of 
the variants are synonymous and thus do not change any amino acids. Other SNPs are 
non-synonymous and result in amino acid substituon. This thesis includes studies of 
two SNPs located in an intronic region of abelson helper integration site (AHI1), a SNP 
located in the promoter region of (UCP2), and a SNP placed in a splicing site of LMNA.  
1.6.1 Approaches to identify genetic variants 
predisposing to diseases 
Only a decade ago linkage analysis and the candidate gene approach were the 
common methods applied to identify potential susceptibility variants associated with 
diseases. These approaches led to the identification of a large number of potential 
candidate genes and quantitative trait loci (QTL). Technologies have led to a new era 
where up to 106 genetic markers are analysed on a single chip. During this year 
genome wide association (GWA) studies have led to a deeper understanding of the 
genetics of many common diseases. Genes for obesity and T2D have been identified; 
however, not all these associations have yet been validated. It is expected that more 
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genes associated with T2D or obesity will be identified in the near future [Li & Loos, 
2008].  
The candidate gene approach 
The candidate gene approach identifies susceptibility genes based on knowledge of 
their biological function or genomic localisation. Genes thought to be involved in the 
disease are identified based on data from animal models, cellular systems, or extreme 
forms of the trait in question. Genetic variants are then tested for association with a 
trait of interest at the population level [Li & Loos, 2008]. 
Linkage studies 
In genome-wide linkage studies whole genomes are examined often using micro 
satellites in order to identify genetic markers that co-segregate with a specific trait. 
The approach is hypothesis-free and aims to identify the approximate location of 
genomic regions that co-segregate with a certain trait. Thus the study requires related 
individuals such as siblings, nuclear families or extended pedigrees. When a region is 
identified, it is subsequently fine-mapped in order to determine more precisely which 
specific variants co-segregate with the disease. Linkage studies have been successful 
for identifying Mendelian disorders, such as MODY; however, they are not suited for 
detecting common low-penetrance variants believed to be relevant for multifactorial 
diseases as T2D [reviewed in Lindgren & McCarthy, 2008]. Regions showing significant 
linkage to inflammatory disease, schizophrenia, and T2D have been identified 
[reviewed in Hirschhorn & Daly, 2005]. A recent meta-analysis combining 27 linkage 
studies including data of more than 10,000 families and more than 31,000 individuals 
of European origin could not explicitly identify a single obesity or BMI locus [Saunders 
et al., 2007]. Linkage studies have successfully been used for identification of rare 
monogenic forms of diseases and have been used for identifying of the most validated 
T2D variants in TCF7L2 [Cauchi & Froquel, 2008]. 
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The genome-wide association 
(GWA) study is a relatively novel 
approach to identify genetic 
disease susceptibility variants [Li 
& Loos, 2008]. Like linkage 
studies GWA studies are 
hypothesis-free. The method is 
very effective as up to 1.5 million 
SNPs are studied on each chip. 
GWA studies use SNPs with a 
minor allele frequency of above 5 
% and the method has already 
resulted in the identification of a 
number of novel variants being 
associated with different diseases 
(Figure 1.7) [reviewed in Li & 
Loos, 2008]. In GWA studies 
thousands of statistical tests are 
performed as a result of multiple 
genetic variants, multiple 
phenotypes and multiple 
statistical models including 
different assumptions regarding the mode of inheritance [reviewed in Salanti et al., 
2005]. Thus correction for multiple testing is necessary and usually a very stringent 
genome-wide significance criteria is required, usually at the significance level of below 
10-7 [Frayling et al., 2007c; reviewed in Seng & Seng].  
Case-control studies  
Case-control studies compare a group of cases, ascertained for a trait of interest 
which is presumed to have a high prevalence of susceptibility alleles for the 
phenotype, with a group of control individuals, not ascertained for the trait and who 
are considered likely to have a lower prevalence of such risk alleles [McCarthy et al., 
2008]. In genetic case-control studies the allele frequency (or haplotype, i.e. a 
combination of alleles at multiple loci that are transmitted together on the same 
chromosome) is compared between cases and control individuals. If there is a 
significant difference in the allele frequency it indicates that this genetic marker may 
increase the risk or likelihood of the trait or be in high LD with another variant 
increasing the risk. It is important to include many individuals, the more the better [Li 
& Loos, 2008]. Furthermore, it is important to match the cases with the controls 
Figure 1.7. Overview of genome wide association study 
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minimizing the effect of confounders which might lead to false association or missed 
association [reviewed in Risch, 2000]. 
Twin studies 
Twin populations represent some of the best resources for evaluating the importance 
of genetic variation in susceptibility to disease. MZ twins share all genetic material 
except for genes for T-cell receptors and immunoglobulins. DZ twins share in average 
half of their genes. When study population of twins contain both MZ and DZ twins the 
contribution of genes can be investigates by means of intra-class correlations in MZ 
and DZ twins. Twin studies allow for control of the influence of genetic factors. Since 
MZ twins are genetically identical correlation performed between with-in-twin pair 
differences in phenotypes any association found, is of non-genetic origin. If a trait is 
highly heritable, MZ twins will be more similar than DZ twins as regards the particular 
trait. Twins are also excellent for studying the significance of environmental factors on 
the phenotype. 
Studies of twins have shown that genetic as well as environmental factors influence 
glucose metabolism and insulin sensitivity. In comparison of elderly MZ and DZ, MZ 
twins had significantly higher plasma insulin during an OGTT. These findings are 
probably due to an adverse intrauterine environment for MZ twins compared to DZ 
twins [Poulsen et al., 1999]. This agrees with the finding of lower birth weight for type 
2 diabetic twins compared to their non-diabetic co-twin [Poulsen et al., 1997].   
Functional studies 
Genetic association studies are important tools for identifying variants predisposing for 
diseases such as T2D; however, after replication in independent study samples re-
sequencing of the locus and additional association studies are performed. By 
performing association studies e.g. genome wide association studies, variants might 
be identified to be associated with a certain trait; however, it is often difficult to 
determine the exact causative variant. Often a few variants in high LD are identified 
and the last step of proof for a true association may involve functional studies. 
Functional studies can be performed by different study designs. In the thesis 
functional studies of LMNA were performed. Different assays might be used for 
different hypothesised function. It may involve physiological studies of the impact of 
the variant on the whole body human level or if the effect size is large enough to do 
studies in animals; e.g. in transgenic or knock-outs. 
HapMap  
Data from the International HapMap consortium and the completion of the reference 
sequence of the human genome have been crucial for the performance of GWA 
studies. The International HapMap Project is an organisation that started with the 
purpose of creating a haplotype map of the human genome, HapMap, describing the  
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common patterns of human genetic 
variation [The International HapMap 
Project, 2003]. 
It has become a key resource for 
researchers aiming to find genetic 
variants affecting health, disease, and 
responses to drugs and environmental 
factors. The publishing of the data has 
so far comprised three phases; the complete data obtained in phase I by genotyping 
of one common SNP every 5,000 nucleotides including more than one million SNPs 
were published in 2005 [The International HapMap Project, 2005] with the following 
data of more than 2.1 million SNPs from phase II published in 2007 [The Internatinal 
HapMap Project, 2007] and recently the Phase III draft from the HapMAp has been 
released (Box 1.1).  
To obtain enough SNPs to create the HapMap a lot of re-sequencing was undertaken. 
Additional SNP data were submitted to the public dbSNP database. In august, 2006, 
there were more than ten million SNPs in the database with more than 40 % being 
polymorphic [NCBI]. The Hapmap Project has provided important knowledge of 
common genetic variants and the linkage disequilibrium (LD) (Box 1.2) structure and 
this has facilitated impressive progress in the gene-disease mapping strategy [Li & 
Loos, 2008]. Knowledge of the LD structure makes it possible to select tag SNPs that 
represent the whole region of interest. Instead of genotyping all SNPs in a region, only 
some selected tag SNPs are genotyped with the advantage of saving time and money 
(Figure 1.8). When the association 
study is performed it is therefore 
not known if it is the tag SNP itself 
or the SNPs that it represents that 
is causative [reviewed in 
Hirschhorn & Daly, 2005].  
 
Box number 1.1 HapMap genotyping 
The genotyping in HapMap was done in 270 
individuals from four populations: 
1) Utah residents with Northern and Western 
European ancestry (n = 90) 
2) Yoruba people from Nigeria (n = 90) 
3) Han Chinese from Beijing (n = 45) 
4) Japanese from Toyko (n = 45) 
Box 1.2. LD 
LD occurs when two or more genetic variants are 
collectively inherited more often than by change. Two 
polymorphic sites are said to be in LD when their specific 
alleles are correlated in a population. The LD between 
many neigboring SNPs generally persists because meiotic 
recombination does not occur at random but is 
concentrated in recombination hot spots [Gabriel et al., 
2002]. The degree of LD is estimated by r2 or D`, which 
are both ranging from 0, indicating no LD, to 1, indicating 
that the two SNPs are in complete LD [reviewed in 
Manolio et al., 2008].  
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1.6.2 Advantages and disadvantages of different study 
strategies 
Linkage analysis and association studies each have their own strengths. Linkage 
analyses are more powerful than association analysis when identifying rare risk alleles 
with high penetrance. Furthermore, the analysis is not restricted to already identified 
SNPs or genes as the analysis results in the narrowing of a chromosomal region 
[Carlson et al., 2004]. 
Association analyses are more powerful for detection of common disease alleles that 
confer modest disease risk because the pattern of allele sharing between unrelated 
individuals is more striking than the pattern of alleles sharing among affected 
individuals within pedigrees (Figure 1.9) [Carlson et al., 2004].  
 
 
Figure 1.8. Selection of tagging SNPs.  
a) Four versions of a DNA string from different people with three SNPs. 
b) Different haplotypes, which is made up of a particular combination of alleles at nearby SNPs. 
Shown here are the observed genotypes for 20 SNPs that extend across 6,000 bases of DNA. 
Only the variable SNPs are shown,including the there SNPs that are shown in panel a.  
c) Three tag SNPs identified within haplotypes that uniquely identify the haplotypes. By 
genotyping the three tag SNPs shown in this figure it is possible to identify which of the 
haplotypes shown here that are present in each individual [The International HapMap project, 
2007]. 
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One obstacle for linkage studies is the late onset of T2D which prevents the collection 
of multigenerational families. Candidate gene studies will remain a valuable approach 
because they allow for more detailed analyses of biologically relevant candidates in 
interaction with other genes and environmental factors. GWA studies require higher 
density of the genotyped SNPs than of the micro satellite markers in the linkage 
analysis. A GWA study requires hundreds of thousands of SNPs while linkage studies 
generally require fewer than 500 markers across the genome [Carlson et al., 2004]. 
1.6.3 Methodological issues 
Performing an association study aiming to identify genetic variants predisposing to a 
disease, the study has to be well powered as it reduces the risk of false positives. The 
power of a study is the probability of successfully detecting an effect of a particular 
size. Power depends primarily on the magnitude of the effect, upon sample size, the 
strength of LD with a marker, the frequency of the disease susceptibility allele and the 
required level of statistical significance [Purcell et al., 2003; Palmer & Cardon, 2005]. 
Furthermore, inadequate phenotype characterisation, genotyping errors, effect size of 
the susceptibility locus influences the results of the study [Zondervan & Cardon, 
2004]. 
GWA studies that include a large number of individuals have a high power; however, 
the change of obtaining false positives is still present. On the other side it is also 
Figure 1.9. Optimal mapping strategies for different types of disease loci. The figure illustrates 
the relatively efficiency of two primary trait-mapping approaches. Generally tests of association 
are more powerful than linkage studies when the predisposing variant is frequent [Ardlie et al., 
2002].  
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possible in GWA studies to miss true findings. When replication of an initial study fails 
to be replicated this might be due a to false-positive finding (type 1 error) or false-
negative associations (type 2 error) in the replication study [Lohmueller et al., 2003].  
Meta-analyses are studies that combine results and estimate an overall risk. This way 
of raising the total number of individuals is a way of overcoming lack of statistical 
power. Unfortunately, heterogeneity between study populations is a problem. The 
degree of heterogeneity between the studies included in a meta-analysis is tested 
which might result in a high degree of heterogeneity and the meta-analysis is not 
reliable. Moreover, the risk of publication bias might be present [Lohueller et al., 
2003] and a meta-analysis should only be considered an alternative and not a 
substitution for a well-designed initial association study.  
Finally, epistasis, the synergistical effect of two or more loci on the susceptibility for a 
trait, is very important when examining the genetic mechanism underlying a complex 
disease. Thus, if epistasis is present the impact of a susceptibility locus on a trait may 
be masked or altered by the effect of another locus which may lead to a reduction in 
the statistical power to detect the true susceptibility locus [Cambien & Tiret, 2007]. 
1.6.4 Genetic variants predisposing to type 2 diabetes 
Given the high heritability and public health importance of T2D, the identification of 
the underlying genes has been a high-priority mission of the scientific community for 
many years as it may provide information of importance for prevention of the disease 
and improve the treatment.  
Genes predisposing to T2D can affect the progression of the disease at many stages. 
Variants interacting with risk factors for T2D such as smoking, 
low birthweight or obesity may also have an impact on T2D; 
however, genes directly involved in the pathogenesis 
of the disease are more intensively studied. Among 
these are genes involved in insulin resistance and 
insulin secretion. The heritability of insulin secretion 
is 67 % [Elbein et al., 1999]. Several studies of the 
insulin secretory capacity of glucose-tolerant 
individuals with predisposing ethnicity or a family 
history of T2D have indicated that β-cell dysfunction 
occurs in genetically predisposed individuals with 
normal glucose tolerance well before the onset of 
overt diabetes [Wajchenberg, 2007]. 
Box number 1.3. Heriability 
Heritability is the proportion of 
phenotype variation in a 
population that is attributable to 
genetic variation among 
individuals. Variation among 
individuals may be due to 
gentic and/or environment 
factors [Kempthorne 1957]. 
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At present 17 genes are considered to be validated T2D susceptible genes. Four of 
these, PPAR, KCNJ11, 
TCF2, WFS1 have been 
identified using candidate 
gene approach [for 
references see Table 1.2] 
and only KCNJ11 and 
PPARG have been 
consistently replicated in 
GWA studies as well 
[Saxena et al., 2006]. 
TCF7L2 having the 
strongest diabetogenic 
effect has been identified 
by fine-mapping of linkage 
peak [Grant et al., 2006]. 
The odds ratio (OR) per 
allele for TCF7L2 is 
substantially higher than 
for the other identified variants. Thus, TCF7L2 is the most important T2D locus 
identified to date [reviewed in Frayling et al., 2007b]. It seems that the predominant 
effect of the majority of genes involved in T2D is to disrupt the pancreatic β-cell 
function rather than influencing insulin sensitivity [reviewed in Lindgren & McCarthy, 
2008]. The remaining genes have been identified in GWA studies and subsequent 
meta-analyses. Many of the genes are involved in β-cell function and not in insulin 
action. The contribution of each common variant is modest (OR = 1.1 - 1.4), and 
identified variants explain only a fraction of the disease pathogenesis. The genes 
and/or regions shown to be associated with T2D are listed in (Table 1.2). 
 
  
SNP/ 
type of 
variant(s) 
Gene 
Major/mi
-nor 
allele 
Discovery 
method 
Function / 
Characteristics 
Odds ratio 
(per 
allele) 
References 
rs1801282/  
Non- 
synony-
mous 
PPARG  
C/G 
 
Candidate-
gene study 
Transcription factor 
involved in adipocyte 
differentiation and 
function  
1.14 
(1.08-1.20) 
Deeb et al. 1998; 
Scott et al. 2007; 
WTCCC 2007; Saxena 
et al. 2007 
rs5215/  
Non- 
synony-
mous 
KCNJ11 
T/C 
Candidate-
gene study 
Subunit of the ATP-
sensitive K+ channel, 
crucial for glucose-
induced insulin secretion  
1.14 
(1.10-1.19) 
Gloyn et al. 2003; 
Nielsen et al. 2003; 
Scott et al. 2007; 
WTCCC 2007, Saxena 
Table 1.2. Confirmed gene regions involved in T2D. 
Box number 1.4: Odds ratio and meta-analysis 
OR is a messure of effect size. It is defined as the ratio of the odds of an 
event occurring in one group to the odds of it occurring in the other group 
or to a sample-based estimate of that. 
If the probabilities of the event in each groups are p (first group) and q 
(second group), then the odds ratio is: 
)1(
)1(
)1(
)1(
pq
qp
q
q
q
p
−
−
=
−
−
 
An odds ratio of 1 indicates that the event under study is equally likely in 
both groups, whereas an odds ratio > 1 indicates that the event is more 
likely in the first group and an adda ratio < 1 indicates that the condition is 
less likely in the first group. 
Meta-analysis combines the results of several studies that address a set of 
related research hypotheses. 
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SNP/ 
type of 
variant(s) 
Gene 
Major/mi
-nor 
allele 
Discovery 
method 
Function / 
Characteristics 
Odds ratio 
(per 
allele) 
References 
et al. 2007 
rs7901695/ 
Intronic 
TCF7L2 
C/T 
Fine-
mapping  
of linkage 
peak 
Transcription factor 
influencing on insulin and 
glucagon secretion 
1.37 
(1.31-1.43) 
Grant et al. 2006; 
Sladek et al. 2007; 
Scott et al. 2007; 
WTCCC 2007 
rs4430796/ 
Intronic 
TCF2 
G/A 
Candidate-
gene study 
Transcription factor 
involved in pancreatic 
development 
1.10 
(1.07-1.14) 
Gudmundsson et al. 
2007; Winckler et al. 
2007 
rs10010131
/ 
Intronic 
WFS1 
G/A 
Candidate-
gene study 
Critical for survival and 
function of pancreatic β-
cell  
1.11 
(1.08-1.16) 
Sandhu et al. 2007 
rs5015480 
rs1111875/ 
Intergenic 
HHEX- 
IDE 
C/T 
GWA HHEX, involved in 
pancreatic development; 
IDE, may affect insulin 
action or secretion 
1.15 
(1.10-1.19) 
Sladek et al. 2007; 
Scott et al. 2007; 
WTCCC 2007; Saxena 
et al. 2007; Zeggini et 
al. 2007 
rs13266634
/ 
Non-
synonymous  
 
SLC30A8 
C/T 
GWA Zinc transporter 
expressed in secretory 
vesicles of β-cells, 
implicated in the final 
stages of insulin 
biosynthesis 
1.15 
(1.12-1.19) 
Sladek et al. 2007; 
Scott et al. 2007; 
Saxena et al. 2007; 
Steinthorsdottir et al. 
2007; Zeggini et al. 
2007 
rs10946398
/ 
Intronic 
CDKAL1 
A/C 
GWA Possible effect on 
pancreatic β-cell 
development, 
regeneration and function  
1.14 
(1.11-1.17) 
Scott et al. 2007; 
WTCCC 2007; Saxena 
et al. 2007; 
Steinthorsdottir et al. 
2007; Zeggini et al. 
2007 
rs10811661 
rs564398/ 
Intergenic 
CDKN2A-
2B 
T/C 
GWA Possible effect in 
pancreatic β-cell 
development, and 
function 
1.20 
(1.14-1.25) 
Scott et al. 2007, 
WTCCC 2007; Saxena 
et al. 2007; Zeggini et 
al. 2007 
rs4402960/ 
Intronic 
IGFBP2 
G/C 
GWA Involved in translation of 
IGF2 involved in 
development growth and 
stimulation of insulin 
action  
1.14 
(1.11-1.18) 
Scott et al. 2007; 
WTCCC 2007; Saxena 
et al. 2007; Zeggini et 
al. 2007 
rs9939609/ 
Intronic 
FTO 
T/A 
GWA Affects type 2 diabetes 
via obesity 
1.17 
(1.12-1.22) 
Frayling et al. 2007a; 
Scuteri et al. 2007; 
Hinney et al. 2007; 
Scott et al. 2007 
rs864745/ 
Intronic 
JAZF1 
T/C 
Meta-
analysis of 
GWA 
The biological link to type 
2 diabetes is unknown 
1.10  
(1.07-1.13) 
Zeggini et al. 2008 
rs12779790
/Intergenic 
CDC123-
CAMK1D 
A/G 
 
Meta-
analysis of 
GWA 
The biological link to type 
2 diabetes is unknown 
1.10 
(1.07-1.14) 
Zeggini et al. 2008 
rs7961581/ 
Intronic 
TSPAN8-
LGR5 
T/C 
Meta-
analysis of 
GWA 
The biological link to type 
2 diabetes is unknown 
1.09 
(1.06-1.12) 
Zeggini et al. 2008 
rs7578597/ 
Non-
synomous 
THADA 
T/C 
Meta-
analysis of 
GWA 
The biological link to type 
2 diabetes is unknown 
1.15 
 (1.10-1.20) 
Zeggini et al. 2008 
rs4607103/ 
Intergenic 
ADAMTS9 
C/T 
Meta-
analysis of 
GWA 
The biological link to type 
2 diabetes is unknown 
1.09  
(1.06-1.12) 
Zeggini et al. 2008 
rs10923931
/Intronic 
NOTCH2 
G/T 
Meta-
analysis of 
GWA 
The biological link to type 
2 diabetes is unknown 
1.13  
(1.08-1.17) 
Zeggini et al. 2008 
Major/minor allele is taken from the genotyping in people from Northern and Western European. 
Based on data from Lindgren & McCarthy 2008, and Zeggini et al. 2008. Odds ratios are based 
on the current available data. Only initial reference and initial/confirming GWA references. 
WTCCC: The Welcome Trust Case Control Consortium  
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There has not been complete consensus in the GWA studies and it has not been 
possible to replicate several of the initial hits [McCarthy et al., 2008]. On the contrary, 
some of the validated associations, PPARG and KCNJ11 were only paid attention in 
Phase I GWA studies because it was found in the Welcome Trust Case Control 
consortium (WTCCC) in 2007 [WTCCC, 2007]. The WTCCC is a collaboration of 24 
leading human geneticists who analyse thousands of DNA samples from patients with 
different diseases with the aim to identify common genetic variation for each condition 
[WTCCC, 2007]. 
1.6.5 Genetic variants predisposing to obesity 
The linkage and candidate gene approaches have identified new genes and QTLs for 
obesity-related traits; however, only few have been convincingly confirmed. The latest 
update of the Human Obesity Gene Map, which covers the literature available at the 
end of October, 2005 reports 127 candidate genes that show associations with 
obesity-related traits [Rankinen et al., 2006]. Among those, findings for 12 genes, 
including UCP2 were replicated in 10 or more studies. Even though many replications 
of the findings are made, many other studies has shown no or even the opposite 
association and the function of the genes remains unclear.  
Mutations in genes which are involved in appetite regulation can cause obesity. Rare 
monogenic recessive forms of human obesity have been identified in the genes that 
encode leptin, the leptin receptor (LEPR), prohormone convertase 1 and 
proopiomelancortin (POMC). They all result in a phenotype with an excessive energy 
intake relative to energy expenditure. Syndromic forms of obesity also exist, at least 
20 rare syndromes are caused by discrete genetic defects or chromosomal 
abnormalities and both autosomal and X-linked syndromes are characterised by 
obesity. Several GWA studies for both T2D and obesity have identified FTO as a 
common obesity susceptible gene [Frayling et al. 2007a; Hinney et al. 2007] and FTO 
is the first validated common obesity gene. The gene regions associated with obesity 
is shown in table 1.3. 
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Table 1.3. Confirmed gene regions involved in obesity, identified in GWA studies. 
SNP Location Gene 
Major/
minor 
allele 
Function / 
Characteristics 
Odds ratio 
(per allele) 
References Replication 
rs7566605 Intergeni
c 
INSIG2 
G/C 
Involved in 
adipocyte 
Metabolism 
1.22  
(1.05-1.42) 
Herbert et al. 
2006; 
Liu et al. 2008 
Inconsistent
e 
rs9939609 Intergeni
c 
FTO 
G/C 
Unknown function, 
influences on BMI 
1.17 
(1.12-1.22) 
Frayling et al. 
2007a; 
Scuteri et al. 
2007; Hinney 
et al. 2007; 
Scott et al. 
2007 
Validated in  
Caucasians 
rs6602024 
 
Intronic PFKP 
G/C 
Subunit of 
phosphofructokinas
e, a critical enzyme 
of glycolysis 
Not provided Scuteri et al. 
2007; Liu et 
al. 2008 
No attempts 
to my 
knowledge 
rs6013029 Intronic CTNNBL1 
G/T 
Unknown function, 
possible role in 
adipogenesis  
1.42 
(1.14-1.77) 
Liu et al. 2008 No attempts 
to my 
knowledge 
rs1778231
3 
Intergeni
c 
MC4R 
T/C 
Regulates appetite 
in combination with 
leptin 
1.3 (1.20-1.41) Loos et al., 
2008  
- 
Monogenic forms of obesity are rare; however, deficiency of the melanocortin-4 
receptor (MC4R) is the most frequent cause of genetic obesity [Bell et al., 2005] and 
deficiency of the MC4R is present in 1-6 % of obese individuals depending on ethnicity 
, with a higher prevalence in cases with increased severity and earlier age of onset. 
Loss of function mutations in MC4R cause severe familial forms of obesity [Vaisse et 
al., 1998, Yeo et al., 1998] and infrequent gain of function polymorphisms have been 
associated with protection against obesity [Geller et al., 2004; Stutzmann et al., 
2007]. In a recent GWA study association of common variants near the MC4R with fat 
mass, weight, and risk of obesity has been established [Loos et al., 2008]. 
Odds ratios given for the first published GWA study, Only GWA references are included, ORsare 
calculated based the current available data [reviewed in Frayling et al., 2007b]. 
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2 Study I: Analysis of association of 
polymorphisms rs1535435 and 
rs9494266 in AHI1 with type 2 diabetes 
The Abelson helper integration site 1 (AHI1) has been associated with T2D in four 
different white populations in a GWA study of Diagen consortium including 500 cases 
and 497 controls; Eastern Finns, Ashkenazi Jews, Germans, and English individuals 
[Salonen et al., 2007]. The ten SNPs showing the lowest p-values in the GWA study, 
including SNPs located in AHI1, MYO10, and TTC7B, were selected for replication in a 
case-control setting.  
The minor alleles of rs1535435 and rs9494266 located in AHI1 were associated with 
T2D in the GWA study, OR = 2.3, p = 2  10-5 and OR = 2.3, p = and 3  10-5, 
respectively, and they were also associated with T2D in the replication case-control 
setting, OR = 3.6, p = 5 10-5 and OR = 3.6, p = 2  10-4, respectively. These two 
variants are present in the same haplotype and were the only variants that reached 
the statistical significance level of 0.05 after adjustment for multiple testing 
(Bonferroni correction). Since AHI1 is found on chromosome 6q23.3 in close proximity 
with regions that have previously shown suggestive linkage to T2D as well as fasting 
insulin and lipid concentrations, it was proposed to be a novel T2D susceptible gene 
[Xiang et al., 2004; Silander et al., 2004; Shtir et al., 2007; Ghosh et al., 2000; 
Duggirala et al., 2001]. 
 
Figur 2.1. LD plot showing the high LD between rs1535435 and rs9494266 
AHI1 encodes the jouberin protein [Dixon-Salazar et al., 2004]. The exact function of 
jouberin has not yet been clarified; however, AHI1 is strongly expressed in the 
embryonic hindbrain and forebrain indicating that AHI1 is required for both cerebellum 
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and cortical development in humans [Dixon-Salazar et al., 2004]. Similarly, it has 
been shown that the expression of AHI1 in mice and humans is highest in the most 
primitive haematopoietic cells and down-regulated during early differentiation. 
Perturbation in AHI1 expression may contribute to the development of specific types 
of leukaemia, e.g. elevated AHI1 mRNA levels are found in chronic myeloid leukaemia 
patients [Jiang et al., 2004]. HOXA9 is one of the important genes in the pathogenesis 
of chronic myeloid leukaemia, but it needs cooperative genes for the pathogenesis. 
AHI1 has been suggested to be one of these cooperative genes as it is located close to 
a known retroviral integration site [Jin et al., 2007]. AHI1 was first identified to be 
associated with the joubert syndrome, which is an autosomal recessive disorder 
characterised by hypotonia, ataxia, mental retardation, altered respiratory pattern, 
abnormal eye movement, agenesis of the cerebellar vermis, and brain malfunction 
known as the molar tooth sign [Joubert et al., 1969; Ferland et al., 2004]. Individuals 
carrying mutations in AHI1 may be at risk of developing both retinal dystrophy and 
renal cystic disease in joubert syndrome [Parisi et al., 2007].  Moreover, AHI1 was 
shown to contribute to schizophrenia in populations of Israeli-Arab and Icelandic origin 
[Ingason et al., 2007; Amann-Zalcenstein et al., 2006; Levi et al., 2005; Lerer et al., 
2003].  
The association with schizophrenia [Ingason et al., 2007; Amann-Zalcenstein et al., 
2006; Levi et al., 205; Lerer et al., 2003] and the known increased incidence of T2D in 
people diagnosed with schizophrenia [Brown et al., 2000] might suggest that AHI1is 
involved in the pathogenesis of T2D. 
2.1 Aim 
The aim of this study was to replicate the association of the two variants in AHII, 
rs1535435 and rs9494266, with T2D in a larger study population comprising 9,154 
individuals and, furthermore, to explore the possible association of rs1535435 and 
rs9494266 with prediabetic quantitative traits.  
2.2 Populations and methods  
rs1535435 and rs9494266 were genotyped in 17,521 Danes. Participants from the 
population-based Inter99 cohort involving 6,162 individuals were characterised by an 
OGTT as having normal glucose tolerance (n = 4,567), impaired fasting glycaemia 
(IFG; n = 508), impaired glucose tolerance (IGT; n = 707) or screen-detected T2D (n 
= 256) and were investigated for an association between genotype and quantitative 
metabolic traits; 124 had known T2D and were excluded prior to these analyses. An 
additional 377 individuals recruited from a population-based sample of young, healthy 
Danish individuals at the Research Centre for Prevention and Health and 8,428 
individuals recruited from the ADDITION study sampled through the Department of 
General Practice at University of Aarhus were enrolled to study metabolic traits. 
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The case-control study included all unrelated T2D patients and healthy glucose-
tolerant control individuals from the Inter99 cohort (patients n = 380, control 
individuals n = 4,567), the Danish ADDITION study (patients n = 1,617; all screen-
detected and untreated), and individuals recruited from the outpatient clinic at Steno 
Diabetes Center (patients n = 2,107 control individuals n = 483). Detailed descriptions 
of the participants can be found in appendix 1. In brief, impaired glucose homeostasis 
(IFG, IGT and diabetes) was defined according to WHO criteria after a 75 g OGTT 
[Alberti et al., 1999]. All participants were of Danish nationality and were provided 
informed written consent before participation. The study was approved by the Ethical 
Committees of Copenhagen and Aarhus and was in accordance with the principles of 
the Helsinki Declaration II.  
Genotyping 
The AHI1 variants rs1535435 and rs9494266 were genotyped using an allelic 
discrimination assay performed with a TaqMan®, ABI 7900 HT system (performed at 
KBiosciences, U.K.) with a success rate > 96.8%. Discordance was < 0.1 % as judged 
from re-genotyping of 1,202 random duplicate samples. Further description of allelic 
discrimination can be found in appendix III.  
Statistical analyses 
Fisher’s exact test and logistic regression analyses were used to analyse differences in 
allele and genotype frequencies between patients and controls; analyses were 
adjusted for age, sex, and BMI. A general linear model was used to test quantitative 
variables for genotype differences adjusting for age, sex, BMI, and diabetes status (0 
vs. 1 variable) in analyses of the complete cohort. Meta-analyses of published data for 
the putative association between rs1535435 or rs9494266 and T2D were performed 
using a Mantel-Haenszel test to estimate the combined OR of these studies. Power 
was calculated using the Genetic Power Calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/) [Purcell et al., 2003] where T2D 
prevalence was 10 % and with a relative risk of 1.15 (as described in the replication 
sample in the original article) [Salonen et al., 2007]. The statistical analyses were 
performed using RGui version 2.7.1 (available at www.r-project.org). p-values were 
not adjusted for multiple hypothesis testing. 
2.3 Results 
rs1535435 and rs9494266 were genotyped in 17,521 Danish individuals previously 
used to replicate the associations of variants in HHEX, CDKN2A/B, IGF2BP2 [Grarup et 
al., 2007], and GCKR [Sparsø et al., 2008] with T2D. We performed a case-control study 
investigating the association between T2D and the two SNPs in 4,104 patients and 
5,050 glucose-tolerant controls.  
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There were no differences in our allele frequencies of 8.4 % and 8.5 % and the 
originally published results [Salonen et al., 2007]. Furthermore, the data obeyed 
Hardy-Weinberg equilibrium (p > 0.05), D′ and r2 values (D′ = 0.99; r2 = 0.97) 
between rs1535435 and rs9494266 were in accordance with the data of Salonen et 
al., and the power to reject the null hypothesis was estimated to about 85 % 
assuming an additive model. 
We found no significant differences our genotype distribution or MAF between T2D 
patients and glucose-tolerant controls for rs1535435 and rs9494266 in this case-
control study with ORs (ORadd = 1.0 (95 % CI 0.9 -1.2); padd = 0.7 and ORadd = 1.1 
(0.9 - 1.2); padd = 0.4), respectively. The results of the case-control study are shown 
in Table 2.1.  
rs1535435 GG GA AA ORAAa pAA ORadd padd ORdom pdomβ ORrec pred 
NGT n 
(%) 
4019  
(84) 
731 
(15) 
40  
(1) 
1.0 
(0.9-1.1) 
0.8 1.0  
(0.9-1.1) 
 
0.7 1.0  
(0.9-1.2) 
 
0.6 0.9 
 (0.4-1.9) 
 
0.8 
T2D n 
(%) 
3228  
(84) 
594 
(15) 
25 
 (1) 
Rs9494266            
NGT n 
(%) 
3,971 
 (84) 
729 
(15) 
35 
(1) 
0.9-1.1 
 
1.0 1.1 
(0.9-1.2) 
 
0.4 1.1  
(0.9- 1.3) 
0.5 1.2  
(0.6-2.6) 
 
0.6 
T2D n 
(%) 
3,222 598 
(15) 
26 
(1) 
        
Analyses examine the rs1535435 and rs9494266 polymorphisms for an association 
with T2D-related quantitative traits in Inter99 were performed in 6,038 participants. 
We found no strong association between rs1535435 and T2D-related traits. Assuming 
an additive model, the A-allele was nominally associated with an increased serum C-
peptide and serum insulin concentrations at 120 minutes during an OGTT, padd = 0.01 
and padd = 0.004, respectively (Table 2.2). Increased area under the curve (AUC) for 
serum insulin, plasma glucose, and serum C-peptide concentrations were also found, 
padd = 0.05, padd = 0.04, padd = 0.03, respectively.  
Table 2.1 Case-control study of type 2 diabetes in 4,104 type 2 diabetes patients and 5,050 
glucose-tolerant controls. 
Allele association is not adjusted for age, sex, and BMI. Calculated p-values were adjusted for 
age, sex, and BMI assuming an additive (padd), dominant (pdom) or a recessive (prec) model.  
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Rs1535435       AA AG GG Add Dom Res 
N (men/women) 4,756 
(2,337/2,419) 
865 (4,63/402) 52 (28/24)    
Age (years) 46 ± 8 46 ± 8 47 ± 8    
BMI (kg/m2) 26.2 ± 5.0 26.2 ± 4.6 25.4 ± 4.3 0.3 0.5 0.1 
Waist-to-hip ratio 0.86 ± 0.09 0.86 ± 0.09 0.86 ± 0.09 0.8 0.8 0.9 
Waist circumference (cm) 86 ± 13 87 ± 13 84 ± 13 0.4 0.6 0.2 
Height (cm) 172 ± 9.0 173 ± 9.0 171 ± 8 0.2 0.4 0.09 
Plasma glucose (mmol/l)       
Fasting 5.5 ± 0.8 5.6 ± 0.9 5.4 ± 0.5 0.5 0.8 0.08 
30-min during an OGTT 8.7 ± 1.9 8.8 ± 1.9 8.8 ± 1.5 0.4 0.4 0.7 
120-min during an OGTT 6.2 ± 2.1 6.3 ± 2.3 6.1 ± 1.7 0.08 0.06 0.8 
AUCglucose (mmol  min) 219 ± 135 229 ± 139 235 ± 120 0.04 0.04 0.4 
Serum insulin (pmol/l)       
Fasting 42 ± 28 43 ± 28 38 ± 23 0.5 0.4 0.8 
30-min during anOGTT 289 ± 178 303 ± 214 261 ± 181 0.4 0.2 0.4 
120-min during an OGTT 215 ± 208 224 ± 224 264 ± 320 0.01 0.02 0.2 
AUCinsulin (pmol  min) 22,706 ± 15,376 23,972 ± 18,119 23,529 ± 22,512 0.05 0.04 0.9 
C-peptide (pmol/l) ................................      
Fasting 594 ± 270 605 ± 279 569 ± 256 0.4 0.4 0.8 
30-min during an OGTT 1,994 ± 710 2,037 ± 755 1,898 ± 719 0.4 0.2 0.5 
120-min druing an OGTT 2,301 ± 1,016 2364 ± 1,010 2,485 ± 1,209 0.004 0.009 0.2 
Incremental AUC (pmol/l) 160,611 ± 57,156 165,031 ± 60,784 166,450 ± 68,274 0.03 0.03 0.05 
Fasting serum lipids (mmol/l)       
Total cholesterol 5.5 ± 1.1 5.5 ± 1.0 5.4 ± 1.1 0.2 0.2 0.5 
HDL-cholesterol 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 0.4 0.4 0.8 
Triglyceride 1.3 ± 1.4 1.4 ± 1.2 1.3 ± 0.9 0.5 0.5 0.9 
HOMA-IR (mmol/l  mmol/l) 10.5 ± 8.0 10.8 ± 8.0 9.4 ± 5.9 0.6 0.5 0.4 
 
We found no strong association between T2D-related traits and rs9494266. Carriers of the minor A-allele had 
significantly increased serum insulin and C-peptide levels at 120 min during an OGTTs, padd = 0.1 and padd = 
0.004, respectively, assuming an additive model (Table 3). Furthermore, we found increased AUC for p-
glucose, padd = 0.1 (Table 2.3).  
Table 2.2. Analysis of association for rs1535435 for T2D–related quantitative traits. 
Data are means ± SD. Inter 99, calculated p-values were adjusted for age, sex, and BMI. 
Individuals are both sexes: NGT (n = 4,522), IFG (n = 503), IGT (693), and screen-detected. 
Values were logarithmically transformed before analyses. Calculated p-values were adjusted for 
age, sex, and BMI assuming an additive (padd), dominant (pdom) or a recessive (prec) model.   
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rs9494266       AA AG GG Add Dom Res 
N (men/women) 4,689 (2303/2386) 865 (465/400) 47 (27/20)    
Age (years) 46 ± 8.0 46 ± 8.0 47 ± 7    
BMI (kg/m2) 26.2 ± 4.5 26.2 ± 4.7 25.3 ± 4.3 0.3 0.4 0.1 
Waist-to-hip ratio 0.85 ± 0.09 0.86 ± 0.09 0.86 ± 0.09 0.9 1 0.8 
Waist circumference (cm) 86 ± 13 87 ± 13 84 ± 14 0.32 0.5 0.07 
Height (cm) 172 ± 9.0 0173 ± 9.0 171 ± 8 0.13 0.3 0.04 
Plasma glucose (mmol/l)       
Fasting 5.5 ± 0.8 5.6 ± 0.9 5.4 ± 0.5 0.6 0.8 0.1 
30-min during an OGTT 8.7 ± 1.9 8.8 ± 2 8.8 ± 1.5 0.31 0.4 0.5 
120-min during an OGTT 6.2 ± 2.1 6.4 ± 2.4 6.1 ± 1.6 0.03 0.03 0.6 
AUCglucose (mmol  min) 218 ± 134 230 ± 141 237 ± 104 0.01 0.02 0.3 
Serum insulin (pmol/l)       
Fasting 42 ± 28 43 ± 29 39 ± 23 0.4 0.3 0.5 
30-min during an OGTT 288 ± 175 302 ± 216 261 ± 184 0.5 0.4 0.3 
120-min during an OGTT 214 ± 205 224 ± 225 238 ± 289 0.02 0.02 0.04 
InsulinAUC (pmol  min) 22,633 ± 15,144 23,861 ± 18,165 22,367 ± 
21,410 
0.1 0.09 0.9 
C-peptide (pmol/l)       
Fasting 594 ± 270 608 ± 295 533 ± 250 0.5 0.4 0.4 
30-min during an OGTT 1994 ± 707 2,029 ± 758 1,882 ± 752 0.7 0.47 0.3 
120-min during an OGTT 2,295 ± 1,011 2,351 ± 1,004 2,375 ± 1,123 0.02 0.02 0.4 
Incremental AUC (pmol/l) 160,332 ± 56,784 16,3716 ± 
60,999 
162,292 ± 
66,568 
0.09 0.08 0.7 
Fasting serum lipids       
Total Cholesterol 5.5 ± 1.1 5.5 ± 1.0  5.3 ±1.1   0.3 0.2 0.3 
HDL-cholesterol 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 0.8 0.6 0.6 
Triglyceride 1.3 ± 1.4 1.4 ± 1.3 1.3 ± 0.9 0.7 0.6 0.8 
HOMA-IR (mmol/l  mmol/l) 10.5 ± 8 10.9 ± 8.3 9.4 ± 6 0.5 0.4 0.59 
Meta-analysis 
We performed meta-analyses for rs1535435 and rs9494266 combining all available 
data. At present, data for rs1535435 and rs9494266 investigating the putative 
association with T2D is only available from WTCCC [Zeggini et al., 2007], Diabetes 
Genetics Initiative (DGI) [Saxena et al., 2007] and our study. Only the Diagen 
consortium has shown an association with T2D; however, neither their data from were 
available for our meta-analysis nor were data for rs1515435 from the DGI study.  
The meta-analyses did not support an association with T2D: ORadd = 0.97, (0.89 - 
1.06); p = 0.6 and ORadd = 0.98 (0.91 - 1.06); p = 0.6), respectively (Figure 2.2). 
Table 2.3 Analysis of association for rs9494266 for T2D–related quantitative traits
Data are means ± SD. Inter 99, calculated p-values were adjusted for age, sex, and BMI. 
Individuals are both sexes: NGT (n = 4,522), IFG (n = 503), IGT (693), and screen-detected. 
Values were logarithmically transformed before analyses. Calculated p-values were adjusted for 
age, sex, and BMI assuming an additive (padd), dominant (pdom) or a recessive (prec) model.  
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2.4 Discussion 
In the present study we investigated the putative association of rs1535435 and 
rs9494266 with T2D in a large case-control setting as well as a possible association 
with T2D-related quantitative traits in a population-based sample of Danes. 
Previously, these two SNPs were associated with T2D [Salonen et al., 2007]. We were 
not able to replicate this association in the present study; however, we found a 
nominal association of rs1535435 and rs9494266 with serum insulin and C-peptide 
concentrations 120 min post oral glucose load during an OGTT. Furthermore, nominal 
associations with decreased LDL, increased AUC plasma glucose and serum C-peptide 
concentrations were shown for the two SNPs, but considering the numbers of tests 
performed, the findings are likely to be false positives as they should be corrected for 
multiple hypothesis testing.  
To date, the GWA study of Diagen consortium is the only GWA study of T2D which has 
shown a significant association at this locus; however, because of the strong p-values 
in the replication study and that 6q23.3 is in close proximity with regions that have 
Figure 2.2. Meta-analysis of a) rs9494266 and b) rs1535435 combining all available data for 
the two SNPs in relation to T2D. Data are OR vs. GG. Imputed data for rs1535435 were 
available from the the WTCCC [Zeggini et al., 2007], but not from the DGI study [Saxena et al., 
2007] Numbers within brackets are T2D patients and glucose-tolerant participants in the 
individual studies. 
Values are ORs with 95 % CI. For each study the vertical marking represents the OR for the 
given genotype and the horizontal line represents its 95 % CI. 
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previously shown suggestive linkage to T2D as well as fasting serum insulin and serum 
lipid concentrations [Xiang et al., 2004; Silander et al., 2004; Shtir et al., 2007; 
Ghosh et al., 2000; Duggirala et al., 2001] we examined the putative associations of 
the two SNPs with T2D.  
In the present study we were not able to replicate the initial findings of the GWA study 
of Diagen consortium in a case-control study of more than 9,000 individuals nor in a 
meta-analysis, which makes it likely that their findings were due to chance. This might 
be due to heterogeneity in their study population that consisted of four different white 
populations. Furthermore, the low power in the sample used in the GWA increases the 
likelihood for false positive findings and the p-values of 2  10-5 and 3  10-5 in the 
initial GWA are only considered borderline significant in a whole-genome context.  
Another explanation for the contradictory results is that the two polymorphisms could 
be in high LD with a causative variant in the population used in the GWA of the Diagen 
consortium of Finns, Ashkenazi Jews, Germans, and UK individuals while this is not 
necessarily the case in our population due to differences in LD bocks between different 
populations.Internal replication efforts are often biased due to errors in phenotyping 
or genotyping and population stratification which might be an explanation for the 
results in the original publication. Therefore, independent validation is of high 
importance which is what we do with this study investigating more than 17,000 
individuals.  
In conclusion, the two previously associated variants rs1535435 and rs9494266 in the 
AHI1 are not associated with T2D or related quantitative metabolic traits in Danes.  
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Study II: Analysis of he UCP2 -866G>A 
polymorphism (rs659366) with obesity, 
type 2 diabetes, and related metabolic 
traits 
Uncoupling protein 2 (UCP2) is ubiquitously expressed and there has been an ongoing 
debate about its function during the last couple of years. Four additional uncoupling 
proteins exist: UCP1, UCP3, UCP4, and UCP5. UCPs uncouple mitochondrial respiration 
from ATP production by letting H+ flux into the mitochondrial matrix instead of passing 
through the ATP-synthase [Fleury et al., 1997; reviewed in Dalgaard et al., 2001], 
which is illustrated in figure 3.1. The proteins UCP2 and UCP3 are 58 % homologous 
with UCP1 and 72 % homologous with each other; however, their functions appear to 
be very different why their names are misleading. UCP1 is exclusively expressed in 
BAT of mammals, UCP3 predominantly in skeletal muscles, and UCP4 and UCP5 are 
expressed in the brain [reviewed in Graier et al., 2008].  
 
UCP1 accounts for 10 % of the protein mass in the inner mitochondrial membrane 
whereas UCP2 and UCP3 exist in tiny concentrations, 0.01 - 0.1 %, in the 
mitochondrial membrane proteins [reviewed in Esteves & Brand, 2005]. Since UCP2 
and UCP3 also are expressed in ectodermic fish and plants that do not require 
Figure 3.1. Illustration of the function of UCP2; UCP2 is an alternative route for the protons 
which are pumped into the matrix by the electron transport chain (ETC) and thereby creating an 
electrochemical gradient, which normally pass through the ATP synthase. The ATP synthase 
uses the energy released from protons moving down the gradient to synthesise ATP.   
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thermogenesis, the proteins may have another function as well [reviewed in Graier et 
al., 2008].  
It is well accepted that UCP2 has an uncoupling function involving the regulation of 
thermogenesis and energy metabolism [Fleury et al., 1997; reviewed in Graier et al., 
2008]; however, it has been suggested that UCP2 is important for mitochondrial Ca2+ 
sequestration through the classical mitochondrial Ca2+ uniport [Trenker et al., 2007]. 
Furthermore, this Ca2+ uptake function of UCP2 and UCP3 might yield mitochondrial 
uncoupling indirectly. The uncoupling is suggested because Ca2+ acidifies the 
mitochondrial matrix and thereby increases the activity of the electron transport chain 
(ETC) without increasing the activity of the ATP synthesis. This reduces the H+ 
gradient which reduces the activity of the ATP synthase [reviewed in Graier et al., 
2008]. An increase in the activity of ETC without a corresponding increase in ATP 
production is defined as uncoupling [Skulachev, 1998]. Moreover, results from studies 
of UCP2 in Chinese hamster ovary cells have postulated UCP2 to be a carrier of ions 
other than H+ [Mozo et al., 2006]. 
UCP2 and fatty acid metabolism 
UCP2 might have a function in carrying excessive free fatty acids out of the 
mitochondria [reviewed in Graier et al., 2008]; however, most of the results have only 
been concerning UCP3. PPARs are important for the fatty acids metabolism and since 
PPARs regulate expression of UCP2 and UCP3 they might also play a role in fatty acid 
metabolism. Furthermore, the expression of UCP2 and UCP3 is up-regulated under 
conditions of high fatty acid availability, such as obesity [Millet et al., 1997], and high 
fat diet [Schrauwen et al., 2003], which also point towards a role of UCP2 in fatty acid 
metabolism. Furthermore, it has been shown that UCP2 and UCP3 are activated by 
fatty acids and blocked by nucleotides [Jezek, 1999; Brand & Esteves; 2005, Jezek, 
2002]. Another postulate is that the free fatty acids enter the mitochondria as neutral 
protonated fatty acids by a so called “flip flop” mechanism, which is associated with a 
simultaneously H+ uniport once UCP2/UCP3 exports fatty acid anions [Jaburek et al., 
2004].  
UCP2 protects against ROS damages 
There is increasing evidence that UCP2 and UCP3 also significantly serve to attenuate 
mitochondrial ROS production; however, the mechanism behind the function of UCP2 
and UCP3 is not entirely resolved and the presence of any of the UCPs has shown a 
protective effect against damages linked to ROS [Mattiasson et al., 2003; Vincent et 
al., 2004]. It is suggested that the overload of the ETC and the following production of 
ROS stimulates UCP2 leading to uncoupling, thereby reducing the production of ROS 
[reviewed in Graier et al., 2008]. 
UCP2 and insulin regulation 
Overexpression of UCP2 has been reported to inhibit glucose-stimulated insulin 
secretion in pancreatic islets from rats [Chan et al., 1999] and INS-1 β-cells 
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[Kashemsant & Chan, 2006], which proposes UCP2 to be a negative regulator for 
pancreatic insulin secretion. Knockout mice Ucp2-/- have increased circulating insulin 
levels and their isolated pancreatic islets secrete more insulin and show a higher 
ATP/ADP ratio in response to D-glucose [Zhang et al., 2001]. On a high-fat diet knock 
out mice have shown increased insulin secretion and decreased plasma triglyceride 
concentrations compared with wild type mice [Joseph et al., 2002]. Ucp2 was up-
regulated in diabetic, obese ob/ob mice in which a lack of Ucp2 restored first-phase 
insulin secretion and reduced the level of hyperglycaemia [Zhang et al. 2001]. No 
effect of Ucp2 disruption on obesity was observed, even upon a high-fat diet 
[Arsenijevic et al., 2000]. The knock out mice have also shown that ablation of ucp2 
results in slightly elevated plasma levels of inflammatory cytokines, e.g. tumor 
necrosis factor α (TNFα) or interferon γ (IFNγ) and persistent nuclear factor κB (NF-
κB) activation, which enhances β-cell function and insulin secretion [Graier et al., 
2008]. 
The UCP2 rs659366 and obesity 
UCP2 is located on chromosome 11q13 and a frequent -866G>A variant, rs659366, 
has been identified in the gene [Esterbauer et al., 2001]. This variant has been shown 
to be located in the core promoter of UCP2 [Dalgaard et al., 2003] -a region with 
putative binding sites for two β-cell transcription factors. The minor allele A of the 
rs659366 has been shown to associate with a reduced risk of obesity among 596 and 
791 white Europeans [Esterbauer et al., 2001], which has been replicated in an 
additional population of 39 obese non-diabetic white European [Krempler et al., 2002]. 
This agrees with the increased 24-hour energy expenditure shown in 83 obese Pima 
Indians [Kovacs et al., 2005] and increased resting-energy expenditure in 147 obese 
children [Le-Fur et al., 2004] and in the German population [Schäuble et al., 2003]. 
No association with obesity has been found in Spanish children and adolescents for the 
rs659366; however, the haplotype (-866G; rs659366)-(Del; 45bp)-(-55T; rs1800849) 
was significantly associated with obesity [Ochoa et al., 2007]. In 632 Japanese there 
was no association with obesity [Ji et al., 2004]. Neither in a Danish study that 
included 719 obese cases 816 controls were there any association with obesity or 
obesity-related intermediary phenotypes [Dalgaard et al., 2003] and no association 
with BMI was shown in 681 French Caucasians with T2D [Reis et al., 2004]. Among 
465 healthy, British men the AA-genotype was more prevalent among obese 
participants [Dhamrait et al., 2004]. 
No consensus has been achieved regarding the association between the variant and 
adiposity. A range of studies reported no association with levels of BMI or waist-to-hip 
ratio [Dalgaard et al., 2003; Mancini et al. 2003; Sesti et al., 2003; D´Adamo et al., 
2004; Ji et al., 2004; LeFur et al., 2004; Bulotta et al., 2005; Kovacs et al., 2005; Cha 
et al., 2007; Gable et al., 2007; Marvelle et al., 2008]. Assuming that a more subtle 
intermediary obesity-related phenotype is affected by the A-allele, a number of 
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interesting observations have been made; among French type 2 diabetic patients the 
UCP2 variant was associated with elevated triglyceride and total cholesterol 
concentrations and increased risk of dyslipidaemia [Reis et al., 2004], and in line with 
this, decreased HDL-cholesterol levels were reported among Korean women [Cha et 
al., 2007]. Contrary, a lack of association with lipid levels has also been reported 
[Mancini et al., 2003; Sesti et al., 2003; Dadamo et al., 2004; Bulotta et al., 2005]. 
Finally, 147 obese children homozygote of the A-allele had increased glucose oxidation 
rate and lower lipid oxidation rate [LeFur et al., 2004].  
The UCP2 rs659366 and T2D 
Numerous studies have investigated the UCP2 rs659366 and its putative association 
with T2D; however, these studies have also been inconsistent. The minor A-allele has 
been associated with T2D in obese white Europeans in 201 type 2 diabetic patients 
and 291 controls [Krempler et al., 2002] and in Italian women in a study that included 
483 type 2 diabetic patients and 565 controls. In Italian women the association was 
suggested to be due to decreased insulin sensitivity [D´Adamo et al., 2004]. The A-
allele has also been shown to associate with modest risk of T2D in Northern Europeans 
among 131 diabetic patients and 118 controls [Wang et al., 2004] and in agreement 
lower insulin secretion was associated with the A-allele of rs659366 in 791 white 
Europeans [Esterbauer et al., 2001]; however, subsequent studies showed no 
association [Dalgaard et al., 2003; Sesti et al., 2003; Dadamo et al., 2004; Ji et al., 
2004; Bulotta et al., 2005]. Contrary, reduced risk was found among 746 type 2 
diabetic patients and 327 controls in Caucasians from Italy [Bulotta et al., 2005], and 
in Swedes among 1,659 type 2 diabetic patients and 724 controls [Lyssenko et al., 
2005]. 
An early onset of type 2 diabetes has been related to both the A-allele [Sasahara et 
al., 2004, Gable et al., 2007] and the G-allele [Lyssenko et al., 2005]. In Japanese 
patients, A-allele carriers needed insulin therapy earlier than G-allele carriers and 
showed higher frequency of insulin therapy in 413 Japanese type 2 diabetic patients 
[Sasahara et al., 2004] and in 681 French Caucasians with T2D [Reis et al., 2004]. 
Also, a lower disposition index has been found although this may be induced by 
changes in insulin sensitivity rather than insulin secretory capacity [Krempler et al., 
2002; Sesti et al., 2003]. Indeed, increased insulin resistance assessed by a 
hyperinsulinaemic-euglycaemic clamp or an intravenous glucose tolerance test among 
A-allele carriers have been reported in some [Krempler et al., 2002; D´adamo et al., 
2004] but not all [Sesti et al., 2003; Ji et al., 2004, Ochoa et al., 2007] studies. In 
465 diabetic men the A-allele has been associated with increased oxidative stress 
[Dhamrait et al., 2004]. 
The UCP2 rs659366 and cardiovascular diseases 
In 3,122 French type 2 diabetic men the A-allele was associated with decreased risk of 
coronary artery disease [Cheurfa et al., 2008]; however, it has also been associated 
with increased risk of hypertension [Ji et al., 2004] and with increased dyslipidaemia 
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among type 2 diabetic patients in 681 French Caucasian [Reis et al., 2004]. Other 
studies have found no association with lipids [Mancini et al., 20003; D´Aadamo et al., 
Bulotta, 2005] and, furthermore, a study showed decreased HDL [Cha et al. 2007].   
Expression of UCP2 in relation to UCP2 rs659366  
It is interesting to investigate if the associations of the A-allele are correlated with 
mRNA expression; however, the results of the expression are also inconsistent. 
Increased [Esterbauer et al., 2001; Krempler et al., 2002] and decreased [Wang et al. 
2004] adipose UCP2 mRNA levels were found in adipose tissues in A-allele carriers.  
2.5 Aim 
By dissipating proton gradients, uncoupling respiration from oxidative phosphorylation 
and converting fuel to heat, UCP2 may play an important role in the regulation of 
human energy metabolism [Fleury et al., 1997. Moreover, UCP2 levels may be 
modulated by free fatty acids, and thus UCP2 may also be involved in fat and skeletal 
muscle lipid metabolism [Saleh et al., 2002]. The inconsistent studies have increased 
the importance to investigate the effect of the rs659366 variant in relation to the 
development of obesity and T2D in large scale study populations. The aim of this 
study was to investigate if the UCP2 A-allele of rs659366 is associated with type 2 
diabetes, obesity, or quantitative metabolic traits in large-scale studies of Danes.  
2.6 Populations and methods 
The UCP2 rs659366 was genotyped in 16,173 Danes comprising 1) the population-
based Inter99 sample of middle-aged Danes sampled at Research Centre for 
Prevention and Health (n = 6,163), 2) type 2 diabetic patients sampled through the 
out-patient clinic at Steno Diabetes Center (n =1,961), 3) a population-based group of 
middle-aged glucose-tolerant individuals recruited from Steno Diabetes Center (n = 
512), and 4) the ADDITION study group sampled through Department of General 
Practice at University of Aarhus (n = 7,220), and 5) population based sample of young 
healthy Danish Caucasians recruited from Research Centre for Prevention and Health 
(n = 317) who underwent a tolbutamide-modified intravenous glucose tolerance test. 
Detailed descriptions of study populations are available in appendix 1. Study groups 1 
and 3 underwent a standard 75 g oral glucose tolerance test (OGTT). Methods for 
Biochemical and anthropometrical measurements are described in appendix 1.  
Genotyping 
The UCP2 rs659366 polymorphism was genotyped using Taqman allelic discrimination 
(KBioscience, Herts, UK). Discordance between 965 random duplicate samples was 0.0 
% and the genotyping success rate was 96.9 %. All genotype groups obeyed Hardy-
Weinberg equilibrium. Further description can be found in appendix 3. 
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Statistical analyses 
Fisher’s exact test was applied to examine differences in allele frequencies and logistic 
regression with adjustment for age and sex was applied to examine differences in 
genotype distributions between affected and unaffected individuals. A general linear 
model was used to test quantitative variables for differences between genotype groups 
among non-diabetic and untreated individuals Meta-analysis of previously published data for the 
association between rs659366 and obesity as well as between rs659366 and T2D and test of homogeneity 
between studies were performed using a Mantel-Haenszel test and the combined OR of these studies were 
estimated. All analyses were performed using SPSS version 14.0 and RGui version 2.5.1. 
A p-value of less than 0.05 was considered to be significant, further description can be 
found in Appendix 2. 
2.7 Results 
The UCP2 variant located in the promoter region was genotyped in 16,173 Danish 
individuals. We carried out case control studies of obesity (BMI < 25 kg/m2 vs. BMI ≥ 
30 kg/m2) and WHO-defined type 2 diabetes. Furthermore, we investigated the 
variant for association with metabolic quantitative traits. 
To investigate if the A-allele in the rs659366 is associated with obesity we performed 
a case control study of individuals with a BMI below 25 as controls and individuals with 
a BMI above 30 as cases. The case-control study of obesity was performed separately 
for the Inter99 and ADDITION study samples. There was a nominal higher prevalence 
of the A-allele carriers in the group of cases with a BMI above 30 kg/m2; however, the 
case-control study in the ADDITION study was negative, see table 3.1. Additional 
exploratory association studies of dyslipidaemia and hypertension were all negative. 
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 N 
(men/women) 
Genotype 
distribution  
n = GG/GA/AA (%) 
MAF  
(95% CI) 
pAF pGD OR 
(95% CI) 
Middle- aged individuals (n = 4,703 )  
Controls 
BMI < 25 
kg/m2 
3,153  
(1,242/1,911) 
1,133/1,499/521 
(36/48/17) 
40.3 
(39.1 - 41.5) 
  0.91 (0.83 - 0.99) 
Cases 
BMI > 30 
kg/m2 
1,550  
(784/766) 
584/756/14  
(38/49/14) 
37.9 
(36.2 - 39.6) 
0.03 0.03  
ADDITION  (n = 4.022) 
Controls 1,567  
(697/870) 
534/799/51 
(34/51/15) 
40.4 
( 38.7 - 42.1) 
  0.99 (0.91 - 1.09) 
Obese cases 2,455  
(1,251/1,204) 
874/1183/398 
(36/48/16) 
40.3 
(38.9 - 41.7) 
0.9 0.2  
The case control study of T2D was performed using 3,214 glucose tolerant controls 
and 4,904 T2D cases. There were no differences in minor allele frequencies (MAFs) or 
genotype distributions between cases and controls (Table 3.2). 
Table 3.1. Case control study of obesity in 4,703 middle-aged individuals and in 4,022 
individuals from the ADDITION. 
Data are number of individuals with each genotype (% below) and frequencies of the minor 
allele (MAF).  
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 N 
(men/women) 
Genotype distribution  
n = GG/GA/AA (%) 
MAF  
(95% 
CI) 
pAF pGD OR 
(95% CI) 
Middle-aged individuals  (n = 8,118 ) 
 
Glucose-tolerant 
individuals 
3,214 
(1,886/1,328) 
1,158/1,546/510 
(36/48/16) 
39.9  
(38.7-
41.1) 
  1 (0.94 - 
1.06) 
 
T2D patients 
4,904  
(2,275/2,629) 
1,806/2,307/791 
(37/47/17)  
39.9 
(38.7-
40.6) 
0.5 0.6  
An analysis examining the possible association between the rs659366 variant and 
quantitative metabolic traits was conducted in a total of 5,781 treatment-naïve 
individuals from the population-based Inter99 study sample. The analysis was 
performed by applying a general linear model assuming a recessive model and 
calculated p-values were adjusted for age, sex and BMI. Significant associations with 
decreased plasma fasting glucose and serum insulin at 120-min during an OGTT were 
found. Furthermore an improved insulin sensitivity expressed as HOMA-IR was 
observed, see table 3.3. 
Table 3.2. Case control study of T2D in 4,904 T2D cases and 3,214 glucose tolerant controls 
Data are number of individulas with each genotype (% below) and frequencies of the minor A-
allele (MAF). 
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Rs659366 GG GA AA  
n (men/woman) 2,164 (1,087/1,077)) 2,694 (1,331/1,363) 923 (451/472)  
Age (years) 46 ± 8 46 ± 8 46 ± 8  
BMI (kg/m2) 26.2 ± 4.4 26.2 ± 4.6 26.1 ± 4.6 0.6 
Plasma glucose (mmol/l)     
Fasting 5.6 ± 0.9 5.5 ± 0.7 5.5 ± 0.7 0.002 
30-min post-OGTT 8.8 ± 2.0 8.6 ± 1.8 8.7 ± 1.8 0.3 
120-min post-OGTT 6.3 ± 2.2 6.2 ± 2.1 6.2 ± 2.0 0.3 
Serum insulin (pmol/l) 
Fasting 43 ± 28 41 ± 27 41 ± 28 0.02 
30-min post-OGTT 291 ± 186 291 ± 182 283 ± 175 0.3 
120-min post-OGTT 220 ± 204 219 ± 224 201 ± 184 0.005 
HOMA-IR 10.9 ± 8.1 10.4 ± 8.0 10.2 ± 7.6 0.0007 
Moreover, meta-analysis investigating association of rs659366 with obesity and T2D 
were performed. Available data and data from present studies were included. For 
obesity 9 studies were included inclusive the present studies of obesity (Steno/Inter99 
and ADDITION) [Esterbauer et al., 2001; Dalgaard et al., 2003, Schäuble et al., 2003; 
Mancini et al., 2003; Le Fur et al., 2004; Ochoa et al., 2007]. For the meta-analysis 
for T2D 6 studies were included inclusive present study (ADDITION) [Krempler et al., 
2002; Dadamo et al., 2004; Ji et al., 2004; Bulotta et al., 2005; Rai et al., 2007]. The 
meta-analysis showed a borderline protective association with obesity for the AA-
genotype, OR = 0.89 (0.80 – 1.0), p = 0.04) (Figure 3.4). The meta-analysis for T2D 
included studies that were too heterogeneity to compare them; however, they showed 
no association with T2D, OR = 0.94 (0.84 - 1.05), p = 0.3 (Figure 3.4). 
 
 
Table 3.3: Analyses of anthropometric and metabolic characteristics of 5,781 middle-aged 
Danes from Inter99.  
Data are mean ± SD.Values of serum insulin and HOMA-IR were logarithmically transformed 
before statistical analysis. p-values were adjusted for age, sex, and BMI. 
Study II 
Page 46 
Figure 3.4. To the left meta-analysis of obesity for rs659366,; OR = 0.89 (0.80 – 1.0). To the 
right meta-analysis of T2D for rs659366; OR = 0.94, 95 % CI (0.84 – 1.05). The meta-analyses 
show the OR vs GG. 
2.8 Discussion 
In the present study we were not able to demonstrate any association of the A-allele 
of UCP2 rs659366 with T2D in 8,118 middle-aged Danes; however, middle-aged A-
allele carriers had decreased fasting glucose levels, decreased insulin release, and 
improved insulin sensitivity expressed as HOMA-IR. These traits indicate that the 
variant may have a protective effect against T2D. 
In our case control study of obesity (BMI < 25 kg/m2 vs. BMI ≥ 30 kg/m2) in middle 
aged individuals we found an association with of the G-allele with obesity; however, 
we found no association with obesity in the ADDITION study. We were not able to 
deduce that the G-allele is associated with obesity; however, it might have an effect 
on obesity as other studies proposed due to our nominal finding in the middle-aged 
individuals. The observed effect of increased insulin sensitivity of the A-allele carriers 
do not agree with the decreased insulin sensitivity found in Italian women of A-allele 
carriers [D´Adamo et al., 2004] and the lower insulin secretion, which was observed 
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associated with the A-allele [Esterbaur et al., 2001]. When combining available data of 
association for rs659366 with obesity in a meta-analysis, it showed a protective 
association with obesity. A meta-analysis for rs659366 with T2D showed no 
association. 
Our results do not clarify whether the rs659366 contributes to obesity and T2D, why 
additional studies are needed to clarify the effect of the variant. The 95 % CI in the 
present study indicate however that an association of the A allele carriers with T2D 
would be modest. An indication that the variant does not contribute to the 
development of T2D is that the GWA study performed of the WTCCC, which also 
included the UCP2 rs659366 did not report any association of rs659366 with T2D. 
False positives are a general problem in association studies, but also missed true 
findings can be a problem. Furthermore, the different findings might not only be due 
to false positives or false negatives, but can also be due to differences in ethnicity. In 
different populations and especially in different ethnic groups, different patterns in LD 
blocks exist. This could be a possible explanation for the contradicting results. For 
example it is reported that the A-allele frequency is higher in Japanese compared to 
Caucasians, which might influence the results [Sasahara et al., 2004].  
A study of 3,782 women with different ethnicities investigated 14 SNPs (including 
rs659366) spanning the UCP2 and UCP3 loci [Hsu et al., 2008]. No single-SNP 
association with type 2 diabetes was observed following correction for multiple testing. 
Haplotype analysis indicated an association with increased risk for type 2 diabetes 
among 968 Caucasian women; this effect was further accentuated by overweight 
although no association with BMI was observed. The four-SNP haplotype in the study 
was in high LD with the rs659366 A-allele, suggesting that an yet unidentified 
variation covered by the haplotype-spanned area may be responsible for the observed 
relationships of the variant with metabolic variables.   
In conclusion, the A-allele of the rs659466 was not associated with obesity or T2D in 
white Danes; however, the A-allele was associated with decreased fasting glucose 
levels, decreased insulin release, and improved insulin sensitivity expressed as HOMA-
IR.  
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3 Study III: Investigation of the putative 
impact of LMNA rs4641 on RNA splicing 
and lamin A and C expression in relation 
to type 2 diabetes                                                                                      
Background 
The lamin gene (LMNA), which is located on chromosome 1q21.2 [Lin & Worman, 
1993; Wydner et al., 1996] encodes four lamins by alternative splicing: A, C, A∆10, 
and C2 [Worman & Courvalin, 2002]. The fibrous proteins, lamin A and C are co-
expressed and form a polymer integrated in the nuclear lamina [Worman & Courvalin, 
2002]; a membrane located just below the inner nuclear membrane consisting of 
lamins and nuclear lamin-associated membrane proteins. Lamins have a scaffolding 
function for several nuclear processes such as transcription, chromatin organisation, 
and DNA replication [Verstraeten 
et al., 2007]. Lamin A and C are 
shown to be very important 
physiological since mice lacking 
lamin A but not lamin C develop 
normally to term; however, after 
two-three weeks their growth 
were reduced and after four 
weeks their growth had ceased 
[Sullivan et al., 1999]. 
  
 
Different types of lamins exist; 
A-type lamins which include lamins A and C, and B-type lamins which include lamin B. 
A-type lamins are expressed in terminally differentiated cell but are largely absent 
from embryonic and adult stem cells whereas B-type lamins are encoded by LMNB1 
and LMBN2 and are expressed in all cells [Rankin & Ellard, 2006]. A-type and B-type 
lamins differ in that B-type lamins remain associated with membrane vesicles during 
mitosis while A-type lamins do not. 
Located just upstream of the alternative splicing site in exon 10 of LMNA is the silent 
nucleotides substitution rs4641 (1908C>T). The genetic variant changes the third 
nucleotide of codon 566 (His566His) in exon 10 and it is hypothesized to influence the 
alternative splicing of the LMNA and thereby the ratio of lamin A to lamin C [Linn & 
Figure 4.1 Nuclear lamina is shown as yellow and blue 
strings inside the nuclear membrane. 
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Worman, 1993]. The SNP is interesting as the T-allele was nominal associated with 
T2D [Wegner et al., 2007]. 
Laminopathies 
 
Multiple diseases and syndromes are caused by 
mutations in LMNA which often are referred to as 
laminopathies; however, the precise mechanism by 
which defective lamin A and C cause these diseases 
remains unclear. Laminopathies include monogenic 
syndromes such as muscular dystrophy, Hutchinson-
Gilford progeria syndromes (figure 4.2), familial partial 
lipodystrophy, and altered fat distribution [reviewed in 
Rankin & Ellard, 2006].  
Mutations causing familial partial lipodystrophy are 
located in exon 8; but mutations in other areas in the 
gene have also been identified [Vigouroux et al., 2000]. 
The most common mutation in the extremely rare 
condition Hutchinson-Gilford progeria syndrome with 
aspects of greatly accelerated aging is a single base pair substitution, 1824C>T within 
exon 11. This creates an abnormal splice donor site leading to expression of a 
truncated unfunctional lamin A [Cao & Hegele, 2003; reviewed in Rankin & Ellard, 
2006].  
Type 2 diabetes linkage studies 
The chromosome 1q21-23 region has been suggested to harbour potential T2D 
susceptibility loci by Pima Indian sib-pair analyses [Hanson et al., 1998] and in Utah 
Caucasians [Elbein et al., 1999], which were replicated among French Whites [Vionnet 
et al., 2000], a UK population [Wiltshire et al., 2001; Frayling et al., 2003], and in 
Hong Kong Chinese [Ng et al., 2004]. An additional study of Pima Indians deduced 
that LMNA rs4641 does not contribute to the linkage of T2D on chromosome 1q 
[Wolford et al., 2001]. Furthermore, the region is linked to the metabolic syndrome in 
Hispanic families [Langefeld et al., 2004]. 
Association studies of T2D and obesity 
The most frequently studied variant in LMNA is rs4641 - at least in relation to type 2 
diabetes and metabolic syndrome [Duesing et al., 2008; Mesa et al., 2007; Hegele et 
al., 2000; Hegele et al., 2007; Murase et al., 2002; Steinle et al., 2004; Weyer et al., 
2001, Owen et al., 2007 Wegner et al., 2007]. The T-allele of rs4641 was nominal 
associated with T2D in a study of 1,324 diabetic patients and 4,386 glucose tolerant 
individuals and elevated fasting plasma glucose in the population-based Inter99 of 
5,395 [Wegner et al., 2007].  
Figure 4.2. A child with 
progeria. 
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Several studies have shown an association between the rs4641 T-allele and T2D-
related traits in ethnically diverse populations [Steinle et al., 2004; Hegele et al., 
2000; Hegele et al., 2007; Wegner et al., 2007]. However, two of these studies 
investigated UK individuals and did not find an association with T2D [Mesa et al., 
2007; Owen et al., 2008]. One of the studies investigating UK individuals included two 
case-control studies of 834 and 1,044 participants, respectively and additionally a 
study investigating quantitative traits of 1,572 individuals [Mesa et al., 2007]. The 
other UK study included 5,046 [Owen et al., 2008]. The two UK studies agreed with a 
study of 3,091 French Europeans, which did not find an association with T2D. A meta-
analysis comprising 15,591 individuals from four published studies [Duesing et al., 
2008; Mesa et al., 2007; Owen et al., 2007; Wegner et al., 2007] has been performed 
investigating the association of the rs4641 T-allele with T2D. This meta-analysis did 
not support a major effect of the rs4641 on T2D susceptibility [Duesing et al., 2008].  
The rs4641 T-allele has previously been shown to associate with obesity in a small 
study comprising 186 non-diabetic Canadian Inuit [Hegele et al., 2001]. Moreover, 
results of 306 non-diabetic individuals indicated that the rs4641 was associated with a 
modest but significant variation in plasma leptin concentrations, leptin-to-BMI ratio, 
BMI, percent body mass, and waist-to-hip ratio in a non-diabetic Oji-Cree population. 
In particular, homozygous carriers of the T-allele had significantly higher mean plasma 
leptin and a tendency towards obesity [Hegele et al., 2000]. Subsequently, these 
findings have been replicated in 186 Canadian Inuit individuals. This study showed 
that T-allele carriers had significantly higher weight, BMI, waist circumference, waist-
to-hip-ratio, sub-scapular skin fold thickness, and sub-scapular to triceps skin fold 
ratio [Hegele et al., 2001]. Increased concentrations for plasma leptin were also 
found, but it was not significant possible due to the smaller sample size. In a Japanese 
study of 171 non-diabetic individuals and 164 type 2 diabetic patients the T-allele was 
significantly associated with hyperinsulinaemia, hypertriglyceridaemia, high 
concentrations of LDL cholesterol, and low concentrations of HDL cholesterol, which all 
are traits of the metabolic syndrome; however, the T-allele was not associated with 
T2D [Murase et al., 2002]. Furthermore, the T-allele was associated with the 
metabolic syndrome and dyslipidaemia in an Amish population of 971 individuals 
[Steinle et al., 2004]. Additionally, a modest increase in risk of diabetic nephropathy 
and cerebral vascular disease in T-allele carriers of 166 Japanese diabetic men was 
found [Liang et al., 2005].  
Expression studies 
A previous study investigated the possible effect of the ratio of lamin A to C mRNA 
levels in subcutaneous adipose tissue in obesity and T2D in Caucasians. The study of 
T2D was performed in 28 diabetic patients and 27 non-diabetic individuals and the 
study of obesity included 52 individuals who were stratified according to four BMI 
intervals (18.5 < BMI ≤ 25 (n = 15); 25 < BMI ≤ 30 (n = 13); 30 < BMI ≤ 40 (n = 
14); BMI > 40 (n = 14) to investigate the ratio of lamin A to C mRNA levels in the four 
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different BMI intervals [Miranda et al., 2007]. Among 54 T2D patients no differences 
in lamin A and C mRNA levels were found between patients in the four BMI intervals. 
Nevertheless, there were significantly higher levels of both lamin A and C mRNA in 
T2D patients compared to non-diabetic individuals independently of BMI and the lamin 
A/C ratio was lower in type 2 diabetic patients.  
In subcutaneous adipose tissue from obese individuals (BMI ≥ 40) there was also a 
tendency toward higher levels of lamin A and lamin C expression compared with 
individuals in the three lower BMI intervals; although only lamin C reached the 
statistical significance level [Miranda et al., 2008]. Nevertheless, the lamin A/C ratio 
was lower in obese individuals (BMI ≥ 40) [Miranda et al., 2008]. 
Alternative splicing 
By alternative splicing exons of the primary gene transcript pre-mRNA are separated 
from introns at splice sites and reconnected. Subsequently translation takes place and 
specific and unique sequences of amino acids are specified. In this way different 
proteins are synthesised from the same gene. It is performed by five small nuclear 
ribonucleo proteins (U1, U2, U4, U5, and U6) and more than 60 polypeptides. 
Different elements are involved in regulation of alternative splicing: Cis-elements, 
which are present on the same strand as the gene they regulate and trans-elements 
that can regulate genes distant from the gene. These elements are either enhancers 
stimulating splicing or silencers repressing splicing. It is essential that cis-elements 
are present in the coding sequences of genes to allow the splicing machinery to 
distinguish between genuine and pseudo-exons and to modulate the selection of 
alternative splice site. Enhancers are more prevalent than silencers; they might be 
present in most if not all exons, including constitutive exons. 
 
In higher eukaryotes the requirement for accurate splicing is accompanied by exon-
intron junctions that are defined by weakly conserved intronic cis elements, the 5´ 
splice site, 3´splice site and branch A site. The classical splice sites include the nearly 
100 % conserved nucleotides GU at the 5´end and an AG dinucleotide at the 3´end, a 
Figure 4.3. Alternative splicing. Boxes represent exons, black horizontal lines represent introns. 
Grey boxes are constitutive exons . Red, yellow, green and blue boxes are different multiple 
cassette exons of which only one of them or few are further delivered to the mRNA. The lines in 
top of the multiple cassette exons shows exons further spliced to mRNA. 
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polypyrimidine tract, and a branch point A situated close to the 3´ splice site, which 
attacks the G in the intronic 5´end when splicing starts to form a 2´,5´-
phosphodiester linkage. Then the 3´end of the upstream exon (G) captures the 3´end 
of the intron by forming phosphodiester bond again so that the exons are joined 
together, leaving a free intron in a lariat form. It is indicated that about 60 % of genes 
are represented by two or more transcripts [reviewed in Cartegni et al., 2002]. SR 
proteins are also important for the alternative splicing: they are proteins that act as 
binding sites for serine and arginine rich proteins and participate in different steps of 
splicing. SR proteins bind to exon skipping enhancers through their RNA-binding 
domain, and promote exon definition by recruiting splicesomal components via 
different proteins-protein interactions. Multiple classes of exon skipping enhancers 
have been described [ Fairbrother et al.,2002; reviewed in Cartegni et al., 2002]. The 
splice sites and branch site do not provide sufficient information for the recognition of 
the spliceosome. Exon skipping enhancers are additional intron and exon sequences 
necessary for efficient and/or accurate splicing of many higher eukaryotic pre-mRNA. 
The cis-acting elements are such exonic splicing enhancers that are found in purine-
rich context. Exon skipping enhancers are mostly found in exons which typically have 
weak splice sites and require ESE for exon inclusion [Liu et al., 1998]. 
Many diseases are caused by mutations which alter an amino acid in the encoded 
protein. But many diseases are also caused by exonic mutations that affect pre-mRNA 
splicing. Nonsense, missense and even translationally silent mutations can inactivate 
genes by inducing the splicing machinery to skip the mutant exons [Wang, 1996].  
Alternative splicing of LMNA 
Alternative splicing within the exon 10 of human LMNA gives rise to pre-lamin A (pre-
curser of lamin A) mRNA and lamin C mRNA. Lamin A and C are identical through 
exon 1 to 9; however, lamin A contains only the first 5` 90 bases of exon 10 and, 
additionally, exons 11 and 12, whereas lamin C contains the whole exon 10 (of 111 
nucleotides), but lacks exons 11 and 12. The rs4641 is located in the splice site in 
exon 10 [Lin & Worman.1993] (Figure 4.1). 
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3.1 Aim 
The aim of the present study is to investigate the impact of rs4641 on LMNA splicing 
of exon 10 by exon trapping and by investigating the lamin A-to-C mRNA ratio in 
human subcutaneous adipose tissue and skeletal muscle in Danish monozygotic (MZ) 
and dizygotic (DZ) twins. Moreover, we will examine if there is an association of the 
mRNA expression levels or the rs4641 genotype with pre-diabetic quantitative 
phenotypes. The primary hypothesis for the association studies are that rs4641 is 
associated with fasting glucose and obesity-related traits in two metabolically well-
characterised populations of Danish twins due to a changed ratio of lamin A to C. 
3.2 Populations and methods  
3.2.1 Methods for gene expression  
The present study of gene expression of LMNA is an extension of two studies initiated 
by Pernille Poulsen in 1994 and 1997 and clinical data were already available [Poulsen 
et al., 1997; Poulsen et al., 2005]. Likewise, the mRNA had been purified from tissues. 
At Steno Diabetes Center the cDNA synthesis was performed by Lise Wegner and I 
performed the measurement of mRNA expression.  
3.2.2 Quantitative PCR 
Gene expression of lamin A and lamin C was measured by quantitative PCR using 
SYBR Green (Appendix III) and the housekeeping gene cyclophilin A (Appendix III) 
was measured using the TaqMan® real-time PCR technique in cDNA from 
subcutaneous adipose tissue and skeletal muscle biopsies. The conventional PCR 
technique is used to amplify DNA sequences [Mullis et al., 1986]. The method can be 
divided into three steps; 1) separation of the two DNA strands by heat denaturation, 
Figure 4.4.Splicing of LMNA to lamin A and lamin C. In the top LMNA is shown. The figure is 
not drawn to scale and exon 1-8 is only illustrated as one box to focus on exon 10-12. Splicing 
in exon 10 gives rise to lamin A containing exons 11 and 12 while lamin C containing whole 
exon 10 but not exons 11 and 12 and is produced when the splicing does not occur. The rs4641 
is illustrated in exon 10.  
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2) annealing of polynucleotides primers, and 3) elongation of the new complementary 
DNA strand. The procedure enables the ability of Thermus aquaticus (Taq) polymerase 
to replicate DNA at temperatures which exceeds the optima of eukaryotic DNA 
polymerase. This property is essential since heating to approximately 95ºC is required 
to denaturate the DNA double strand [Busting, 2004]. Quantitative-PCR (Q-PCR) 
measures the quantification of mRNA or DNA sequences of interest as it is possible to 
monitor the PCR amplification cycle by cycle [Higuchi et al., 1993]. By this method 
measurements of accumulation of a product during the exponential stages of the PCR 
is obtained compared to conventional PCR which only measures the end point of the 
product.  
For measuring lamin A and C mRNA expression SYBR Green was used and ABI PRISM 
7900HT Sequence Detection System (TaqMan ®) was used to measure cyclophilin A. 
[ABIa].  A primer set flanking the region of interest is used for the two methods. SYBR 
Green is a minor groove DNA-binding dye and binds non-specifically to all DNA also to 
primer-dimers whereas a probe, which was used to measure cyclophilin A is more 
Figure 4.5. Q-PCR using SYBR Green. SYBR Green fluoresces when it binds to double 
stranded DNA. When DNA is denaturated the dye is not bound and it does not fluoresce 
(green circles). When the primers anneal to DNA and double stranded DNA is synthesized, 
the dye binds to the synthsesised DNA and fluoresces. 
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specific and its use is a more accurate method. SYBR Green was used to measure 
lamin A and C mRNA as we had to distinguish between lamin A and lamin C and since 
there were not enough nucleotides to place a probe between the primers, we used the 
non specific dye, SYBR Green. 
SYBR Green dye binds to double stranded DNA and increases the intensity of 
fluorescent emission. The fluorescent dye makes it possible to detect the amount of 
DNA by lasers and detectors during each cycle by the PCR apparatus as the amount of 
fluorescent dye increases proportionally with the increase in double stranded DNA 
(Figure 4.5).  
TaqMan ® technique uses a sequence specific RNA or DNA-based probe to quantify 
DNA containing the probe sequence. This allows multiplexing, which is assaying for 
several genes in the same reaction by using specific probes with different-coloured 
labels, provided that all genes are amplified with similar efficiency. Because SYBR 
Green and ABI PRISM 7900HT Sequence Detection System were used for measuring 
mRNA of different genes it was not possible to multiplex in this present study. 
The probe used in the TaqMan® real-time PCR technique is designed to bind between 
the primers to the minor grove or the DNA strand. Thereby a short probe is still able 
to bind relatively strongly to the DNA. The 5´end of the probe is labelled with a 
fluorescent reporter dye and the 3´end with a quencher dye which absorbs the 
emitted light. DNA is initially denaturated at 95 ºC. Hereafter the temperature is 
lowered to 60 ºC allowing the primers and probe to anneal to the DNA string. During 
the annealing phase, the primers and the probe bind to the single stranded DNA and 
the amplification starts. When the primers are extended, the strand extension 
complexes run into the probes, which will be displaced by the Taq DNA polymerase, 
the reporter group will be cleaved from the probe and is the capable of emitting light 
which is detected by the real time PCR-apparatus (Figure 4.6). 
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Fluorescence detected by the PCR apparatus is plotted against the PCR cycle number. 
After a number of cycles the reaction enters the exponential phase where the amount 
of DNA is doubled in each cycle. The cycle number at which the reporter due 
fluorescence intensity increases above a threshold value, is termed Ct. this value 
reflects the quantity of the initial target gene cDNA in the sample. The reaction is 
completed after 40 cycles [Bustin, 2004]. 
In this project the absolute quantification method is used; however, it is also possible 
to use a relative method in which differences in Ct-values between the target gene and 
the endogenous control are calculated. 
For the absolute quantification method a standard curve with known amount of cDNA 
on the PCR plate and the quantity of the target gene can be estimated form the 
standard curve.  
Optimization of Q PCR 
The Ct-values have to be approximately between 15 and 30. If cDNA concentrations 
are too high it may disturb the amplification and low cDNA concentrations are also 
associated with an error due to the fact that initial errors will be more profound in high 
Ct values. Using a dissociation curves it was tested if the primers produced primer 
dimers. Primer concentrations of 150 nM, 300 nM, 600 nM, and 900 nM were tested 
and we decided to use a concentration of 150 nM. If the concentration of primers was 
too low the Ct-value would represent the primer concentration instead of the cDNA 
concentration. However, this does not seem to bee a problem in this case as the Ct-
values changed as the cDNA values changed. It is important not to use higher primer 
concentrations that appropriate as it increases the amount of primer dimers. 
Figure 4.6. TaqMan ® Q-PCR method. The quencher prevents the detection signal from the 
reporter dye. When Taq polymerase reaches the reporter part of the probe the reporter part is 
cleaved off and when the reporter part and quencher are separated the fluorescence light is 
emitted and is measured [ABIb] 
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It was tested how large concentrations of cDNA was needed in order to obtain Ct-
values in the range between 15 and 30. It was decided to use 2 µL 5 ng/uL cDNA from 
subcutaneous abdominal fat biopsies and 1 µL of the skeletal muscles of 10 ul/L. Since 
the amplification of cDNA is exponential, a difference of 1 Ct-values reflects a double 
amount of initial cDNA in the sample. A maximally acceptable difference between Ct-
values of sample duplicates was defined as 50 % [ABI1]. Protocol for the Q-PCR can 
be found in Appendix III.  
3.2.3 Study populations  
Two study populations of twins were used: Population 1 consisting of monozygotic 
(MZ) and same-sex dizygotic (DZ) twins and population 2 consisting of MZ and same-
sex DZ young and elderly twins. 
Participants were identified through the Danish Twin Register. Population 1 is 
population-based and consists of 586 elderly Danish twins of (67 ± 4.9 years) of 
whom 389 were glucose-tolerant, 118 had impaired fasting glucose, and 80 had T2D 
[Poulsen et al., 1999; Poulsen et al., 2002]. Among the type 2 diabetic patients 32 
had known T2D and 48 had previously unknown T2D. They were examined in 
1994/1995 (n = 606) and in 2004/05 (n = ~ 400). The individuals were selected 
randomly among same sex, MZ, and DZ twin pairs born in Zeeland, Funen, and 
Jutland.  
Population 2 consists of 194 MZ and DZ twins from two different age groups: elderly 
(62 ± 1.9 years) and young (28 ± 1.9 years) without known T2D born in Funen 
County. The individuals were selected as a random sample of same sex MZ and DZ 
Figure 4.7. Amplification plot of lamin A using SYBR Green. The x-axis represents the PCR 
cycle number and the y-axis shows the increase in detected fluorescence, ∆Rn on log scale. 
After approximately 22 cycles the PCR reaction enters the exponential phase, where the amount 
of amplified DNA is doubled in each cycle. The Ct-value is recorded within the exponential phase 
and is defined as the cycle in which the fluorescence reaches detection threshold. When the 
DNA amount increase above a given concentration, the reaction is partly inhibited, reflected by 
the entering into the linear and plateau phases. Screen dump from SDS 2.3 software, ABI. 
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twin pairs. Among elderly (n = 86) 64 were NGT, 19 had IGT, and 3 had previously 
unknown T2D. Among the young twins (n = 110) 108 were NGT and 2 had IGT. 
The exclusion criteria for the two populations were: 
• Either twin from the pair not willing to participate 
• Information of pre- or post maturity (birth before or later than three weeks 
from term)  
• Known diabetes, serious heart, liver, or kidney disease 
• Medication with influence on glucose or lipid metabolism including oral 
contraception which could    not be withdrawn 
• Pregnancy or lactation 
Zygosity status of the twins was determined by serological testing. In our analysis of 
quantitative traits only treatment-naïve individuals were included. The study was 
approved by the ethics comities and conducted according to the principles of the 
Helsinki Declaration. 
Study population examination 
Both populations underwent anthropometric measurements of height, weight, waist 
circumference, and hip circumference. All individuals underwent a 75 g OGTT. Blood 
samples were withdrawn from participants who had fasted for 12 hours. Afterwards 
the glucose load was ingested and peripheral venous blood was drawn 30 and 120 min 
later for population 1 and 30, 60, and 120-min after for population 2. Furthermore, a 
questionnaire about medication was given and information about the causes of their 
possible disease, about their familial predisposition and their birth weight data from 
which birth records were available was obtained. In addition, various fasting serum 
and plasma samples, triglycerides, total cholesterol, HDL, LDL, blood for DNA 
extraction were withdrawn. For population 1 biopsies were taken from abdominal 
subcutaneous adipose tissue.  
In population 2 further measurements of VO2 max was estimated by an indirectly 
measure of the maximal oxygen uptake per kg body weight from a maximal bicycle 
load. To asses insulin sensitivity the individuals underwent a 2-hour-euglyceamic, 
hyperinsulinaemic clamp. Two biopsies were obtained from the vastus lateralis before 
and after the hyperinsulinaemic euglycaemic clamp. First phase insulin response 
during an intravenous glucose tolerance test and pancreatic β-cell function were 
estimated during an IVGTT. 
From the clamp glucose disposal rate (Rd), hepatic glucose production (HGP), glucose- 
and fatty acids oxidation were obtained. By indirect calorimetry glucose oxidation 
(GOX) and fat oxidation (FOX) rates were estimated. Body compositions of population 
2 were also measured by DXA scan with measures of total and regional body fat 
percentages. All physical examination were conducted by Dr. Pernille Poulsen at 
Odense University Hospital. Further description can be founding Appendix I. 
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3.2.4 Statistical analysis 
Test of normality 
By plotting of the variable in a residual plot they were all examined for normality. If 
the test for normality failed, data were transformed by natural logarithm to yield a 
normal distribution. 
T-test 
A t-test was performed to test if there were any differences in mRNA expression of 
lamin A and lamin C between the two age-groups in population 2. 
Paired t-test 
A paired t-test was used to compare if insulin stimulation influences lamin A and lamin 
C mRNA expression. Samples were compared before and after the clamp.  
Proc mix models 
Phenotypes were compared using SAS (version 9.1; SAS institute) proc MIXED 
models. A mixed analysis of variance (ANOVA) (referred to as proc MIXED in SAS) was 
used either to calculate adjusted mean values or to create linear models. As 
mentioned, MZ twins share their entire genome and DZ twins share half of their 
segregating genes. Thus observation on twin pairs can not be considered independent 
which is a requirement when performing an ordinary ANOVA. Furthermore, the effect 
of being a member of a twin pair may be different for MZ and DZ twins. A feature of 
the mixed ANOVA is that it makes possible adjustment for pair and zygosity status. 
Covariates, a variables that are possibly predictive of the outcome under study, are 
sex, age, BMI, zygosity, rs4641. 
When using the mixed ANOVA model, it is furthermore assumed that the association 
between explanatory variables and response variables are linear. Another assumption 
is that the included response variables are independent. However, this will seldom bee 
true in a biological model, and some degree of interrelation may therefore be 
accepted. In each mixed ANOVA, residuals for the response variable were plotted 
versus the predicted values. The residual plot was subsequently analysed for 
normality. If the residuals were not normally distributed, the response variable was 
log transformed. In analyses where groups were compared, it was ensured, that the 
within group residual were equal. It was decided to adjust for sex and BMI. 
3.2.5 Genotyping 
Genomic DNA was extracted from blood using conventional methods. The rs4641 was 
genotyped using allelic discrimination performed with an ABI 7900 system 
(KBioscience, UK). The overall genotyping success rate was > 97 % and the error rate 
was 0 %. The method is described in Appendix III. 
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3.2.6 Methods for exon trapping 
Exon trapping was used to investigate the alternative splicing of LMNA. This is a 
method developed to trap exons with the intension to identify new exons and was 
originally called exon amplification [Buckler et al., 1991]; however, in this case the 
purpose was to identify the effect of rs4641 on alternative splicing of LMNA. Detailed 
descriptions of transfection, isolation of RNA, cDNA, PCR synthesis, and primer 
sequences are found in Appendix XX. Before starting the analyses we investigated the 
splicing by the program ESEfinder 3.0., on the internet [http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home]. 
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To investigate alternative splicing by exon trapping the aim was to amplify and insert 
two inserts, one containing CC (wt) and one containing TT of the rs4641 into the 
specialised vector, pSPL3, shown in figure 4.9. The pSPL3 vector contains an origin of 
Figure 4.8. Schematic of the exon trapping method. 
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replication and APr marker for growth in E. coli, an SV40 segment provided for 
replication and transcription in COS-7 cells, HIV-1 tat splicing signals, and a multiple 
cloning site. The splicing at the splice donor and splice acceptor sites of the HIV-1 tat 
gene is slow, which may enhance their joining with cloned splice sites and they are 
compatible with splice sites from unrelated genes. The multiple cloning sites of pSPL3 
are flanked by functional splice donor and acceptor sites. The pSPL3 derivatives are 
propagated in E. coli and the DNA is isolated (Appendix III). 
 
 
The purpose was to transfect the pSPL3 containing the two different inserts into COS-
7, African-green-monkey kidney cells transformed by a derivative of SV40 and permit 
a high level of replication and transcription from pSPL3. Splicing should occur between 
pSPL3 and insert sequences when the cloned DNA contains a sequence in the right 
orientation. If the rs4641 enhanced splicing, splicing would occur at the splice site in 
exon 10 more often in the construct having CC (wt) in the insert. 
The cells should do alternative splicing of the constructs and the splicing should be 
inspected by isolating RNA (Appendix III) from the cells and subsequently synthesising 
cDNA and PCR amplification using vector-derived primers. If the variant caused 
alternative splicing different lengths of spliced products would be visible on a gel. It 
  Figure 4.9. pSPL3. 
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would then be possible to identify the nature of the alternative splicing by sequencing 
the PCR products. 
Procedure 
The pSPL3 was transformed into competent cells to amplify the plasmid, an overnight 
culture and glycerol stock were made with subsequent mini-preps and midi-preps 
using Charge switch prep-kit from Invitrogen (Appendix III). To evaluate the sequence 
of the plasmid it was digested with NheI, EcoRI, and HindI (Appendix III). Primers 
were designed for a polymerase chain reaction (PCR) to amplify the two different 
variants of rs4641 homozygous and wt DNA. The amplified DNA had to contain intron 
9 with branch A, as it is involved in splicing, exon 10, a part of intron 10, but not 
branch A in intron 10. Furthermore, BamHI and XhoI sites were included in the 
multiple cloning site of pSPL3 and since these were not located in the LMNA sequence, 
these were used as digestion sites for the cloning transformation and the sites for 
these were added to the PCR-primers (Appendix III). For restriction digestion BamHI 
and XhoI need only two extra nucleotides surrounding the digestion site why to 
additional nucleotides were added at the primers.  
GGGCCCCTTTCTAGAGCTCTCTGTTGCAGGCTCCAGACTTCTCCACCCAGTAGGCAAACCAAAAGATGCTTCCTCAA 
 
CAGCACAAGGGGTGGAAGTTAGACAGTGAGGATTGTTAAAGGCAGAGCCATACTCCTACCCGGAGAGCTTGACAGTG 
          Forward 
TCCCTCTGGGGTGGAAATGAGTTCCTTAGCTCCATCACCACAGAGGACAGAGTAAGCAGCAGGCCGGACAAAGGGCA 
 
GGCCACAAGAAAAGTTGCAGGTGGTCACTGGGGTAGACATGCTGTACAACCCTTCCCTGGCCCTGACCCTTGGACCT 
 
GGTTCCATGTCCCCACCAGGAAGTGGCCATGCGCAAGCTGGTGCGCTCAGTGACTGTGGTTGAGGACGACGAGGATG 
 
AGGATGGAGATGACCTGCTCCATCACCACCAC/TGTGAGTGGTAGCCGCCGCTGAGGCCGAGCCTGCACTGGGGCCA  
                           Rs4641(1908)    
CCCAGCCAGGCCTGGGGGCAGCCTCTCCCCAGCCTCCCCGTGCCAAAAATCTTTTCATTAAAGAATGTTTTGGAACT 
 
TTACTCGCTGGCCTGGCCTTTCTTCTCTCTCCTCCCTATACCTTGAACAGGGAACCCAGGTGTCTGGGTGCCCTACT 
 
CTGGTAAGGAAGGGAGTGGGAACTTTCTGATGCCATGGAATATTCCTGTGGGAGCAGTGGACAAGGGTCTGGATTTG 
 
TCTTCTGGGAAAGGGAGGGGAGGACAGACGTGGGGCATGCCCGCCCTGCCTCTCTCCCCCATTCTTGTTGCATGCAT 
 
ATCCTCTCATTTCCCTCATTTTTCCTGCAAGAATGTTCTCTCTCATTCCTGACCGCCCCTCCACTCCAATTAATAGT 
Revers  
GCATGCCTGCTGCCCTACAAGCTTGCTCCCGTTCTCTCTTCTTTTCCTCTTAAGCTCAGAGTAGCTAGAACAGAGTC 
 
To prepare the pSPL3 and the insert for the transformation they were all digested with 
BamHI and XhoI and the digested DNA was loaded onto a gel to separate linearised 
plasmid from uncut DNA using Qiaquick gel extraction kit (Appendix III). The pSPL3 
was further extracted using phenol chloroform extraction (Appendix III). Following, 
the inserts were ligated with pSPL3 using the rapid-ligation kit from Roche (Appendix 
III) and further transformed into competent bacteria, spread out and placed in 37 
degrees overnight. 
Figure 4.10. Overviw of the sequense which the primers amlify. Two sets of primers are placed 
in the sequence, indicated by blue. The grey is the sequence for branch point. The pink is 
rs4641. The dark red tyingis the exon 10. 
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Plasmid DNA from colonies on the plates was examined either by digestion or by 
colony-PCR (Appendix III). Control digestion was performed by inoculation a few 
colonies to LB medium and growing them overnight, shaking and by 37 º C. Mini-
preps (Appendix III) were made and these were digested with BamHI and XhoI, 
loaded on a gel and the sizes of the bands were inspected. The bands had to be 764 
nucleotides to confirm an insert in the pSPL3. Colony-PCR was used to screen a larger 
number of colonies for having a possible insert in a short time. A number of colonies 
were inoculated in water and were further used for a PCR with primers located in the 
pSPL3 plasmid.  
When having difficulties of cloning inserts into pSPL3 or other plasmids, TOPO-cloning 
(Appendix III) is an alternative method (Appendix III). It is based in the use of a 
specialised vector, the TOPO-vector, which is used as a transit vector. Taq polymerase 
is used for amplifying PCR products intended for TOPO-cloning as it adds single 
deoxyadenosines (A´s) to the ends of the 3` ends of the PCR-products. The linearised 
vector has a single overhanging deoxythymidine (T) residue and ligation of taq-PCR 
product is done without ligase but with the use for an activated form of 
topoisomerase. The TOPO-plasmid is shown in figure 4.11. 
 
 
 
Ligating inserts excised from the TOPO-vector into pSPL3 should be easier than 
ligating PCR amplified inserts directly into the pSPL3. This is due to more exact 
restriction enzyme digestion of the insert when it is located in a vector, because the 
restriction enzymes are more precise when there are more bases surrounding the 
restriction site (Figure 4.12).  
Figure 4.11. pCR 2.1-TOPO. 
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When the insert was ligated into the TOPO vector it had two possible directions. To 
examine if the direction was right, mini-preps of the colonies were performed. The 
mini-preps were then digested with XhoI and a combination of Pst1 and Xba1. If the 
insert had sense direction the XhoI restriction would result in a 800 bp section and if it 
was antisense it would result in a 50 bp section. By the restriction with Pst1 and Xba1 
it would result in a 100 bp section for sense direction and in a 800 bp section for the 
antisense direction. If the product had the right direction, it would further be 
transfected into COS-7 cells.  
3.3 Results 
3.3.1 Results of association studies 
Influence of rs4641 on anthropometry and body composition 
We examined the rs4641 in relation to anthropometric traits in population 1 and in 
young and elderly twins from population 2.  
Neither in population 1 of 534 treatment-naïve twins nor in population 2 of 189 twins 
did we find any differences in any of the anthropometric measurements between 
genotype groups (Table 1). 
Figure 4.12. Overview of TOPO-cloning. The TOPO-vector, pSPL3,and the inset are cut with the 
same restriction enzymesand the insert is transformed into the TOPO-vector. Then it is cut with 
the same restriction enzymes again and transformed into pSPL3. 
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rs4641 CC CT TT P 
Population 1     
n (men/women) 283 (135/148) 218 (107/111) 33 (20/13)  
Age (years) 67 ± 5  66 ± 5 66 ± 5  
BMI (kg/m2) 25.8 ± 4.00 26.1 ± 4.5 24.9 ± 4.3 0.40 
Waist-to-hip ratio 0.87 ± 0.10 0.88 ± 0.10 0.86 ± 0.07 0.20 
Population 2 young individuals     
n (men/women) 63 (33/30) 37 (21/16) 6 (4/2)  
Age (years) 28 ± 2 28 ±2 27 ± 1  
BMI (kg/m2) 23.7 ± 2.6 24.5 ± 3.1 27.4 ± 5.3 0.1 
Total fat (%) 21.9 ± 7.1  22.2 ± 7.0 23.7 ± 8.3 0.7 
Trunk fat (%) 18.3 ± 6.6 18.6 ± 6.5 20.9 ± 7.8 0.5 
Leg fat (%) 25.9 ± 9.7 26.4 ± 9.9 26.9 ± 10.7 0.6 
VO2 max (ml · kg-1· FFM · min-1) 39.3 ± 7.7 39.7 ± 6.1 39.5 ± 15.6 0.5 
Population 2 elderly individuals     
n (men/women) 40 (17/23) 38 (15/23) 5 (5/0)  
Age (years) 63 ± 2 61 ± 2 59 ± 0  
BMI (kg/m2) 25.1 ± 3.9  27.0 ± 5.0  25.9 ± 3.8 0.1 
Total fat (%) 27.6 ± 10.1  29.1 ± 9.1 20.2 ± 5.5 0.09 
Trunk fat (%) 24.8 ± 11.2 25.7 ± 9.5 19.4 ± 6.9 0.3 
Leg fat (%)  31.3 ± 11.2 33.5 ± 10.6 20.2 ± 5.2 0.8 
VO2 max (ml · kg-1· FFM · min-1) 25.9 ± 7.05  25.8 ± 6.5 34.8 ± 5.0 0.2 
Influence of rs4641 on glucose tolerance and insulin secretion during an 
OGTT in population 1 
We further investigated the rs4641 with the putative association with glucose 
tolerance and with insulin secretion. In population 1 (n=534) we were not able to 
demonstrate any differences in glucose tolerance between the three genotype groups 
(Table 2). Carriers of the minor T-allele had a borderline increased insulin release at 
30-min during an OGTT. The incremental 30-min AUC for insulin and for C-peptide 
were increased among T-allele carriers. The incremental area under the curve is the 
area under the curve at a certain time minus the area under the curve at fasting. 
Additionally, T-allele carriers had significantly higher insulinogenic index. The 
insulinogenic index measures β-cell function during an OGTT and is defined as the 
ratio between AUC for insulin at 30-min divided by in AUC for glucose at 30-min.   
Table 4.1. Anthropometric measures of population 1 (n=534) and population 2 (n=189)
Data are means ± SD. p-values were adjusted for age, sex, and BMI. Obesity measures were 
not adjusted for BMI. 
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rs4641 CC  CT  TT P 
Population 1     
n (men/women) 283 (135/148) 218 (107/111) 33 (20/13)  
Age (years) 67 ± 5  66 ± 5 66 ± 5  
Plasma glucose 
(mmol/l) 
    
Fasting 5.8 ± 0.9 5.9 ± 0.9 5.6 ± 0.6 0.5 
30-min 9.4 ± 1.7 9.4 ± 2.0 8.7 ± 1.8 0.3 
120-min 7.2 ± 2.8 7.2 ± 2.8 6.2 ± 1.7 0.2 
Inc AUC 30-min  53.7 ± 18.9 52.5 ± 22.2 46.1 ± 22.0 0.2 
Inc AUC 120-min  276.1 ± 143.6 271.1 ± 149.9 208.2 ± 124.1 0.1 
Plasma insulin 
(pmol/l) 
    
Fasting 44 ± 25 45 ± 27 40 ± 26 1.0 
30-min 321 ± 244 286 ± 183 348 ± 279 0.05 
120-min 291 ± 261  314 ± 314 249 ± 183 0.7  
Inc AUC 30-min 4,153 ± 34,13 3,618 ± 2497 4,615 ± 3,991 0.03 
Inc AUC120-min 27,710 ± 21,263 26,564 ± 20,293 27,869 ± 19,976 0.50 
Insulinogenic index 86 ± 79 82 ± 100 118 ± 107 0.006 
HOMA-IR 1.7 ± 1.1 1.8 ± 1.2 1 ± 1 1.00 
HOMA-IS  57.8 ± 32.9 55.9 ± 27.8  53 ± 26  0.50  
C-peptide (pmol/l)     
Fasting 683.5 ± 287.1 689.7 ± 331.1 619.4 ± 259.3 0.60 
30-min 2,180.5 ± 917.0 2,066.4 ± 856.7 2,322.9 ± 1093.4 0.04 
120-min 3,153.6 ± 1226.4 3,236.5 ± 1471.7 2,884.0 ± 1243.9 0.90 
Inc AUC 30-min  22,484.1 ± 11,800.8 20,650.7 ± 10220.8 25,555.0 ± 14,648.4 0.06 
Inc AUC 120-min  200,902.6 ± 75,114.8 197,208.8 ± 82949.1 204,132.7 ± 87,273.8 0.20 
Table 4.2. Population 1. Glucose tolerance and insulin secretion during an OGTT in relation to 
rs4641. 
Data are means ± SD. p-values were adjusted for age, sex, and BMI. Insulin, and values 
derived from insulin were logarithmically transformed before analyses. Inc incremental; AUC 
area under the curve.  
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Influence of rs4641 on insulin secretion during an IVGTT in population 2 
In young individuals from population 2, the T-allele carriers had increased fasting 
plasma insulin; however, we did not demonstrate the same effect in the elderly twins.   
Rs4641 CC CT TT P 
Population 2 young  
twins 
    
n (men/women) 63 (33/30) 37 (21/16) 6 (4/2)  
Age 28 ± 2 28 ±2 27 ± 1  
Plasma Insulin (pmol/l)     
Fasting 31 ± 10 34 ± 20 57 ± 20 0.006 
IncAUC 10-min 2,836 ± 1903 2,557 ± 1799 3,395 ±  2,011 0.6 
Population 2 elderly 
twins 
    
n (men/women) 40 (17/23) 38 (15/23) 5 (5/0)  
Age 63 ± 2 61 ± 2 59 ± 0  
Plasma Insulin (pmol/l)     
Fasting 33 ± 18 29 ± 22 28 ± 22 0.2 
IncAUC 10-min 2,059 ± 1821 1,829 ± 1267 1,061 ± 396 0.7 
Influence of rs4641 and peripheral insulin sensitivity of study population 2 
The study group 2 was examined for hepatic and peripheral insulin sensitivity and 
differences in genotype distribution for the different traits were analysed. The young 
T-allele carriers were more insulin resistant in the liver at the basal level. After the 
clamp the differences disappeared. We calculated the differenced in hepatic glucose 
production at base line and after the clamp and compared the differences between 
genotypes groups; however, we were not able to demonstrate any significant 
differences neither for the young twins nor for the elderly twins.  
Table 4.3.Population 2, young (n = 83) and elderly twins. Insulin secretion during an IVGTT in 
relation to rs4641 
Data are means ± SD. p-values were adjusted for sex and BMI. Insulin and values derived from 
insulin were logarithmically transformed before analyses. Inc: incremental. AUC: area under the 
curve. 
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Rs4641 CC CT TT P 
Population 2 – young twins     
N(men/women) 63 (33/30) 37 (21/16) 6 (4/2)  
Age (years) 28 ± 2 28 ±2 27 ± 1  
Basal (mg · kg-1 · min-1)     
Hepatic glucose production (HGP) 3.1 ± 0.6 3.0 ± 0.5 2.8 ± 0.4 0.7 
Glucose disposal rate (Rd) 3.1 ± 0.5 3.0 ± 0.5 2.9 ± 0.5 0.6 
Glucose oxidation 3.1 ± 0.6 3.0 ± 1.4 0.4 ± 1.2 0.40 
Non-oxidative glucose metabolism 1.1 ± 0.9 0.7 ± 1.0 1.0 ± 0.5 0.2 
Hepatic insulin resistance index 102.9 ± 37.0 116.6 ± 52.9 185.9 ± 42.6 0.005 
Clamp (mg · kg-1 · min-1)     
Hepatic glucose production (HGP) 1.6 ± 0.5 1.4 ± 0.4 1.2 ± 0.4 0.03 
Glucose disposal rate (Rd) 11.9 ± 2.9 11.8 ± 3.4 9.5 ± 3.9 0.9 
Glucose oxidation 4.8 ± 1.3 4.8 ± 1.4 3.6 ± 0.7 0.7 
Non-oxidative glucose metabolism 7.1 ± 2.7 7.1 ± 2.9 5.9 ± 3.3 0.9 
Disposition index 10-08 22.9 ± 9.0 2.8 ± 7.7 5.9 ± 4.6 0.9 
HGPbas-HGPclamp 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.2 0.4 
Population 2 – elderly twins     
N(men/women) 40 (17/23) 38 (15/23) 5 (5/0)  
Age (years) 63 ± 2 61 ± 2 59 ± 0  
Basal (mg · kg-1 · min-1)     
Hepatic glucose production (HGP) 3.2 ± 0.5 3.0 ± 0.3 2.7 ± 0.2 0.05 
   Glucose disposal rate     (Rd) 3.2 ± 0.4 3.1 ± 0.4 2.7 ± 0.1 0.05 
Glucose oxidation 2.0 ± 1.1 1.6 ± 0.8 1.5 ± 0.5 0.1 
Non-oxidative glucose metabolism 1.2 ± 1.1 1.5 ± 0.9 1.2 ± 0.5 0.3 
Hepatic insulin resistance index 124.9 ± 107.4 120.12 ± 79.0 68.8 ± 49.4 0.4 
Clamp (mg · kg-1 · min-1)     
Hepatic glucose production (HGP) 1.7 ± 0.8 1.59 ± 0.6 1.3 ± 0.4 0.2 
Glucose disposal rate (Rd) 10.1 ± 3.8 10.0 ± 2.7 8.4 ± 4.2 0.9 
Glucose oxidation 4.4 ± 1.5 4.0 ± 1.0 2.5 ± 0.6 0.1 
Nonoxidative glucose metabolism 5.8 ± 3.7 6.1 ± 2.5 5.8 ± 3.9 0.6 
Disposition index 10-08 12.0 ± 9.0 2.8 ± 7.7 5.9 ± 4.6 0.9 
HGPbasal-HGpclamp 1.5 ± 0.8 1.4 ± 0.6 1.37 ± 0.5 0.4 
Anthropometry and metabolism in dizygotic twins discordant for T-allele 
dosage of rs4641  
Investigating DZ twins discordant for allele dosage allows the adjustment for common 
gene variants (approximately 50 %) and common environmental factors. Twin pairs 
discordant for T-allele dosage were identified in both populations and compared. In 
discordant DZ pairs from population 1 (n = 63 pairs) the T-allele was associated with 
increased fasting plasma glucose and increased plasma glucose at 120-min during an 
OGTT. The T-allele was also associated with decreased fasting C-peptide and 
decreased C-peptide incremental area under the curve 120-min during an OGTT. 
Table 4.4.Hepatic and peripheral insulin action in young (n=106) and elderly (n=84) twins. 
IVGTT in relation to LMNA rs4641 genotype   
Data are means ± SD. p-values are adjusted for sex and BMI. Values derived from insulin were 
logarithmically transformed before analyses. 
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Population 1 0-1 T-alleles 1-2 T-alleles p-value 
n (men/women) 63 (35/28) 63 (35/28)  
Age 67 ± 5  66 ± 5  
BMI 25.57 ± 3.7 25.64 ± 4.1 0.9 
Plasma glucose 
(mmol/l) 
   
Fasting 5.62 ± 0.6 6.13 ± 1.4 0.006 
30-min 9.12 ± 1.4 9.63 ± 2.5 0.2 
120-min 6.50 ± 1.5 8.12 ± 4.6 0.01 
Inc AUC 30-min 52.64 ± 18.69 52.43 ± 22.9 1.0 
Inc AUC 120-min 250.29 ± 90.7 298.93 ± 213.8 0.1 
Plasma insulin (pmol/l)    
Fasting 43.00 ± 24.1 42.51 ± 26.1 0.9 
30-min 342.27 ± 291.6 276.41 ± 238.2 0.1 
120-min 297.20 ± 285.2 249.44 ± 193.0 0.1 
Inc AUC 30-min 4,489.52 ± 4,158.3 3,508.57 ± 3,382.1 0.1 
Inc AUC 120-min 29,186.95 ± 24,887.5 23,346.43 ± 18,462.6 0.06 
C-peptide    
Fasting 673.76 ± 296.715 634.75 ± 296.5 0.4 
30-min 2212.11 ± 1061.4 1,942.86 ± 1,044.0 0.1 
120-min 3,195.69 ± 1321.4 2,847.70 ± 1264.3 0.04 
Inc AUC 30-min 23075.32 ± 13916.5 19,621.7 ± 13,261.4 0.1 
Inc AUC 120-min 203,468.71 ± 
88914.6 
178,069.52 ± 
83,303.7 
0.03 
Insulinogenic index 95.8 ± 112.1 81.8 ± 95.4 0.4 
HOMA-IR 1.7 ± 0.9 1.7 ± 1.3 0.4 
HOMA-IS 60.2 ± 38.1 51.8 ± 30.6 0.1 
In population 2 there was no association investigating DZ twins discordant for allele 
dosage for the rs4641 in 14 pairs. 
 
Population 2  0-1 T-alleles 1-2 T-alleles p-value 
n (men/women) 14 (6/8) 25 (6/8)  
Age (years) 44.9 ± 17.8 44.9 ± 17.8  
BMI 23.5 ± 3.0 25.6 ± 3.7 0.05 
Plasma glucose (mmol/L)    
Fasting 5.3 ± 0.7 5.2 ± 0.3 0.7 
30-min 8.4 ± 1.6 8.1 ± 1.3 0.4 
60-min  6.5 ± 1.0 6.0 ± 1.2 0.05 
Plasma insulin (pmol/L)    
Fasting 25.55 ± 19.6 32.02 ± 20.3  0.2 
Inc AUC 10-min 83.15 ± 8.7 88.84 ± 16.6 0.2 
Basal (mg ⋅ kg -1 ⋅ min-1)    
Hepatic glucose production 3.12 ± 0.3 3.08 ± 0.5 0.7 
Glucose disposal rate (Rd) 3.13 ± 0.28 3.04 ± 0.5 0.5 
Glucose oxidation 1.89 ± 0.79 2.29 ± 1.05 0.3 
Non-oxidative glucose metabolism 1.23 ± 0.8 0.75 ± 1.0 0.2 
Clamp (mg ⋅ kg -1 ⋅ min-1)    
Hepatic glucose production 1.49 ± 0.92 1.65 ±  0.48 0.4 
Glucose disposal rate (Rd) 12.00 ± 2.8 11.43 ± 2.3 0.5 
Glucose oxidation 4.78 ± 1.4 4.88 ± 1.4 0.8 
Non-oxidative glucose metabolism 7.22 ± 2.4 6.54 ± 2.2 0.4 
Table 4.5. Dizygotic twins discordant for T-allele dosage of rs4641 in population 1
Data are means ± SD. The twins who had 0-1 T-alleles were compared with twins who had 1-2 
T alleles 
Table 4.6. Dizygotic twins discordant for T-allele dosage of rs4641 in population 1
Data are means ± SD. The twins who had 0-1 T-alleles were compared with twins 
who had 1-2 T alleles.  
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3.3.2 Results of gene expression  
The LMNA mRNA levels were investigated in adipose tissue of twins from population 1 
and in skeletal muscle of twins from population 2 to examine if there were any 
differences between genotype groups in gene expression. Furthermore, the aim was to 
investigate if differences in levels of lamin A, lamin C, and the ratio between lamin A 
and C were associated with any pre-diabetic traits. 
There were no differences between the genotype groups in mRNA levels of lamin A, 
lamin C, and lamin A to C ratio in population 1. In young twins from population 2 
there were no differences in lamin A, lamin C, and the ratio between lamin A and C 
before the clamp between the genotype groups; however, after the clamp there was a 
significant increase in lamin A for the T-allele carriers, but there was no difference in 
lamin C and lamin A to C ratio after the clamp between the genotype groups. In 
elderly twins from population 2 there were no differences between the genotype 
groups except for the lamin A to C ratio which was increased after the clamp (Table 
4.7). 
 C/C C/T T/T padd 
Population I     
Age 73.5 ± 5.2 73.5 ± 5.2 73.5 ± 5.2  
Lamin A  (n = 122) 1.0 ± 0.9 0.9 ± 1.0 0.8 ± 0.3 0.7 
Lamin C (n = 127) 1.1 ± 0.8 1.1 ± 1.0 1.0 ± 0.33 0.8 
Lamin A/C (n = 124) 0.5 ± 0.26 1.1 ± 3.5 0.6 ±  0.3 0.1 
Population 2 young 
twins 
    
Age 28 ± 2 28 ± 2 27 ± 1  
Lamin Abasal (n = 23) 1.9 ± 2.0 0.8 ± 1.1 2.2 ± 3.0 0.3 
Lamin Cbasal (n = 39) 0.8 ± 0.5 0.6 ± 0.4 0.4 ± 0.2 0.4 
Lamin A/Cbasal  (n = 2) 2.1 ± 0.7 3.1 ± 2.7 0.4 ± - 0.7 
Lamin Apost (n = 26) 2.5 ± 1.8 1.3 ± 1.2 2.9 ± 2.6 0.03 
Lamin Cpost (n = 42) 0.9 ± 0.5 0.5 ± 0.3 0.6 ± 0.2 0.1 
Lamin A/Cpost (n = 25) 2.2 ± 2.1 2.2 ± 2.1 3.8 ± 0.7 0.6 
Population 2 elderly 
twins 
    
Age 63 ± 2 61 ± 2 59 ± 0  
Lamin Abasal (n = 10) 3.4 ± 5.3 3.8 ± 4.0 5.9 ± -  
Lamin Cbasal (n = 18) 8.2 ± 9.3 5.4 ± 3.0 3.5 ± 4.7 - 
Lamin A/Cbasal (n = 21) 0.9 ± 0.3 0.9 ± 0.3 0.6 ± 0.3 0.3 
Lamin Apost (n = 13) 6.6 ± 9.7 8.8 ± 6.7 6.7 ± - 0.3 
Lamin Cpost (n = 26) 7.9 ± 7.2 10.3 ± 10.3 7.9 ± 8.2 0.2 
Lamin A/Cpost (n = 18) 0.9 ± 0.4 1.7 ± 0.6 1.4 0.03 
To investigate if there were any differences in gene expression between young and 
elderly individuals they were compared with a t-test (Table 4.8). All the p-values were 
significant and the expression for lamin A and lamin C before and after the clamp was 
increased in elderly twins compared with the young twins; however, the ratios of 
lamin A to C before and after the clamp were decreased (Table 4.8). 
Table 4.7. mRNA expression of lamin A and lamins C and the ratio lamin A/C in relation to 
rs4641 
Data are mean ± SD. The level of mRNA LMNA expression is normalized to the mRNA 
expression of cyclophilin A. The p-values are calculated using a dominant model. Some of the 
standard deviations were not possible to calculate as too few people had the CC-genotype. 
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 Lamin Abasal Lamin Cbasal Lamin A/Cbasal Lamin Apost Lamin Cpost Lamin A/Cpost 
Pop 2 young  
(n = 20) 
1.53 ± 1.7 0.70 ± 0.4 2.4 ± 2.0 1.79 ± 1.6 0.73 ± 0.5 2.7 ± 2.3 
Pop 2 elderly 
(n = 13) 
3.67 ± 4.1 6.6 ± 7.3 0.86 ± 0.3 7.45 ± 7.9 8.47 ± 8.1 1.13 ± 0.6 
P 0.033 2.16 · 10-06 5.8 · 10-4 1.4 · 10-3 2.5 · 10-8 9.3 · 10-3 
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Also we investigated if the mRNA expression of lamin A, C, and lamin A/C ratio was 
influenced by insulin stimulation with a paired T-test comparing the data before and 
after the clamp (Table 4.9). There were no differences before and after the clamp in 
population 1 or in population 2.  
 
n = 34 Young P Elderly P 
Lamin Abasal 1.23 ± 1.40  103.2 ± 30.2  
Lamin Apost 1.7 ± 2.00 0.17 800 ± 1121 0.53 
Lamin C 0.77 ± 0.48  15.5 ± 27.8  
Lamin C post 0.62 ± 0.37 0.26 7.6 ± 4.5 0.31 
Lamin A/C basal 2.54 ± 2.29  0.8 ± 0.3  
Lamin A/C post 2.81 ± 2.83 0.70 1.3 ± 0.8 0.16 
Table 4.8. mRNA expression between young and elderly twins in population 2 before and after 
a hyperinsulinaemic euglycaemic clamp indenpendently of genotype of rs4641. 
Data are mean ± SD of mRNA expression normalized to the mRNA expression of cyclophilin A.
Figure 4.12. Data are mean ± SD of mRNA expression normalized to the mRNA expression of 
cyclophilin A. The level of mRNA lamin A and lamin C expression are normalized to the mRNA 
expression of cyclophilin A. mRNA expression for young compared to elderly twins at baseline 
and post hyperinsulinaemic euglycaemic clamp. E means elderly twins and Y means young 
twins.  
Table 4.9. mRNA expression in population 2of lamin A, C, and A/C ratio at baseline and after a 
hyperinsulinaemic euglycaemic are compared with a paired t-test  
Data are mean ± SD. Expression of mRNA for lamin A and lamin C is normalized to the mRNA 
expression of cyclophilin A. Data are mRNA expression for baseline and post hyperinsulinaemic 
euglycaemic clamp.  
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3.3.3 Results of exon trapping experiments  
By investigating the influence of rs4641 on splicing of LMNA by ESEfinder 3.0 it was 
shown that the splicing changed when T was included for the rs4641 in the sequence 
investigated compared to when the C (wt) was included. The score for the wt for the 
5SSU2 protein was higher than for the genotype homozygous for the T-allele 
indicating that splicing is more enhanced in C-allele carriers. Thus higer levels of lamin 
A is expected in the CC genotype. 
Figure 4.12: Data are mean ± SD. Expression of lamin A and lamin C is normalized to the mRNA 
expression of cyclophilin A. Data are mRNA expression at baseline and post hyperinsulinaemic 
euglycaemic clamp in young twins.  
Figure 4.13. Data are mean ± SD of mRNA expression normalized to the mRNA expression of 
cyclophilin A. 
Data are mRNA expression at baseline and post hyperinsulinaemic euglycaemic clamp in elderly 
twins. Only data for lamin C and the lamin A to C ratio were available. 
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Minipreps of the pSPL3 were done and the digestion of the restriction with NheI, 
EcoRI, and HindI are shown on gel number 1.There are three replicated minipreps all 
digested with EcoRI and three with NheI and three with HindI. The restrictions 
elucidated that the plasmid truly was pSPL3.  
 
 
The cloning procedure was repeated numerous times; however, when examining the 
clones obtained by digestion with BamHI and XhoI none of the colonies had any insert 
(gel number 2). When repeating the cloning, different attempts were made to ligate 
the inserts with the plasmids: New-PCR products were used, different concentrations 
of inserts and pSPL3, Fermentas ligation kit used instead of Roche rapid ligation kit. To 
be sure that the multiple cloning site had the described sequence, it was sequenced by 
MWG Biotech and it showed that the sequence was as expected.  
Gel number 4.1 
1. Digested by Hind1 and EcoRI (fragmenst at 3514, 1805, and 712 were expected) 
2. Digested with NheI and EcoRI (fragments of 5107 and 924 were expected) 
3. Digested with Nhe1 and EcoRI  
4. Digested with HindI and EcoRI 
5. Digested with HindI and EcoRI 
6. Digested with NheI and EcoRI. The marker in the right is 1KB +. They all have the 
expected sizes. Lane number 3 and number 6 are not digested completely. 
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Afterwards new primers were designed containing new restriction sites PstI and XhoI. 
By using the new primers genomic DNA was amplified. The PCR-product was inserted 
into the TOPO-vector and by digestion of mini-preps of the TOPO-clones it turned out 
that two of the clones contained the insert of 764 nucleotides. The mini-preps were 
digested with EcoRI as the TOPO-vector contained EcoR1 restriction sites surrounding 
the PCR-product. The inserts were contained in number 2 and 5. 
 
 
Gel number 4.3. Number 3 and 5 clones have inserts of 764 bp. The marker to the left is 1kb 
plus. 
Gel number 4.2. From the left: two wt, two homozygous fro the T-
allele, and 1kb + marker. Wt and homozygous are digested with 
BamH1 and Xho1 
 
1 KB+ 
1 KB+ 
 
100 bp+ 
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The insert in the TOPO-vector have two possible directions. To examine the direction 
of the insets restrictions of the mini-pres was done with XhoI and a combination of 
PstI and XbaI. If the insert is in sense direction the XhoI restriction will result in a 800 
bp section and if it is antisense it will result in a 50 bp section. By the restriction with 
PstI and XbaI it will for sense direction result in a 100 bp section and for the antisense 
direction in an 800 bp section.   
 
 
 
Clone number 3: The first lane has a band at about 800 indicating that the insert has 
sense direction. The two bands in lane number two has two double bands at about 
1000 and 3000 bp this indicates that the insert is a mix between two clones of which 
only one of them has the insert. Clone number 5: The large bands of restriction of 
clone number 5 indicate that the clone does not have an insert after all. 
I tried to clone the insert in clone number 3 into pSLP3 by digesting with PstI and XhoI 
followed by ligation and transformation. However, this cloning failed. Thus despite 
several approaches, it was impossible to clone an inset into pPSL3.  
When the constructs are finally made they should be transfected into the COS-7 cells 
and the remaining part of the exon trapping procedure may be carried out as 
described in the method section.  
 
Gel number 4.4. Analysing the direction of The inserts.  
1: 1 kb+ DNA ladder 
2: number 3 digested with XhoI 
3: number 3 digested with PstI and XbaI 
4: number 5 digested with XhoI   
5: numner 5 digested with PstI and XbaI 
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3.4 Discussion 
In this study we examined the influence of rs4641 on different T2D-related traits and 
the splicing of LMNA. Furthermore, we investigated if rs4641 influenced expression of 
LMNA and if there was any correlation between the gene expression and the traits 
associated with rs4641. 
We found no association with any of the anthropometric traits in the population 1 or 2 
and rs4641 genotype. By investigating glucose tolerance and insulin secretion during 
an OGTT we found that carriers of the minor T-allele in population 1 had a borderline 
increased plasma insulin secretion and plasma C-peptide at 30-min during an OGTT, 
and the incremental area under the curve for plasma insulin at 30-min during an OGTT 
was increased among T-allele carriers; however, considering the fact that these traits 
were not included in our primary hypothesis these significant values would not survive 
correction for multiple testing. 
The T-allele carriers in population 1 had an increased insulinogenic index, which is a 
measure of the β-cell function suggesting that the T-allele carriers in population 1 had 
an increased β-cell function compared with non-T-allele carriers. For this index the CT-
genotype individuals had a slightly higher value; however, taken the large standard 
deviation in consideration for the three genotypes there is an increased index for the 
T-allele carriers. The p-value is 0.006 and might not survive a correction for multiple 
testing.   
The twins from population 2 underwent an IVGTT. Before the IVGTT the young T-allele 
carriers had increased fasting serum insulin level; however, we were not able to 
demonstrate this association in the elderly twins. In addition, in population 2 the 
young T-allele carriers were more insulin resistant in the liver before the 2-hour 
euglycaemic hyperinsulinaemic clamp and after the clamp they had lower hepatic 
glucose production. The increased hepatic insulin resistance is a pre-diabetic trait 
while decreased hepatic glucose production is not; however, the elderly T-allele 
carriers also had borderline lower hepatic glucose production before the clamp.  
By investigation of discordant DZ pairs from population 1 (n = 63 pairs) we found that 
the T-allele was associated with increased fasting plasma glucose and increased 
plasma glucose at 120-min during an OGTT in accordance with the finding of Wegner 
et al. [2007]. The T-allele was also associated with decreased fasting C-peptide and 
decreased C-peptide incremental area under the curve at 120-min during an OGTT. 
We were not able to demonstrate the same effect in population two. It is still unknown 
if the young twins from population 2 will develop diabetes and pre-diabetic traits later 
in life and they might still be too young to show any pre-diabetic traits. The elderly 
twins in population 2 are selected for not having T2D why these twins are healthier 
than the general population and these individuals do not represent the Danish 
population.   
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This investigation of discordant DZ pairs is a very powerful test and the elevated 
plasma glucose among T-allele carries is in accordance with earlier results [Wegner et 
al., 2007]. However, we were not able to find an association of rs4641 with fasting 
plasma glucose as it was demonstrated in the Inter99 cohort [Wegner et al., 2007] 
when the twins were investigated as non-related individuals. This might be due to 
lower power in the study compared to the study in Inter99 which included many more 
individuals.  
We have not been able to calculate power in the study as the participants are twins 
and therefore strongly related and why a normal power calculation can not be used; 
however, the study only included 746 individuals, which does not gives a high power. 
We did not find any convincing association with any pre-diabetic traits in the elderly 
twins in population 2 which might be due to strict inclusion criteria as they are 
selected for not having T2D. We investigated if the variants in high LD with rs4641 
were investigates in other GWA studies and if they had been associated with any 
disease or metabolic traits. This was not the case. 
In further studies it would be interesting to investigate the association with fasting 
plasma glucose in a larger sample trying to replicate the finding in the Inter99 cohort. 
Furthermore, it would be interesting to investigate determinants of tissue LMNA 
expression including fat percentage, VO2 max, birth weight, zygosity and sex. This 
could be done by multiple regression analyses with a stepwise elimination of 
insignificant co-variables until obtaining the final reduced models. 
Expression studies  
For the expression studies only very few individuals passed our inclusion criteria which 
were: Replicates had to be available for both A, C, and cyclophilin A and for population 
2 furthermore samples had to be available both before and after the euglycaemic 
hyperinsulinaemic clamp. The replicates were excluded if the Ct-values differed more 
than 40 %. Because of large variation we priori decided only to include values ± 2 
SD´s from the mean. This resulted in very low power of the study as most of the 
samples were excluded; however; the calculations were carried out anyway. 
We investigated the putative effect of rs4641 on the mRNA levels of LMNA. We found 
no differences in mRNA expression between the genotypes in population 1. In young 
twins from population 2 we found a significant increased lamin A mRNA level for the T-
allele carriers after the clamp. Furthermore, there was an increased lamin A/C ratio for 
the elderly twins after the clamp. By comparing the expression of lamin A and C 
between young and elderly twins we found significant increased expression in elderly 
twins; however, the ratio of lamin A to C was decreased in elderly twins. The data 
show very low p-values probably due to erroes in the study and as very few 
individuals are included in the study, the data are not due to true differences between 
the young and elderly twins. 
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Because of the very few individuals included in the expression study of mRNA of lamin 
A, lamin C and cyclophilin A the association is not convincing. We had to distinguish 
between lamin A and lamin C we only had very few nucleotides at which we could 
place the primers why we had to design the assay our selves and because of this 
assay design there was only room for 2 µL cDNA in each sample. Accuracy of pipetting 
only 2 µL is difficult to achieve and the huge variation within the samples might be 
due to inaccuracy in pipetting. It might also be due insufficient optimising of the PCR 
reaction. It is optimal to run triplets as recommended by the kit and instrument 
manufacturer (ABI). We only ran duplicates in order to save reagents and due to 
limited access to mRNA samples. 
If it was possible to design sequence specific probes for the two isoforms it would be 
of interest to multiplex the PCR. Then the three genes could be measured in one 
reaction only which get a quite accurate ratio, although the duplicates or triplicates 
still would have to pass our quality requirements. Furthermore, by multiplex only 
needed to run 1/3 of the reactions had to be done. Nevertheless, this was not possible 
in this study because the nucleotide difference between the two isoforms did not leave 
us with enough nucleotides to design isoform-specific probes and primers. To rerun 
the samples it would be preferable to redesign the assay in which larger volumes of 
cDNA are used. 
Exon trapping 
Unfortunately, we did not manage to get any results of the exon trapping 
experiments. It would have given us important knowledge of the splicing of LMNA. By 
knowing if the rs4641 influences alternative splicing and changes the ratio of lamin A 
to C it is possible to hypothesize if it is due to changed ratio of the lamin A to C that 
rs4641 is associated with T2D and other quantitative traits.  
By ESEfinder (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) it is possible to 
evaluate the splicing of a given gene. ESEfinder estimate putative binding sites for 
splicosomes for a sequence of interest. By investigating the splicing of LMNA by 
ESEfinder we found that splicing was more enhanced in the C-allele compared with in 
T-allele. Increased splicing in the C-allele is predicted to result in higher levels of the 
lamin A isoform and a higher A to C ratio. At the time I received the pSPL3 from David 
Calabrese, PRA, Maloney Lab, Pulmonary & CCM, UCHSC, they had not performed any 
experiments with the plasmid yet; however, after we finished our experiments we 
were informed that they also had problems working with the plasmid and were not 
able to clone any inserts into it. It is not possible to buy the plasmid as it is not on the 
market anymore, maybe because it is very difficult to use; however, it would be 
interesting to get another plasmid and try to carry out the exon trapping again or 
investigating the rs4641 influence on alternative splicing with a different method, e.g., 
by constructing minigene constructs vontaining C and T-variants of rs4641. A 
minigene is a genomic fragment that includes alternative exon or exons and the 
surrounding introns as well as flanking constitutively spliced exons. The minigene is 
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cloned into a eukaryotic expression vector which is further transfected into a specific 
cellular environment. Thus the transfected minigene should contain all necessary RNA-
elements to show the same alternative splicing patterns as the corresponding 
endogenous alternatively spliced gene [Zhang et al., 2007]. The splicing pattern is 
then examined by splicing/isoform-specific Q-PCR. 
In conclusion, there is no association of rs4641 any of pre-diabetic quantitative 
phenotypes, lamin A and C expression. It was not possible to detect if rs4641 
influenced the alternative splicing of LMNA. Further studies are needed with more 
individuals to clarify the association of the rs4641 with T2D and related traits. 
Discussion and perspectives 
Page 82 
4 Discussion and perspectives 
Type 2 diabetes and obesity are conditions in which many factors are involved and 
they are both growing public health problems with a tremendous impact on morbidity 
and mortality. The aetiologies of T2D and obesity are complex involving both genetic 
and environmental factors. Identification of genetic variants and understanding of 
gene-environment interactions in the development of T2D and obesity would give an 
advantage in prevention and treatment on a society level but especially for each 
individual as it enables personalized prevention and treatment. It is of high priority to 
prevent T2D and obesity instead of desperate and countless attempts of treatment. 
Beside this, increased knowledge within the field will provide possibilities to discover 
new drug targets hopefully leading to new therapeutic opportunities as well as 
classification and prediction would be much more efficient. 
The aim of the thesis was to contribute to the identification of genetic variants 
involved in the pathogenesis of T2D and obesity and T2D related traits. Variants in 
AHI1 and UCP2 have been investigated by genetic-epidemiological studies and a 
variant in LMNA has been investigated both by genetic and epidemiological studies as 
well as by functional studies.  
GWA studies are relatively new strategies to identify genetic variants predisposing to 
common metabolic diseases. The studies have already led to identification of several 
variants associated with type 2 diabetes and obesity and some of them have already 
been replicated in different populations including our Danish populations. At the time 
identification of a genetic variant predisposing to T2D or a phenotype trait is 
performed, validation is needed by replication in a different study population. This is 
one of the major difficulties in genetic epidemiology due to e.g. differences in 
ethnicity. Different study populations have different LD blocks and this can be the 
reason why some findings are not possible to replicate. Another reason why replication 
is difficult can simply be due to false positives which might be because of insufficient 
power in the study or because of multiple testing or false negatives. Moreover, 
functional studies are of great importance in order to justify the suggested biological 
mechanism underlying the association.  
Technical capabilities to produce very large amounts of genomic data have evolved 
rapidly in the past decade and more powerful genome studies will be leading in the 
future. Probably whole genome sequencing will be the new attempts to identify new 
genetic variants. Today GWA studies investigate genetic variants with a frequency 
above 5 % while future GWA studies most likely will begin to focus on genetic variants 
with a frequency below 5 % as well. To detect the true causative disease susceptibility 
variant, the whole genome sequencing approach covering both coding and non-coding 
variants including common and rare variants seems an attractive solution; in fact, the 
‘1000 Genome Project’ was launched in January 2008 [Siva, 2008]. The aim of this 
international mega-effort is to sequence the genome of thousand people from around 
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the world. It will capture variants with a frequency of 1% or more across most of the 
genome. Even though the project does not cover the entire genome it is expected to 
contribute considerably to fully understand the genetic basis of type 2 diabetes and its 
related complex diseases. 
In conclusion rs1535435 and rs9494266 in AHI1 are not associated with type 2 
diabetes or any pre-diabetic traits. The rs659366 in UCP2 is not associated with 
obesity or T2D in our populations; however, we found increased insulin sensitivity for 
the A-allele carriers. Additional studies are needed to clarify the association of 
rs659366 with T2D and obesity. The rs4641 in LMNA was not associated with any pre-
diabetic traits. Furthermore, it was not possible to determine the influence of the 
rs4641 on alternative splicing by exon trapping or by expression studies why 
additional studies are needed to determine the function of rs4641.  
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Appendix I: Study populations 
Biochemical and anthropometric measurements 
In all study groups, height and weight were measured in light indoor clothing and 
without shoes, and BMI was calculated as weight in kg divided by height in meters 
squared (kg/m2). Waist circumference (cm) was measure in the upright position 
midway between the iliac crest and the lower costal margin, and hip circumference 
(cm) was measured at its maximum. 
Serum LDL-cholesterol was calculated as total serum cholesterol minus serum HDL-
cholesterol minus serum triglyceride/2.2. Serum VLDL-cholesterol was calculated as 
serum triglyceride divided by 5 [Friedewald et al., 1972]. 
Measurements of fasting plasma glucose and fasting serum insulin can be used to 
calculate the validated homeostasis model assessment of insulin resistance (HOMA-IR) 
index which is (fasting plasma glucose mmol/l • fasting serum insulin pmol/l)/ 22.5 
[Matthews et al., 1985] 
Inter99 
The Inter99 is a population-based sample of unrelated Danish Whites. It is collected of 
the Research Centre for Prevention and Health at Glostrup University Hospital. 
Individuals living in the South-Western part of Copenhagen County in December 1998, 
born in 1939-1940, 1944-45, 1949-50, 1954-55, 1959-60, 1964-65, and 1969-1970 
(n = 61, 301) were drawn from the Danish Population register (CPR). From this study 
population an age- and sex-stratified random sample called Inter99 (n = 13,016) were 
examined further, some were excluded, due to e.g. death, alcoholism, drug abuse, 
leaving 6,784 individuals for analysis.  The median age for this population was 45.1 
years (range 30-60), with 48.7 % being men and 51.3 % women. 
All participants filled out questionnaire concerning lifestyle such as smoking habits, 
food- and alcohol intake, physical activity and possibilities to change lifestyle; 
educational- and working status; information about family occurrence of chronic 
disease such as T2D and cardiovascular disease; health status such as medication and 
use of the health care system [Jørgensen et al., 2003]. Information about lifestyles, 
such s smoking and physical activity was reported. All the participants in the study 
were Danish Whites by self-report. Informed written consent was obtained from all 
participants, and studies were conducted in accordance with the Helsinki Declaration II 
and were approved by the ethics committee of Copenhagen. 
All physical examination were conducted by medical staff at Steno Diabetes Center 
and Research Centre for Prevention and Health. Blood pressure after 5 minutes of 
lying down, height without shoes, weight, and waist and hip circumference were 
measured. Fasting blood samples were drawn for assessment of total serum 
cholesterol, HDL-cholesterol and triglyceride levels, whereas VLDL-cholesterol and 
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LDL-cholesterol levels were calculated by Friedewald´s equation. An oral glucose 
tolerance test (OGTT) was performed, giving the participants, without known diabetes, 
57 g anhydrous glucose dissolved in 250 ml of water. Plasma glucose, serum insulin 
and C-peptide were measured fasting and after30 and 120 minutes. 
Methods for measurements of clinical and biochemical variables 
• Lipid concentrations: Total cholesterol was measured by the Cholesterol CHOD-
PAP method, HDL-cholesterol levels were measured using an enzymatic 
technique (Boehringer, Mannheim, Germnay) and triglycerides levels were 
measured using the Triglyceride GPO-PAP method. 
• Glucose concentration: Plasma glucose concentrations were measured 
automatically using hexokinase 1GP-DH technique (Granutest, Merck; 
Damstadt, Germany). 
• Insulin concentrations: Serum insulin levels were measured by enzyme-linked-
immuno-adsorbant-assay (ELISA) excluding intact pro-insulin (Dako insulin kit 
K6219, Dako diagnostics Ltd, Ely, UK). 
 
Classification of the glucose tolerance status was done according to the criteria se by 
WHO in 1999. Individuals with self reported diabetes were classified as known 
diabetics. Individuals nor reporting having diabetes and who had fasting plasma 
glucose ≥ 7.0 mmol/L or 120 min. plasma glucose ≥ 11.1 mmol/l were diagnosed as 
having screen detected diabetes. Individuals were diagnosed with IGT when having 
fasting plasma glucose < 7.0 mmol/l and 120 min. plasma glucose ≥ 7.8 mmol/l but < 
11.1. Those with fasting plasma glucose ≥ 6.1 mmol/l but < 7.0 mmol/l and 120 min 
plasma glucose < 7.8 mmol/l were diagnosed with impaired fasting glycemia (IGF). 
Normal glucose tolerance (NGT) was defined as fasting plasma glucose < 6.1 mmol/l 
and 120 min plasma glucose < 7.8. 
Based on measures of plasma glucose levels, the glucose tolerance status were 
successfully determined for 6,410 participants, where 4,735 (2,209 men and 2,526 
women) were NGT, 520 (380 men, 140 women) were IFG, 751 (369 men and 382 
women) were  were IGT, 256 (167 men and 98 women) were diagnosed with screen 
detected diabetes, and 139 (72 men and 67 women) had known T2D [Glümer et al., 
2003]  
PASSION 
This cohort includes 8,539 individuals and contains the Inter 99 cohort and other small 
cohorts. 
P: Probands: n = 135 (67/68) with T2D; Age: 60 ± 13 years; Average BMI: 29.4 ± 
5.3 kg/m2. 
A: Asso-control study. T2D patients (n = 557) sampled from Steno Diabetes Center 
with matched controls for age, sex, and BMI; n = 287 (476/368); Age: 58 ± 12 years; 
Average BMI: 27.9 ± 5.2. 
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S: Sopson; cohort with microalbuminuria selected from the outpatient clinic at Steno 
Diabetes Center [Gæde et al., 2003] n = 160 (119/41); Age: 55 ± 7; Average BMI: 
29.9 ± 4.4 kg/m2. 
S: Sixty-year-old study: A population-based sample of 60 years old glucose tolerant 
individuals; n = 695 (325/370) from Copenhagen [Drivsholm et al., 2001]; Age: 61 ± 
1 years; Average BMI: 26.8 ± 4 kg/m2 
I: Inter99; n = 6,514 (3,169/3,345); Age: 46 ± 8; Average BMI: 26.3 ± 5 kg/m2 
O: Oluf Pedersen research samples. n = 102 (56/46); Age: 54 ± 9; Average BMI: 
29.3 ± 4.9 kg/m2 
N: Nation wide collection of T2D patients. n = 86 (62/26). All hospitals and doctors in 
Denmark were requested to send blood samples along with patients data such as BMI 
to Steno Diabetes Center. Age: 58 ± 11 years; Average BMI: 31.1 ± 5.3 kg/m2. 
ADDITION 
The ADDITION study (Anglo-Danish-Dutch Study of Intensive Treatment and 
Complication Prevention in Type 2 Diabetic Patients Identified by Screening in Primary 
Care) includes participants that were recruited via a step-wise strategy based on a 
mailed risk questionnaire followed by measurements of random blood glucose, HbA1C, 
fasting plasma glucose, and oral glucose tolerance test to diagnose diabetes. Patients 
from Denmark are included in the present study. In Denmark, approximately 120,000 
persons aged 40 to 69 years were invited by mail. They were asked to score their risk 
for diabetes. Of those at high risk 28,266 consulted their general practitioner.  
Based on HbA1C and random plasma glucose measurements their fasting plasma 
glucose was determined in 11,646. All 10,672 participants have undergone a thorough 
phenotype characterisation including standardised questionnaire and interview (age, 
sex, socio-economic status, smoking habits, alcohol and food intake, physical activity, 
information about family history in relation to diseases predisposing to CVD, and 
detailed information about health status in relation to medical treatment and/or 
symptoms) and physical examination (standardised measurements of height, weight, 
waist- and hip circumferences, blood pressure, resting ECG, lung function). Among the 
10,672 participants with extensive base-line data more than 4,000 are obese, more 
than 5,000 have hypertension, and 1,250 have verified type 2 diabetes. An additional 
600 participants had type 2 diabetes at follow-up. In this cohort total serum 
cholesterol and serum HDL-cholesterol is measured by enzymatic test using the 
Hitachi 071 system (Roche Diagnostic GmbH, Mannheim, Germany [Lauritzen et al., 
2000] 
Young healthy Danish Caucasians 
Blood samples were drawn after 12 hour overnight fast. Serum triglycerided, total 
cholesterol, and HDL-cholesterol were analysed using standard methods (Boehringer 
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Mannheim, GmbH Diagnostic, Germany). Serum insulin levels were determined by 
Elisa excluding des (31,32).and intact proinsulin by applying the Dako insulin kit with 
an overnight incubation (code No. K6219; Dako Diagnostic, Ltd, Ely, UK [Clausen et 
al., 1997] 
Fasting serum leptin levels were measured by means of human leptin RIA kit (Linco, 
St Charles, MO, USA) [Echwald et al,. 1999]. Body fat content (kg) and fat percent 
were estimated using a bio-impedance technique.  
Lean mass was calculated as body weight (kg) minus fat free mass (kg). Data on birth 
weight and birth length were obtained from the Danish midwife original records. The 
ponderal index was calculated as (birth weight (kg) / (birth length (m)3) [Clausen et 
al., 1997]. 
Diabetic patients from Steno Diabetes Center 
and Healthy individuals from Steno Diabetes 
Center 
These two cohorts are sampled at Steno Diabetes Center and consist of 521 glucose 
tolerant controls and 2,111 type 2 diabetic patients. 
Blood samples were drawn after a 12 hour overnight fast. Serum triglyceride, total 
serum cholesterol and HDL-cholesterol were analysed using enzymatic colorimetric 
methods (GPO-PAP and CHOD-PAP; Roche Molecular Biochemicals, Mannheim, 
Germany). 
Twin populations 
Two twin populations were used in this thesis; they were identified through The 
Danish Twin Register. Population 1 (n = 586) consists of MZ twins and same sex DZ 
twins and population 2 (n = 194) consists of MZ and same sex DZ twin young and 
elderly twins. 
Analysis of plasma glucose and insulin 
Plasma was made by centrifugation of blood samples for population 1 and 2 and 
plasma glucose and insulin was analysed.  
Euglyceamic, hyperinsulinaemic clamp and intravenous glucose tolerance test 
In the clamp period, plasma insulin concentration is initially raised and subsequently 
kept constant for 120 min by a continuous infusion of insulin. During the insulin 
infusion, plasma insulin concentration is raised to 400-500 pmol/L. The plasma 
glucose concentration is kept constant at 5 mmol/l by a continuous infusion of variable 
amounts of glucose solution. Blood glucose is monitored every 5-10 min and the 
values are used to regulate the rate of glucose infusion. At steady-state, the rate of 
glucose appearance (from infusion and HGP) equals insulin-stimulated glucose 
   Page v 
disposal rate (RD clamp). Thus RD clamp constitutes an estimate of insulin-stimulated 
cellular glucose uptake when it is assumed that urinary glucose excretion is negligible. 
In the present study Rd clamp is expressed as mg glucose per kg FFM per min. The 
infused glucose solution is enriched with a tracer (3-3H-glucose) which makes 
assessment of HGP possible. 
The clamp was carries out at subjects who had fasted for 12 hours. A bolus of 3-3H-
glucopse (22 µCi) was given at 0 min followed by a 0.22µCI infusion throughout the 
basal, IVGTT, and clamp periods. Steady-state was assumed in the last 30 min of the 
basal period. Basal insulin sensitivity was assessed by collection of blood samples 
every 10 min. Subsequently, the IVGTT was carried out by injection of a bolus of 18% 
glucose solution (0.3 g  kg-1 bodyweight with an upper limit of 25 glucose). Blood 
samples for plasma glucose and insulin measurements were drawn during the IVGTT 
period at 0, 2, 4, 6, 8, 10, 15, 20, 30 min. After IVGTT, a primed-continuous insulin 
infusion (40 mU m-2  min-1) was initiated and continued for 120 min. Plasma glucose 
was monitored every 5-10 min by means of Glucose Analyzer 2 (Beckman 
Instruments). Steady-state was defined as the last 30 min of the clamp period when 
tracer equilibrium was anticipated. Collection of blood samples and monitoring of 
plasma glucose was performed as in the basal period [Poulsen et al., 2005].   
Indirect calorimetry  
Indirect calorimetry was performed during two (basal and insulin-stimulated) 30 min 
steady state periods using a Delatrac computerized flow through a canopy gas 
analyser system (Deltratrac, Datex, Helsinki, Finland). Gas exchange was determined. 
After an equilibrium period of 10 min, the average gas exchange was recorded. Urine 
was collected after the clamp period. The O2 and CO2 exchange rates and urinary 
carbamide content were used to calculate to estimate insulin stimulated glucose 
oxidation (GOX) and fat oxidation (FOX) rates. 
Insulin sensitivity 
Rd clamp: During the steady-state period of the euglycaemic, hyperinsulinaemic clamp 
the rate of glucose infusion equals the rate of glucose disposal, Rd.  
Steele´s equation for not non-steady state was used even though steady-state was 
sought to be obtained. 
SA
dt
dSA
cpVR
Ra
Da −
=
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HGP: The HGP was calculated within the basal and clamp steady state periods using 
the following equation:  
 
HGP = Ra – Rinf 
Rinf is the rate of glucose infusion. 
HGP is suppressed during the clamp amd therefore the more negative the differences 
between HGP during and before the clamp, the more insulin sensitive is the liver. The 
difference ∆HGP is expressed in absolue values. 
∆HGP = |HGP clamp – HGP basal| 
β-cell function: 
Phi1IVGTT: First phase insulin response in relation to plasma glucose concentration, 
PHi1IVGTT was calculated as the area under the curve (AUC) for insulin divided by AUC 
for glucose during the initial 10 min of the IVGTT. 
Di1IVGTT: The first phase insulin disposition index is the insulin secretory capacity 
relative to insulin sensitivity. Di1IVGTT was used as measure of β-cell function in this 
thesis, It was calculated as: 
Di1IVGTT = Phi1IVGTT • Rinf 
 
Glucose and fat turnover rates 
GOX: The glucose oxidation rate (GOX) was calculated by indirect calorimetry in the 
clamp steady-state period.  
GOX = 4.55 VCO2 (L •min
-1) – 3.21 VO2 – 2,87 n (g • min
-1), 
n is urinary nitrogen calculated from the carbamide concentration in the collected 
urine. 
FOX: The fat oxidation rate, calculated by indirect calorimetry analogous to GOX.  
FOX = 1.67 VO2 (L •min
-1) – 1.67 VCO2 – 1.92 n (g • min
-1), 
n is urinary nitrogen calculated from the carbamide concentration in the collected 
urine. 
Physical fitness  
VO2max was calculated from the maximal work load on ergometer bicycle, wattmax, and 
the body weight. 
kgin weight 
kgin  weight  3.5 wattmax 
 2max ••=VO  
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Appendix II: Statistical methods 
All statistical analyses are performed using RGui version 2.51. A p-value of less that 
0.05 is considered to be statistical significant. 
Case-control studies 
In case-control studies the difference in allele frequencies and genotype distributions 
between cases and controls are compared by Fisher´s exact test using a 2 x 2 
contingency table where the total number of observation are classified by two factors, 
the number of alleles (A1 and A2) in affected and unaffected. 
 Affected Unaffected 
A1 A B 
A2 C D 
A1 and A2: Alleles; a, b, c,d: numbers of alleles. 
A p-value is calculated by logistic regression to determine if allele frequencies differ 
between affected and unaffected by adding either an additive, dominant of recessive 
model. The p-value can be adjusted for the effect of sex, age, and BMI where 
appropriate. Estimates from the logistic regression are given as OR with 95 % 
confidence interval. 
The null hypothesis does not include genetic contribution and states that the 
probability of being affected (p) is explained solely as an intercept (α) and 
independent contributions of the estimated variables considered; in this study sex, 
age, and BMI (β1sex, β2age, β3BMI). In an alternative hypothesis, an additive 
contribution (β4XGM) is added to the null hypothesis. GM refers to the genetic model 
applied e.g. additive, dominant or recessive and X is a chosen design variable here a 
dummy variable indicating the genotype. In his study XGM for an additive model is 
defined as 0, 1 or 2 for wild type, heterozygous and homozygous individuals, 
respectively, while in the recessive model as 0, 0, 1, respectively. If data is explained 
significantly better by the alternative hypothesis, then β4XGM ≠ 0 and a genetic impact 
is assumed. The p-value is obtained using likelihood functions and 2χ -testing. 
 
Null hypothesis:            log (p/(1-p)) = α + β1sex +  β2age + β3BMI 
Alternative hypothesis: log ( p/(1-p)) = α β4XGM + β1sex +  β2age + β3BMI 
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Associations studies of quantitative traits 
Differences in anthropometrics and quantitative traits between genotype groups are 
evaluated using a general linear model assuming an additive, dominant or recessive 
model and the calculated p-values are adjusted for age, sex, and BMI when 
appropriate. Before statistical analysis some traits are transformed either 
logarithmically or cubically in order to fit data to a normal distribution. A general linear 
is used in analysis of a quantitative trait to test for a genetic effect on the trait 
studies. In model  0 the value of quantitative trait (y) is explained by an intercept (α) 
and the independent contribution of the estimated variables (β1sex, β2age, β3BMI) 
while in Model 1 a genetic component β4XGM is included. An ANOVA test based on F-
statistics is used to compare the two models and hence describe which model explains 
data better. 
Model  0: y = α + β1sex + β2age + β3BMI  
Model 1: y = α + β1sex + β2age + β3BMI + β4XGM 
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Appendix III: Methods and protocols 
TaqMan allelic discrimination 
Two probes are designed for binding specifically to the wt allele and one binding to the 
minor allele between the two primers. Allele calling will show if the DNA is 
heterozygous (1/2), homozygous (1/1), or homozygous (2/2). Each probe contains 
5´reporter dye and 3´quencher dye. When the probe is intact the quencher dye 
suppressed the reporter fluorescence. During the PCR, forward and reverse primers 
hybridise to a specific sequence of the target DNA. The TaqMan probe hybridises to a 
target sequence within the PCR-product. By cleavage of reporter dye and quencher by 
the 5´nuclease activity of the TaqDNA polymerase they are separated and it results in 
increased fluorescence of the reporter dye. During PCR, forward and reverse primers 
hybridize to a specific 
If Fam is covalently linked to the 5´end of the probe for detection of allele 1 
(illustrated as red signal) and if VIC is covalently linked to the 5´ end of  the probe for 
detection of allele 2 (illustrated with yellow signal) it is illustrated in the table how the 
signals will be. 
Genotype Allele Signal 
Heterozygous (1/2) 
 
Homozygous (1/1) 
 
Homozygous (2/2) 
 
Protocols for gene expression 
RNA extraction and purification 
RNA was extracted and purified from skeletal muscle tissue using Trizol method from 
Invitrogen. This procedure was carried out by technicians at Steno Diabetes Center. 
cDNA synthesis 
cDNA synthesis is series of complex enzymatic steps copying mRNA into double-
stranded cDNA. 
Table A.1 Allele calling. 
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Protocol Q-PCR using SYBR Green 
cDNA for a standard curve is prepared by pooling of several cDNA samples. The cDNA 
for the standard curve is from the same tissue origin as the samples to be analysed. 
The following dilutions are made from the stock solution:1, 1/2, 1/4, 1/8, and 1/16. 
2 µl 5 ng/uL cDNA from subcutaneous abdominal fat biopsies and 1 µl of the skeletal 
muscles of 10 ul/l) is added to 384-well plate. Each sample is applied in duplicates. 
The Q-PCR was carried out on ABI Prism 7900 HT (Applied Biosystem). 
The sequences of the primers: 
LTD 390 5´TCT GAG TCA CCT GGA CCA CC-3´ 
LTD 391 5´ATC TCA GTG GTA TTT GTG AGA-3 
Protocols for Exon trapping  
The pSPL3 was received from  
Maloney Lab 
University of Colorado, HSC 
Pulmonary & CCM 
Primer design  
The specificity of the PCR product is highly dependent on the primers because the 
primers ought to hybridise well to its target. When designing primers the overall GC % 
should be the same in the two primers and approximately equal to the template DNA. 
Primers should not contain self-complementary sequences that can form hairpin 
structures or sequence that can hybridise between the primers and form primer 
dimers.  
Specific mismatches in the 5´end of the primer do not prevent annealing of the 
primers or subsequent polymerase extension of the strand, and they allow one to 
introduce restriction sites as was done for the exon trapping.  
Optimisation of PCR  
To obtain a specific PCR product it is necessary to optimise the reaction. Optimisation 
is often done by changing the concentration of MgCl2 and the annealing temperature. 
The hybridisation becomes more efficient when the annealing temperature is 
increased. The same can be accomplished by changing the MgCl2 concentration. 
Finally, cycling conditions can also be varied as well as the template DNA 
concentration, primer concentration, polymerase concentration, or additives like DMSO 
and betain can be used. 
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LTD 394 and LTD 395 were the first set of primers using BamHI and XhoI restriction 
enzymes and LTD 398 and LTD 399 were the second set of primers using XhoI and 
PstI. 
LTD 394:5'- CTC TCG AGA AGG GGT GGA AGT TAG ACA GTG AG-3' 
LTD 395:5'- CTG GAT CCG AGG GGC GGT CAG GAA TG-3' 
LTD 398:5'- GAC TCT CGA GAA GGG GTG GAA GTT AGA CAG TGA G-3' 
LTD 399:5'- GAC TCT GCA GGA GGG GCG GTC AGG AAT G-3' 
The amplified PCR product was 764 nucleotides. 
Reagent Volume 
dH2O 19.3 µL 
MgCl2 1.5 µL 
PCR buffer 2.5 µL 
Primer 394 0.25 µL 
Primer 395 0.25 µL 
Taq polymerase 0.2 µL 
DNA template 100 mg/µL 1 µL 
 
PCR program: 
3 min 95ºC 
35 timer: 
 30 sec 95º C denaturating 
 30 sec 63.9º C annealing 
 1 min 72º C elongation 
5 min 72 ºC elongation 
Transformation 
1. 5 ul (plasmid pslpl3) was transformed into 100 ul competent cells (DH5α).  
2. On ice for 5 min. 
3. Heat shock 45 sec at 42ºC in water. 
4. 1 ml soc is added. 
5. 1 hour at 37 ºC vigorous shaking (200 rpm). Spread out on LB-ampicillin 
plates.  
6. Left in incubator at 37ºC overnight. 
The transformation is also carried out with a control plasmid. 
Controls:  
control plasmid (yes 2), plasmid non-cut, restricted plasmid but not ligated,  
PCR protocol 
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When colonies appear on the plates selected colonies were spread out separately and 
inoculated in LB-medium and incubated overnight in at 37 ºC, vigorous shaking (200 
rpm). 
Protocol for mini prep preparation 
1. 5 ml overnight bacterial LB culture was harvested by centrifugation at room 
temperature for 15 minutes.  
2. The cell pellet was resuspended in 300 µl resuspension buffer containing RNase A. 
Pipetting up and   down to completely resuspend the pellet.  
3. 300 µl lysis buffer was added, inverting the capped tube 6 times.  
4. Incubated at room temperature for 4 minutes.  
5. The tube were vortexed containing the chargeSwitch® magnetic beads to fully 
resuspend and evenly distribute the beads in the storage buffer. 
6. 300 µl chilled precipitation buffer was added and mixed by inverting the capped 
tube until a white, free-flowing precipitate was formed.  
7. The tube was centrifuged 10 minutes at 4°C.  
8. The supernatant was transferred to a new micro centrifuge.  
9. 40 µl of ChargeSwitch® magnetic beads was added to the lysate.  
10. Gently mixed by pippteing up and down.  
11. Incubated at room temperature for 1 minute. 
12. Placed on the magnetic rack for 2 minute.  
13. The supernatant was discarded.  
14. The tube was removed from the rack. 
15. 1 ml wash buffer was added to the tubes and pipeted up and down.  
16. Placed in the rack again for 2 minutes.  
17. The supernatant was removed. 
18. The tube was removed from the rack. 
19. 50 µl elution buffer was added and pipeted up and down 10 times.  
 
   Page xiii 
Protocol for midi-preps preparation 
A single colony was inoculated in a starter culture of 5 ml LB medium containing AMP. 
Incubated for 7 h at 37°C with vigorous shaking (300 rpm). 
50 ml of the starter culture is diluted 1/1000 into LB containing amp. Grown at 37°C 
for 15–16 h with vigorous shaking (approx. 250 rpm). 
The bacteria were harvested by centrifugation at 6000 x g for 15 min at 4°C. All traces 
of supernatant were removed by inverting the open centrifuge tube until all medium 
has been drained. 
The bacterial pellet was resuspended in 6 ml buffer P1.  
6 ml buffer P2 was added, mixed by vigorously inverting the tube. Incubated at room 
temperature (15–25°C) for 5 min. the QIAfilter Cartridge was prepared during the 
incubation. The cap was screwed onto the outlet nozzle of the QIAfilter Midi or 
QIAfilter Maxi cartridge. The QIAfilter cartridge was placed into a convenient tube. 
6 ml chilled buffer P3 was added and mixed thoroughly by vigorously inverting 4–6 
times. 
The lysate was poured into the barrel of the QIAfilter Cartridge. Incubated at room 
temperature for 10 min. 
 A hispeed midi tip was equilibrated by applying 4 ml buffer QBT and allow the column 
to empty by gravity flow. 
The cap is removed from the QIAfilter outlet nozzle and the plunger is inserted into 
the QIAfilter maxi cartridge. The cell lysate was filtered into the previously equilibrated 
hispeed tip. 
The cleared lysate was allowed to enter the resin by gravity flow. 
The hispeed midi tip was washed with 20 ml buffer QC. 
DNA was eluted in 5ml buffer QF in a 10 ml tube. 
DNA was precipitated by adding room temperature 3.5 ml isopropanol. 
The plunger was removed during the incubation from a 20 ml syringe and attached to 
the QIAprecipitator midi module onto the outlet nozzle. 
The QIAprecipitator was placed over a waste bottle and the eluate/isopropanol was 
transferred to a 20 ml syringe, and the plunger was inserted.  
The QIAprecipitator was removed from the 20 ml syringe and the plunger was pulled 
out. The QIAprecipitator was re-attached and 2 ml 70 % ethanol was added to the 
syringe. The DNA was washed by inserting the plunger and pressing the ethanol 
through the QIAprecipitator using constant pressure. 
The QIAprecipitator was removed from the 20 ml syringe the plunger was inserted and 
the membrane was dried by pressing air through the QIAprecipitator. This step was 
repeated. 
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The outlet nozzle of the QIAprecipitator was dried with absorbent paper to prevent 
ethanol carryover. 
The plunger from a new 5 ml syringe was removed and the QIAprecipitator was 
attached onto the outlet nozzle. The QIAprecipitator was hold over a 1.5 ml collection 
tube. 1 ml of Buffer TE was added to the 5 ml syring. The plunger was inserted and 
eluted DNA was pressed into the collection tube using constant pressure. 
The QIAprecipitator was removed from the 5 ml syringe, the plunger was pulled out 
and the QIAprecipitator was reattached the to the 5 ml syringe. 
The eluate from step 19 was transferred to the 5 ml syringe and eluted for a second 
time into the same 1.5 ml tube. 
Restriction enzyme digestion  
The volumes differed; however, generally the following protocol was used, digestived 
for 3 hours at 37º C. 
ddH2O Up to 50 µl 
10 x buffer 5 
100 x BSA 5 
Enzyme 0.5 µl 
DNA 1 µg 
Total 50 µl 
 
QIAquick Gel Extraction Kit Protocol 
1. The DNA fragment was excised. 
2. The gel slice was weighed. 3 volumes of Buffer QG to 1 volume of gel was added 
3. Incubated at 50°C for 10 min and vortexed every 2-3 min during the incubation. 
4. 1 gel volume of isopropanol was added to the sample and mixed. 
5. The sample was applied to QIAquick column, and centrifuged for 1 min. 
6. Flow-through was discarded. 
7. 0.5 ml of buffer QG was added to QIAquick column and centrifuged for 1 min. 
8. 0.75 ml was added of Buffer PE to QIAquick column and centrifuged for 1 min. 
9. The flow-through was discarded and centrifuged for 1 min 17,900 x g. 
10. Place QIAquick column into a clean 1.5 ml micro centrifuge tube. 
11. 30 µl of buffer EB was added and centrifuged the column for 1 min.  
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Phenol-chloroform extraction by Klenow Fill-In Kit 
1. 150 µl of 1× STE buffer was added  
2. 50 µl of 10× STE buffer was added 
3. 500 µl of phenol–chloroform was to each reaction. 
4. Vortex, then micro centrifuged for 2 minutes room temperature at maximum 
speed. 
5. the upper aqueous layer was transferred to a fresh tube. 
6. The step was repeated. 
7. 500 µl chloroform was added, vortex. 
8. Centrifuged for 2 min at room temperature at max speed. 
9. Upper aqueous layer was transferred to a fresh tube. 
10. 1 ml Ethanol was added. 
11. 30 minutes at −20°C 
12. Micro centrifuged for 10 minutes at 4°C. 
13. Supernatants was discarded.  
14. Pellet was washed with ice-cold 70% (v/v) ethanol. 
15. Dried. 
16. DNA was resuspended in 25 µl of TE buffer. 
 
For colony PCR the following primers were used: 
Colonies were selected for analysis and inoculated in 10 µl water. PCR was run with 
following primers and 2 µl of the solution. 
LTD 396:5'- GGC ACC ATG CTC CTT GGG ATG TTG-3' 
LTD 397:5'- CAC TCT ATT TTG TGC ATC AGA TG-3' 
 
Rapid Ligation kit, Roche  
Control for ligation was plasmid alone. 
1. Vector DNA and insert DNA was diluted in 1 x conc. DNA dilution buffer to a final 
volume of 10 µl. 
1. T4 DNA ligation buffer was mixed. 
2. 10 µl T4 DNA ligation buffer (vial 1) was added to the reaction, mixed. 
3. 1 µl T4 DNA ligase was added, mixed. 
4. In incubated for 5 min at 15-25°C. 
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TOPO cloning 
Following were mixed: 
3.2 µl PCR fragment 
0.8 µl salt solution 
0.8 µl TOPO vector 4.1 
Incubated for 30 minutes at room temperature. Afterward the reaction was placed on 
ice. 
